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ABSTRACT OF THE DISSERTATION 
 
Quantitative Phosphoproteomics through β-Elimination and Michael Addition with 
Natural Abundance and Stable Isotope Labeled Thiocholine 
by 
Meng Chen 
Doctor of Philosophy in Chemistry 
Washington University in St. Louis, 2010 
Professor Richard W. Gross, Chairperson 
 
 
      The reversible covalent phosphorylation of cellular proteins is widely believed to be 
the most important mechanism for the regulation of multiple signal transduction 
pathways in cell growth, division, and death by acting as a molecular switch at multiple 
nodes in metabolic networks. In this dissertation, first, a novel mass spectrometric 
strategy is reported that exploited the unique chemical properties of thiocholine that was 
introduced into protein phosphosites through alkaline β-elimination and Michael addition 
(BEMA), allowing the specific detection, identification and quantitation of 
phosphorylated serine/threonine containing peptides. Through replacement of the 
phosphate with thiocholine as the Michael donor, this strategy resulted in a marked 
increase in ionization sensitivity during ESI accompanied by enhanced peptide sequence 
coverage during CID. Moreover, the definitive localization of phosphorylated residues is 
greatly facilitated through the generation of diagnostic triads of fragment ions resulting 
from peptide bond cleavage and further neutral loss of either trimethylamine (-59 Da) or 
thiocholine thiolate (-119 Da) during CID in tandem mass spectrometric analyses such as 
MS2 and MS3. Synthesis of stable isotope labeled thiocholine enabled the quantitation of 
iii 
 
protein phosphorylation with high precision by ratiometric comparisons. The utility of 
this approach was demonstrated in an intact cell system through identification of the 
endogenous phosphorylation sites in iPLA2β during heterologous expression in Sf-9 cells. 
A total of 12 unique phosphopeptides and 19 phosphorylation sites were identified with 
the developed strategy whereas the conventional approach identified only five peptides 
and six phosphorylation sites. Lastly, the BEMA strategy was applied to in vivo tissue 
system for the quantitative analysis of the murine myocardial mitochondrial 
phosphoproteome following cardiac ischemia. A total of 36 phosphopeptides from 35 
mitochondrial proteins with 50 phosphosites (37 of which were previously unknown), 
were identified. 
      Collectively, we have demonstrated β-elimination of phosphate and subsequent 
Michael addition (BEMA) with natural abundance and stable isotope labeled thiocholine 
is an effective strategy for in vivo quantitative phosphoproteomics of both cell-based and 
tissue-based systems.  
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CHAPTER   1 
 
 
INTRODUCTION 
 
 
      Posttranslational modifications (PTMs) of proteins are covalent transformations of 
terminal residues or side chains of the polypeptide backbone that occur after protein 
synthesis from mRNA, encoding each protein’s primary sequence [1]. The chemical 
repertoire of protein functional diversity is greatly expanded through the addition of 
specific functional groups (e.g., phosphorylation, acetylation, glycosylation) that confer 
novel chemical properties to the primary amino acid sequence encoded by the mRNA 
transcribed from DNA. These PTMs serve multiple functions to facilitate 
enzyme-substrate recognition, catalytic efficiency, and the subcellular localization of the 
protein and the cadre of associated proteins that allow adaptive responses to cellular 
perturbations [2-5]. Currently, more than 200 different PTMs have been discovered located 
at tens of thousands of individual sites; they greatly expand the chemical diversity encoded 
by each organism’s genomic structure [6].  
      Protein phosphorylation is the addition of a phosphate group to the side chain of an 
amino acid residue through esterification. This process is catalyzed by a class of enzyme, 
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called protein kinases. Phosphorylation is typically a reversible post translational 
modification because cells contain numerous phosphatases that can reversibly remove the 
phosphate moiety [7]. Collectively, the reversible cycle of phosphorylation and 
dephosphorylation is a central determinant of cellular metabolic flux through exploiting 
the differential catalytic or regulatory properties of the modified entity. Phosphorylation 
has historically been considered to be the most ubiquitous and important post translational 
modification of proteins; phosphorylation facilitates multiple changes in cellular 
regulation and signaling thereby promoting key chemical alterations that lead to effective 
adaptive regulation. In the human genome, about 2% of the encoded proteins are dedicated 
to maintaining the appropriate phosphorylation state of targeted proteins through the 
actions of a wide array of protein kinases and phosphatases [8-9]. Moreover, 
approximately 30% of all known proteins in cells are rapidly and reversibly 
phosphorylated to various extents during pathophysiologic perturbations to facilitate 
cellular adaptation [10-12].  
      Although phosphorylation has been demonstrated to occur on the hydroxyl group of 
serine, threonine, tyrosine, the carboxylic moiety of aspartic acid and glutamic acid [13]; 
the thiol group of cystine [14] or on basic amino acid residues such as arginine, lysine and 
histidine [15-16]; reversible phosphorylations on serine, threonine and tyrosine residues 
are of the greatest importance and collectively account for almost 99% of the protein 
phosphorylation in eukaryotic cells [17]. Variations in the phosphorylation state of proteins, 
often accompanied by changes in their tertiary structures, lead to alterations in their 
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enzymatic activities and provide essential clues to the molecular mechanisms mediating 
cellular activation after receptor stimulation or cellular adaptations reflecting fluctuations 
in the nutritional state, cellular environment and metabolic history of the cell [18]. The 
reversible covalent phosphorylation of cellular proteins is widely believed to be the most 
important mechanism for the regulation of multiple signal transduction pathways in cell 
growth, division, and death by acting as a molecular on/off switch at multiple nodes in 
metabolic networks [19-21].  
      Therefore, comprehensive protein-phosphorylation studies that identify the 
phosphosites and the level of phosphorylation have been conducted, leading to the growth 
of a new field termed “Phosphoproteomics”. More specifically, the total chemical 
characterization of phosphoproteins includes the detection, identification and quantitation 
of component phosphopeptides as well as the localization of the exact residues that are 
phosphorylated and the patterns of phosphorylation that are manifest in each protein. 
      Historically, labeling of proteins with radioactive phosphate (32P) has typically been 
recognized as one of the “gold standards” for the detection of phosphorylated proteins and 
the identification of changes in protein phosphorylation. In this approach, 32P is introduced 
into phosphoproteins to enable detection usually by scintillation counting or 
autoradiography. This technique was first introduced by Rall and Sutherland in 1956 [22]. 
There are generally two categories of 32P radiolabeling: in vivo (within the living) and in 
vitro (within the glass) involving different approaches. In living systems, the 32P labeled 
orthophosphate is transported across cells and converted into [γ-32P]-ATP that serves as the 
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phosphate donor. The radioactive 32P orthophosphate can be delivered either in cell culture 
experiments (by inclusion into the media), through perfusion in isolated organ systems or 
by introduction into live animals, and by other more specialized methods. Next, 
radiolabeled phosphates are transferred to amino acid targets (typically hydroxyl) by 
various endogenous protein kinases [23-24]. In contrast, in vitro systems require 
[γ-32P]-ATP and the addition of exogenous protein kinases that are suitable for substrate 
protein or peptides contained in the target systems [25]. In both cases, 32P labeled proteins 
are typically separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) according to their electrophoretic mobilities, which are a function of their 
respective molecular weights. Traditionally these radiolabeled phosphoproteins are fixed 
in the gel prior to detection by autoradiography. Comparative quantitation of protein 
phosphorylation is achievable through the ratiometric comparisons of protein mass and 32P 
radioactivity as revealed by Cerenkov radioactivity counting of excised bands [26].  
      Radiolabeling is a very sensitive method in terms of the detection of phosphoproteins. 
There are, however, several disadvantages associated with it. First, large amounts of 32P are 
required to detect the phosphorylation of low abundance proteins owing to isotopic 
dilution from endogenous unlabelled ATPs; second, the success of labeling depends on the 
relative rate of phosphorylation and dephosphorylation as well as the incubation time; third, 
phosphosite localization requires mutagenesis, currently making it extremely difficult for 
phosphosite determination in individual proteins and rendering the large scale high 
throughput analysis of the phosphoproteome through this approach an intractable problem  
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[17, 27].  
      Fluorescence labeling is a sensitive nonradioactive alternative to 32P radiolabeling 
with a detection limit at the nanogram level [28]. The fluorophore, which is a functional 
group that can absorb energy of a specific wavelength (absorption spectrum) and re-emit 
the energy at a different but specific wavelength (emission spectrum) to identify a molecule 
of interest that is either covalently [29] or non-covalently [30] introduced into  
phosphoproteins. Fluorescence labeling has been traditionally coupled with SDS-PAGE 
where proteins are separated, stained, detected and quantitated with fluorescence 
spectroscopy [31]. 
      Phosphoproteins can also be detected by using immunoblotting methods [32], which 
employ high-quality antibodies derived specifically for phosphorylated serine, threonine 
and tyrosine residues. This technique will be discussed later in the enrichment of 
phosphopeptides.  
  The strategies discussed above only provide an indication of the presence of 
phosphoproteins and not information on the specific location or the extent of 
phosphorylation of specific residues at each phosphosite. In early studies, Edman 
degradation was the classic technique to locate the site of the phosphorylated amino acid 
residues and could yield semi-quantitative results when coupled with HPLC. This 
technique of stepwise degradation was first introduced by Pehr Edman in 1950 [33] who 
demonstrated that phenyl thiohydantoins (PTH) derived from amino acid could be used to 
cleave sequentially amino acids from the N-terminus of a protein or peptide. The strategy 
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was later named “Edman Degradation”, in his honor, and was used for decades to sequence 
proteins and peptides. Under the mild alkaline conditions of this method, the N-terminus of 
a peptide chain reacts with phenyl isothiocyanate (PITC) to form a phenylthiocarbamyl 
(PTC) derivative. Next, the first peptide bond from the N-terminus is cleaved under acidic 
conditions to give rise to a thiazolinone amino acid derivative. This thiazolinone derivative 
is isolated and transformed into the more stable isomer 3-phenyl-2-thiohydantoin 
(PTH)-amino acid derivative, which can be identified and quantitated by HPLC through 
comparing its elution profile with that of the standard PTH-amino acid derivative. The 
shortened peptide subsequently undergoes additional cycles of this series of reactions. 
Thus, by the identification of each individual PTH-amino acid derivative, the sequence of 
the peptide is established from the N-terminus. Further, phosphorylated serines, threonines 
and tyrosines can be located within the peptides.  
      Even under favorable conditions, Edman degradation can sequence a polypeptide 
chain that contains only 30 to 50 amino acids owing to the deteriorating overall yield after 
each cycle of reactions. Thus, useful information typically can only be obtained for only 
15-20 residues [34]. It also requires pure peptides or proteins for unambiguous localization 
of each amino acid. Other limitations include modest sensitivity at the picomole level and 
time-consuming reaction and analysis processes [17]. Although automation is achievable 
through the development of automatic sequenators [35], many N-termini of proteins are 
blocked, precluding Edman degradation of these residues.   
      Unlike the techniques mentioned above, mass spectrometry (MS) is a 
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multi-dimensional technique that is extremely sensitive, amenable to high-throughput 
analyses, and can integrate protein phosphorylation detection, localization and quantitation 
in a single experiment. Accordingly, mass spectrometry has become the state-of-the-art 
technology for global phosphoproteomics in large part owing to the rapid advances in the 
development of instrumentation, bioinformatics platforms, and application paradigms that 
have revolutionized the field of MS during the past decade.  
      For MS studies, typically three major steps are employed in the analysis of a sample: 
1) The generation of the ions in the ion source; 2) The selection and separation of the ions 
in the mass analyzer; 3) The detection and visualization of the ions by the ion detector that 
is coupled with data acquisition and analysis programs.  
      In the ion source, energy is transferred to the sample molecules, facilitating the 
molecules to escape from its original phase, either liquid or solid, into the gas phase. 
Neutral sample molecules are turned into charged ions through different mechanisms, such 
as protonation/deprotonation, electron rejection/capture or adduct formation, usually 
involving gas-phase reactions during the ionization process. Ion sources fall into two main 
categories, liquid-phase sources and solid-phase sources, based on the different phases of 
the samples and their surrounding matrices.       
      Traditional ion sources include Electron Ionization (EI) [36-37], Chemical 
Ionization (CI) [38], Fast Atom/Ion Bombardment (FAB) [39], Secondary Ion Mass 
Spectrometry (SIMS) [40-41] and other derivatives of these processes.  However, these 
ion sources are not suitable for large biomolecules, such as proteins and peptides; because 
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either insufficient energy is provided for sample vaporization or sublimation, or excessive 
amounts of energy are applied that often result in extensive fragmentation and the loss of 
information from the intact analytes of interest. The development of Electrospray 
Ionization (ESI) [42] and Matrix-assisted Laser Desorption Ionization (MALDI) [43] has 
revolutionized the analysis of a wide variety of molecules, which has been recognized 
through the award of Nobel Prizes in Chemistry in 2002 to John Fenn and Koichi Tanaka. 
During electrospray, a strong electric field is applied to the solvent-containing analytes of 
interest; these are passed through a heated capillary and dispersed into gas phase to form a 
charged fine aerosol. The organic solvents, such as methanol, isopropanol and acetonitrile 
are quickly vaporized under inert gas, such as nitrogen, shrinking the sizes of droplets 
which in turn increases the droplet surface charge density and causes the droplets to divide 
owing to a stronger coulombic force than the cohesion force. Subsequently, the droplets go 
through shrinking cycles, and gas-phase ions are eventually formed either through 
desorption from the charged droplet surface [44] or until the droplet contains a single 
charged analyte molecule [45]. During the ionization process in MALDI, pulses of intense 
laser are shot onto a thin solid mixture of matrix molecules and analytes. These matrix 
molecules, such as alpha-cyano-4-hydroxycinnamic acid (α-CHCA), sinapic acid (SA) and 
2,5-dihydroxy benzoic acid (2,5-DHB),  strongly absorb laser wavelengths and transfer 
the energy absorbed from the laser shot to the analytes, causing the sublimation of matrix 
molecules and the formation of a matrix plume where analyte molecules are ionized 
through gas-phase proton transfer [46].    
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      After the ions are formed, they are transferred to the mass analyzer and separated 
according to their mass-to-charge ratio (m/z) through different schemes. A magnetic sector 
analyzer separates ions according to their respective momentums [47]; a quadruple 
analyzer determines m/z according to ion stability path [48]; kinetic energy is measured 
and differences are compensated by using an electrostatic sector analyzer [49]; a 
time-of-flight (TOF) analyzer measures ion flight time (i.e., velocity) [50]; whereas a 
quadruple ion trap [51], a Fourier transform-ion cyclotron resonance (FT-ICR) [52] and an 
Orbitrap analyzer  all rely on ion orbital frequencies and restoring potentials to determine 
m/z [53]. Different mass analyzers can be coupled together to form hybrid instruments that 
access the advantages of each individual analyzer, such as accurate mass analyses that are 
routinely performed today using time-of-flight (TOF), Fourier transform ion cyclotron 
(FT-ICR) and  Orbitrap mass analyzers.  
      Another important function of coupled or hybrid instrumentation is to perform 
tandem mass spectrometry (MS/MS, or MS2) on the ions of interest. The first step is to 
obtain the information regarding the ions of interest through scanning with one mass 
analyzer. Then an ion of interest (precursor ion) is selected by the first mass analyzer, 
fragmented through gas-phase collisions with air or other inert gases in the collision cell, 
which may also be a mass analyzer [54]. The fragment ions, or product ions, resulting from 
the collision are subsequently analyzed by a second mass analyzer to reveal the structural 
information of the analyte [55]. Ion trap analyzers are capable of performing tandem mass 
spectrometric analyses independently, in time rather than in space, but their mass accuracy 
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is limited especially by current technology [51]. 
      To achieve better sensitivity when analyzing complex samples, MS is often coupled 
with a separation technique, such as gas chromatography (GC) [56-57], high-performance 
liquid chromatography (HPLC) [58] or capillary electrophoresis (CE) [59-60]. The 
analytes are separated according to their different physical or chemical properties, and they 
are either directly introduced into the mass spectrometer for analysis (on-line) or collected 
and analyzed off-line.  
      Despite possessing advantages such as high sensitivity, high-throughput, high 
tolerance of sample impurity and the ability to carry out the detection, identification, 
localization and quantitation of phosphorylation sites simultaneously, mass spectrometric 
procedures for the analysis of protein phosphorylation still have considerable limitations 
owing to the intrinsic chemical properties of phosphorylated proteins. Peptides containing 
phosphorylated serine/threonine (pS/pT) residues rapidly undergo neutral loss of 
phosphoric acid (H3PO4) through cyclo-elimination occurring in low-energy 
collision-induced dissociation (CID); this reaction leads to loss of sequence coverage [61]. 
In addition, typical signaling proteins undergo reversible phosphorylation and are often 
present in extremely low abundance. Furthermore, protein phosphorylation patterns, which 
are of great biological significance, are heterogeneous and extremely difficult to determine. 
Phosphorylated peptides generally have poor ionization efficiencies in the positive ion 
mode due to the acidity of the phosphate group and ion suppression [17]. Therefore, 
various methods are available to improve the analysis of the phosphoproteome from 
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different perspectives.    
      Precursor-ion scanning utilizes the signature fragment ion of phosphate (PO3-, m/z = 
79) from phosphopeptides during CID in the negative-ion mode [62-63]. This scanning 
mode is highly effective for the identification of phosphopeptides. Nonetheless, the exact 
location of the phosphorylated residue cannot be determined in these studies using the 
negative-ion mode. Phosphosite localization usually requires a separate sample run under 
acidic conditions in the more sensitive positive-ion mode. Another scanning mode that 
takes advantage of the neutral loss of phosphoric acid is neutral-loss triggered in an MS3 
experiment with an ion trap mass analyzer [64-65]. As mentioned above, the neutral loss of 
H3PO4 will prevent the cleavage of the peptide bond in CID. However, data-dependent 
MS3 was employed to analyze further fragment ions that are 98 Da less than the precursor 
ions to reveal sequence information. Multistage activation utilizes a similar approach to 
induce the fragmentation of precursor ions and the target fragment ions resulting from the 
neutral loss of phosphoric acid in one single experiment [66-67]. This effectively combines 
product-ion spectra from MS2 and MS3 into a single spectrum. The actual utility of both 
neutral-loss triggered MS3 and multistage activation in large-scale phosphoproteome 
analysis is debatable compared to utilizing a high-mass accuracy instrument employing 
conventional strategies [68].  
      The above-mentioned neutral loss of H3PO4 is associated with commonly employed 
collision induced dissociation (CID). In CID, peptide fragmentation depends on the 
protonation of the peptide-bond nitrogen and an increase in vibrational energy that a 
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peptide gains through the collision with inert gas (e.g., helium, argon) that allows it to 
traverse the energy barrier required for the cleavage of a peptide bond. Thus, the 
fragmentation behavior of a peptide in CID depends on its specific sequence and the 
posttranslational modifications (PTMs) [61]. Other fragmentation methods can circumvent 
the unwanted neutral loss of phosphate; these include electron-capture dissociation (ECD) 
[69] and electron-transfer dissociation (ETD) [61]. In ECD, proteins and peptides that are 
bearing multiple positive charges from the protonation process during electrospray react 
with electrons in a Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer 
causing fragmentation of the peptide backbone in a series of radical-induced reactions that 
are independent of the nature of the amino acid residues, leaving the PTMs intact [70-71]. 
However, the utility of ECD is somewhat limited because that it can only be coupled with 
FT-ICR, which is more expensive to build and maintain than any other mass spectrometer 
since the storage of the electron requires static electric and magnetic fields [72]. On the 
other hand, in the recently developed method of ETD, an electron is transferred to a peptide 
through the gas-phase reaction between the peptide molecule and an anionic compound 
that serves as an electron carrier. The electron carrier usually has a very low 
electron-affinity; it is often an anion that can easily lose the extra electron; an example 
neutral is anthracene. Similar to ECD, ETD leads to the generation of c and z fragment ions 
instead of the b and y ions that form in CID, and the phosphate group on the amino acid 
residue remains intact [73-74]. ETD can be coupled with routine mass spectrometers such 
as quadruple ion trap and linear ion trap, expanding its utility in phosphoproteomics. 
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However, doubly charged peptides generally have poorer sequence coverage than do 
high-charge peptides in ETD because they undergo non-dissociative electron transfer [75] 
and, thus, must usually be coupled with traditional CID for improved results [76-77].  
      Because the abundance of phosphoproteins is low, efforts have been focused on the 
development of enrichment strategies. Immunoblotting is a very sensitive method for the 
detection of phosphoproteins as discussed earlier. Similarly, antibodies have been utilized 
to enrich phosphorylated proteins and peptides found in a complex mixture. Although 
antibodies are available specifically for phosphorylated serines, threonines and tyrosines 
[78-80], those for phosphorylated serines and threonines are less effective than those for 
phosphorylated tyrosines. Numerous studies on phosphorylated tyrosine residues involved 
in signal transduction pathways show, through enrichment by immunoprecipitation and 
subsequent analysis, improved signal to noise ratio. [81-82].  
      Immobilized metal affinity chromatography (IMAC) is used to enrich 
phosphopeptides based on the affinity interaction between the phosphate group and metal 
ions (e.g., Fe3+, Ga3+) that are immobilized on a stationary phase [83-84]. For improved 
selectivity of IMAC, methyl esterification was adapted to reduce the undesirable binding 
of acidic/electron rich residues [85]. However, the identification of phosphopeptides is 
complicated by incomplete and or nonspecific methyl esterification [86]. Other enrichment 
strategies, such as utilizing titanium dioxide (TiO2) [87] and zirconium dioxide (ZrO2) [88] 
have shown better specificity towards phosphopeptides. Titanium dioxide is the most 
commonly employed enrichment resin. This strategy is based on the affinity between the 
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phosphate group and titanium dioxide through formation of a bridging bidentate surface 
complex [89]. It can be used offline in the form of a micro-column [86], or coupled with 
traditional HPLC columns in an online multidimensional liquid chromatography setting 
[90]. Strong cation exchange chromatography (SCX) is another widely used enrichment 
method that does not have specificity for phosphopeptides compared to other enrichment 
strategies but can considerably reduce sample complexity. The reduction in sample 
complexity results from the early elution of phosphorylated peptides owing to their low 
charge state in acidic conditions. The majority of the tryptic peptides are doubly (+2) or 
triply (+3) charged under these conditions and, thus, elute later than their phosphopeptide 
counterparts. Strong cation exchange chromatography is usually utilized in tandem with 
other enrichment or separation techniques, such as TiO2 or reverse-phase (RP) 
chromatography either offline [91] or online [92].    
      Because phosphorylated tyrosines comprise only approximately 0.1% of the total 
phosphorylation present in proteins and can be effectively enriched through 
immunoprecipitation with commercially available antibodies as mentioned above, focus 
has been centered on improved strategies for analysis of phosphorylated serines (~90%) 
and threonines (~10%). Chemically replacing the phosphate on serine or threonine with 
other functional groups via alkaline induced β-elimination and subsequent Michael 
Addition (BEMA) is one such approach that was first introduced by Myers et al in 1986 
[93]. Phosphorylated tyrosines are stable under alkaline conditions becuase the β-proton is 
on the benzene moiety and is not readily eliminated [27]. The major limitation of this 
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strategy is the non-specific β-elimination reaction that occurs on other residues besides 
phosphorylated serine and threonine. Residues such as alkylated cysteines, O-glycosylated 
serines and threonines as well as non-phosphorylated serines and threonines undergo 
β-elimination and generate the same product residues of dehydroalanine or 
β-methyldehydroalanine as phosphoserine and phosphothreonine, respectively, and, 
therefore, non-specific loss cannot be differentiated from a genuine phosphosite [94]. This 
was solved by the introduction of catalytic specificity through the use of a bivalent metal 
hydroxide. More specifically, through employing barium hydroxide (Ba(OH)2) as the 
catalyst for the β-elimination of the phosphate group, β-elimination of alkylated cysteines 
or O-glycosylated serines and threonines occur two orders of magnitude more slowly than 
β-elimination from pS/pT and  non-phosphorylated serine and threonine residues are 
unaffected [95].   
      The BEMA strategy not only eliminates the unfavorable neutral loss of H3PO4 but 
also increases the ionization ability of the phosphorylated peptides by removing the acidic 
phosphoric acid side chain. Furthermore, various functional groups can be incorporated 
into the phosphopeptides to act as molecular handles to achieve different goals. Affinity 
pairs can be applied in the BEMA reaction, in which one is attached to the side chain (e.g. 
biotin) while the other serves as stationary phase for the enrichment, such as avidin [96]. 
Alternatively, a perfluorinated tag and fluorous solid phase extraction columns can be 
employed [97]. The functional group could also serve as a resource for characteristic 
fragment ions in tandem mass spectrometry analysis, such as using 
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2-dimethylamino-ethanethiol as the Michael donor followed by hydrogen peroxide 
oxidation to generate a thioester ethanesulfoxide derivative that generates a characteristic 
fragment ion in the low-energy CID mode [98]. The utilization of cysteamine as the 
nucleophile in BEMA can even convert the formally phosphorylated peptides into a 
substrate of trypsin so that phosphorylation information is obtained at the time of 
enzymatic proteolysis [99]. The utility of the BEMA strategy is further extended through 
stable isotope labeled Michael donors, which together with their natural abundance 
counterparts, enable comparative quantitative phosphoproteome analysis [100-102].  
      Stable isotope labeling with amino acids in cell culture (SILAC) is a common 
strategy for comparative quantitative phosphoproteomics [103-105]. SILAC utilizes cells 
grown in separate media conditions to label cellular proteins with light (natural abundance) 
and heavy (isotope labeled) amino acids. Then the proteins from two different cell culture 
conditions are mixed together at a normalized total protein content, trypsinized, separated 
using HPLC and analyzed by mass spectrometry. The same phosphopeptides labeled with 
light and heavy amino acids will elute from the HPLC column at the same time, and their 
peak intensity ratio indicates the different extents of phosphorylation of this peptide in two 
different cell states. Thus, the quantitation information is obtained at the molecular ion 
level. However, the obvious limitation of SILAC is that it cannot be used to conduct 
quantitative phosphoproteome analysis in tissue samples; these analyses are more likely to 
reveal the biological significance of changes in protein phosphorylation in living animals.  
      Isobaric tags for relative and absolute quantitation (iTRAQ) is also a useful labeling 
 
17 
 
technique for multiplexed quantitative phosphoproteomics [106-107]. Peptides digested 
from the proteins of up to four different biological states are modified with different 
isobaric tags at their N-termini. The same phosphopeptides from different states are 
indistinguishable from one another in a molecular ion scan because they possess the same 
m/z. However, during the tandem mass spectrometric analysis, the isobaric tags can 
produce different reporter fragment ions in the low-mass region (m/z = 114-117). Therefore, 
by comparing the relative abundances of the reporter ions, the phosphorylation change of 
this peptide is revealed. iTRAQ can be used in the analysis of tissue samples because the 
modifications are at peptide level. However, given that the quantitation is achieved at the 
MS2 level, the sensitivity of this strategy is limited and could lead to large run-to-run 
deviations and, thus, poor reproducibility.  
      With the insight to develop a BEMA based technology with a molecular handle that 
possesses strong nucleophilicity, the ability to increase peptide ionization efficiency and a 
unique structure that would produce characteristic fragment in tandem mass spectrometric 
analysis, we demonstrate in the first part of this thesis, the development of a novel strategy 
employing the unique chemical properties of the quaternary amine present in thiocholine 
(2-mercapto-N,N,N-trimethyl-ethanaminium) in conjunction with alkaline β-elimination 
and Michael addition (BEMA) reactions for the specific detection, identification and 
quantitation of phosphorylated serine/threonine-containing peptides. Through replacement 
of the phosphate with thiocholine, the negative charge on the phosphopeptide is switched 
to a quaternary amine containing a permanent positive charge (Scheme 1.1). This strategy 
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results in a markedly increased ionization sensitivity during ESI (with a sub-500 amol/µL 
detection limit) accompanied by the enhanced production of informative peptidic fragment 
ions during CID that affords increased sequence coverage. Moreover, the definitive 
localization of phosphorylated residues is greatly facilitated through the generation of 
diagnostic triads of fragmentation ions resulting from peptide bond cleavage and further 
neutral loss of either trimethylamine (-59 Da) or thiocholine thiolate (-119Da) during CID 
in MS2 and MS3 experiments (Scheme 1.2). Synthesis of stable isotope labeled thiocholine 
enabled the quantitation of protein phosphorylation with high precision using ratiometric 
comparisons of heavy and light thiocholine (Scheme 1.3).  
      The second part of this thesis describes the application of the developed BEMA 
strategy for the identification of endogenous phosphorylation sites of the hexahistidine 
tagged calcium-independent phospholipase A2β (iPLA2β) heterologously expressed in Sf9 
cells. In parallel, traditional direct analysis of phosphopeptides with data-dependent 
acquisition MS2 and neutral loss of phosphoric acid triggered MS3 was also used to analyze 
iPLA2β phosphorylation. The two methods were compared and evaluated to show that the 
BEMA strategy was substantially more effective in the identification of phosphopeptides 
and localization of phosphosites with better ion scores as well as higher sequence coverage 
than the traditional direct analysis. 3-D structure modeling of the iPLA2β protein was also 
generated with I-TASSER [108-110] to reveal the spacial relations between the 
phosphorylated residues and the catalytic site of the enzyme. 
      The third part of this thesis identifies the quantitative alterations in the myocardial 
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mitochondrial phosphoproteome induced by cardiac ischemia was studied by using mass 
spectrometry with the developed strategy, β-elimination of phosphate and subsequent 
Michael addition (BEMA), with natural abundance thiocholine and stable isotope labeled 
thiocholine. In addition to increased ionization efficiency, sensitivity and improved 
identification through characteristic diagnostic triads in MS2 and MS3 levels enabled by 
BEMA strategy, a highly selective phosphopeptide enrichment technique using titanium 
dioxide resin (TiO2) was incorporated prior to the BEMA reactions to reduce sample 
complexity and improve reaction yields for phosphopeptides [87]. The MASCOT search 
engine was used to conduct all database searches [111]. The results generated by MASCOT 
were re-scored by Percolator [112-113], a program that utilizes a semi-supervised machine 
learning algorithm called support vector machine (SVM) to compare true and false 
positives, for improved phosphopeptides identification.  
      In this study, the phosphoproteome of mitochondria obtained from isolated 
Langendorff-perfused mouse hearts that underwent global ischemia was investigated. The 
comparative quantitation of phosphorylation changes as a result of ischemia was achieved 
by comparing the phosphopeptides modified by heavy thiocholine from mitochondria of 
ischemic hearts to those modified by light thiocholine from control hearts that were 
perfused normally. We identified 141 phosphopeptides from 133 unique proteins with 227 
phosphorylated sites from 6 independent biological replicates generated from 24 perfused 
mouse hearts (12 control-perfused, 12 global ischemic), including 36 phosphopeptides 
from 35 mitochondrial proteins with 50 phosphosites and 37 new mitochondrial 
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phosphosites that have not been reported previously. This study has demonstrated that 
β-elimination of phosphate and subsequent Michael addition (BEMA) using light and 
heavy thiocholine together with a TiO2 phosphopeptide enrichment method and a 
Percolator re-scoring algorithm represents a very effective mass-spectrometry based 
strategy for comparative quantitative phosphoproteome analysis of in vivo tissue-based 
systems.  
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Schemes  
 
Scheme 1.1 Chemical modification of phosphoserine and phosphothreonine containing 
peptides via β-elimination in the presence of Ba(OH)2 and Michael Addition with 
thiocholine as the Michael donor. 
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Scheme 1.2 Collision induced dissociation (CID) resulting in the neutral loss of either (A) 
trimethylamine (m = 59 Da) or (B) the thiocholine thiolate (m = 119 Da) from the 
thiocholine peptide adduct. 
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Scheme 1.3  
A. Synthesis of thiocholine through acidic hydrolysis of S-acetylthiocholine (72% yield). 
 
 
 
B. Synthesis of thiocholine-13C,d3. The thiol group of 2-(dimethylamino)ethanethiol was 
protected by thioesterification with acetic anhydride prior to the addition of methyl-13C,d3. 
The final product was obtained through acidic hydrolysis (50% yield). 
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CHAPTER 2 
 
 
Facile Identification and Quantitation of Protein Phosphorylation via β-Elimination 
and Michael Addition with Natural Abundance and Stable Isotope Labeled 
Thiocholine 
 
 
2.1 Abstract 
   
    Herein, we employ the unique chemical properties of the quaternary amine present 
in thiocholine (2-mercapto-N,N,N-trimethyl-ethanaminium) in conjunction with alkaline 
β-elimination and Michael addition (BEMA) reactions for the specific detection, 
identification and quantitation of phosphorylated serine/threonine-containing peptides. 
Through replacement of the phosphate with thiocholine, the negative charge on the 
phosphopeptide is switched to a quaternary amine containing a permanent positive charge. 
This strategy resulted in a marked increase in ionization sensitivity during ESI (sub-500 
amol/μL detection limit) accompanied by a markedly enhanced production of informative 
peptidic fragment ions during CID that dramatically increase sequence coverage. 
Moreover, the definitive localization of phosphorylated residues is greatly facilitated 
through the generation of diagnostic triads of fragmentation ions resulting from peptide 
bond cleavage and further neutral loss of either trimethylamine (-59 Da) or thiocholine 
thiolate (-119 Da) during CID in MS2 and MS3experiments. Synthesis of stable isotope 
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labeled thiocholine enabled the quantitation of protein phosphorylation with high 
precision by ratiometric comparisons using heavy and light thiocholine. Collectively, this 
study demonstrates a sensitive and efficient strategy for mapping of phosphopeptides by 
BEMA using thiocholine through the production of a diagnostic repertoire of unique 
fragment ions during LC-MS2/MS3 analyses, facilitating phosphosite identification and 
quantitative phosphoproteomics. 
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2.2 Introduction  
 
      In the human genome, about 2% of the encoded proteins are dedicated to 
maintaining the appropriate phosphorylation state of targeted proteins through the actions 
of a wide variety of protein kinases and phosphatases [1-2]. Moreover, approximately 30% 
of all known proteins in cells are rapidly and reversibly phosphorylated to various extents 
during physiologic or pathophysiologic processes, making phosphorylation one of the 
most common post-translational modifications (PTMs) of proteins [3]. Although 
phosphorylation can occur on many amino acid residues (e.g., aspartic acid, glutamic acid, 
arginine and etc), reversible phosphorylations of serine, threonine and tyrosine 
collectively account for almost 99% of the protein phosphorylation in cells. The 
reversible covalent phosphorylation of cellular proteins is widely believed to be the most 
important mechanism for the regulation of multiple signal transduction pathways [4-6].  
      The intrinsic chemical properties of phosphorylated peptides render the detection, 
identification of the phosphorylation sites, and quantitation of alterations in 
phosphorylation state a challenging problem in proteomics [7-8]. Peptides containing 
phosphorylated serine/threonine (pS/pT) rapidly undergo neutral loss of phosphoric acid 
through cyclo-elimination during low-energy CID, and this leads to the loss of peptide 
sequence coverage. Typical signaling proteins are present in extremely low abundance. 
While the phosphorylation patterns of these signaling proteins are of great biological 
significance; they are highly diversified and oftentimes extremely difficult to determine 
owing to the presence of multiple S or T residues. Moreover, phosphorylated peptides 
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generally have poor ionization efficiencies in the positive-ion mode owing to the acidity 
of the phosphate group and ion suppression [9-12]. 
      Complementary approaches have been developed to overcome these difficulties. 
Enrichment using immobilized metal affinity chromatography (IMAC) after esterification 
of carboxylates has been useful in many cases [13-15]. However, identification of 
phosphopeptides is complicated by polydispersity generated by potentially incomplete 
and nonspecific methyl esterification [16]. Other enrichment strategies, such as use of 
titanium dioxide [17-18] and zirconium dioxide [19] have shown great efficiency, but 
these approaches are still hindered by the intrinsic chemical properties of the phosphate 
moiety that facilitates its neutral loss. The utility of electron transfer dissociation (ETD) 
in phosphopeptide analysis is becoming increasingly appreciated [12]. ETD generates c- 
and z-type ions in which the neutral loss of H3PO4 does not occur [20-21].  
      Finally, phosphorylated tyrosine comprises only about 0.1% of the total 
phosphorylation in proteins, and its enrichment and analysis can be effectively achieved 
through immunoprecipitation with high quality commercially available antibodies 
[22-23]. Accordingly, analytic efforts have focused on identification and quantitation of 
phosphorylated serine (~90%) and threonine (~10%) residues that account for the 
overwhelming majority of phosphorylation in cells. Chemical replacement of the 
phosphate on serine or threonine with other functional groups by β-elimination and 
subsequent Michael addition (BEMA) was first introduced by Meyers et al. in 1986 [24]. 
Since then, this strategy has been widely studied and applied effectively with different 
Michael donors in the enrichment, identification, quantitation of peptides containing 
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phosphoserine and phosphothreonine [25-27]. In prior work, Steen et al. demonstrated 
the efficacy of 2-dimethylamino-ethanethiol followed by hydrogen peroxide oxidation to 
generate thioester ethanesulfoxide derivatives that produced informative fragment ions 
during low-energy CID [28]. However, controlled oxidation with the generation of a 
single predominant reaction product is not straightforward. With cysteamine as the 
Michael donor, Knight et al. developed a strategy to cleave enzymatically proteins at 
their phosphorylation sites [29]. Although information on the phosphorylated proteins can 
be obtained through enzymatic proteolysis, lysine residues have to be quantitatively 
blocked through additional chemical reactions to ensure the exclusive cleavage at 
modification sites. During the development of our strategy, Li et al. used BEMA with 
several nucleophiles including thiocholine for the detection of phosphopeptides by 
Raman spectroscopy and mass spectrometry. However, prior mass spectrometric analyses 
were limited to detection of molecular ions in full MS scans without exploring the unique 
advantages of this strategy for covalent identification of specific phosphorylation sites 
through the enhanced generation of informative fragment ions in either the MS2 or MS3 
modes [30]. 
      In this study, we report a novel strategy for specific detection, identification and 
quantitation of pS/pT-containing peptides. Thiocholine is introduced into the peptide at 
the phosphorylation site via high-yield Ba2+ catalyzed β-elimination of phosphate and 
subsequent Michael addition (Scheme 1.1). Sample complexity is reduced through 
reductive alkylation of cysteines and development of optimized BEMA conditions for pS 
or pT individually. This charge-switch strategy with the thiocholine quaternary amine 
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results in a marked increase in ionization efficiency during ESI with detection levels in 
the sub 500 amol/μL range. The increased endogenous positive charge also engenders 
higher charge states of thiocholine-labeled tryptic peptides facilitating the production of 
peptidic fragment ions resulting in increased sequence coverage. Furthermore, 
phosphopeptide identification has been substantially improved by exploiting the facile 
neutral loss of trimethylamine (59 Da) and the thiocholine thiolate (119 Da) from the 
thiocholine adduct (Scheme 1.2). Thus, CID contains not only the b and y series of 
peptidic fragment ions but, in addition, a diagnostic array of fragment ions during MS2 
and MS3 analyses. Finally, through the synthesis and use of stable isotope labeled 
thiocholine, quantitative analysis of alterations in the phosphorylation state of proteins 
during cellular perturbations can be performed through ratiometric comparisons of 
phosphopeptides containing stable isotope labeled thiocholine to those containing natural 
abundance thiocholine. 
.  
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2.3 Materials and Methods 
 
Materials 
Phosphoprotein β-Casein and phosphopeptide FQpSEEQQQTEDELQDK were obtained 
from Sigma-Aldrich (St. Louis, MO), phosphopeptide DHTGFLpTEYVATR was 
obtained from BIOMOL (Plymouth Meeting, PA); POROS 20 R2 resin was purchased 
from ABI (Foster City, CA); Slide-A-Lyzer MINI Dialysis Unit, 7K MWCO was 
purchased from Pierce (Rockford, IL); Rapigest was purchased from Waters (Milford, 
MA); Protein Kinase A and trypsin were purchased from Promega (Madison, MI); 
α-cyano-4-hydroxycinnamic acid (α-CHCA) solution was obtained from Agilent (Santa 
Clara, CA). All solvents for mass spectrometric analyses were obtained from Honeywell 
Burdick&Jackson (Muskegon, MI). All other chemicals were obtained from 
Sigma-Aldrich (St. Louis, MO) 
 
Synthesis of Thiocholine Chloride and Thiocholine-13C,d3 Chloride 
Thiocholine chloride was prepared as previously described by Moss et al. with minor 
modifications [31]. Briefly, S-acetylthiocholine chloride, 1 g (5 mmol), was dissolved in 
10 mL of nitrogen-purged Millipore-purified water, followed by addition of 3.5 mL 
concentrated HCl to give a solution of 3 N HCl. The solution was heated to 80 °C under 
nitrogen for 30 min and HCl was evaporated from the solution while drying under 
vacuum. The dried product was then triturated with anhydrous diethyl ether (3~5 mL) 
and absolute ethanol (3~5 mL). Additional anhydrous ether was added to precipitate the 
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product (10 mL) which was filtered and re-crystallized using hot anhydrous ethanol and 
anhydrous diethyl ether (0.56g, 3.6 mmol).{ 1H NMR (D2O) δ 2.75-2.85 (m, 2H, CH2S), 
3.0 (s, 9H, N(CH3)3), 3.35-3.45 (m, 2H, CH2N)}(Appendix A).  
Thiocholine-13C,d3 chloride was prepared similarly to thiocholine chloride, except 
that the precursor S-acetylthiocholine-(N,13C,d3) was synthesized according to Ouyang et 
al. [32]. Briefly, 2.82 g (20 mmol) 2-(dimethylamino)ethanethiol hydrochloride and 2.82 
mL (30 mmol) acetic anhydride were mixed and refluxed for 10 min. The mixture was 
allowed to stand overnight and transferred to a mortar where the solid was triturated with 
ethyl ether (3-5 mL), the precipitate (2.9 g, 20 mmol)) was resuspended in 5 mL acetone 
and the pH was neutralized using NaHCO3. Next, 5 g (25 mmol) of iodomethane-13C,d3 
was added and incubated at room temperature under nitrogen for 48 h. Subsequently, 
thiocholine-13C,d3 chloride was obtained using the same hydrolysis method as that for the 
naturally occurring isotope described above (1.6 g, 10 mmol). {1H NMR (D2O) δ 
2.75-2.85 (m, 2H, CH2S), 2.97, 2.98 (d, 6H, N(CH3)2), 3.35-3.45 (m, 2H, 
CH2N)} )}(Appendix B).  
The free thiol concentrations of both light and heavy thiocholine were determined 
using Ellman’s assay [51]. Briefly, 40 mg 5,5‘-dithiobis(2-nitrobenzoic acid) (DTNB) 
was added in 0.1 M phosphate buffer (pH 8.0) 10 mL. 0.1 mL of this prepared solution 
(Ellman’s reagent) was mixed with 2 mL of 0.1 M phosphate buffer (pH 8.0) containing 
0.1 mg of EDTA in a cuvette. The absorbance of the resultant solution was measured at 
412 nm. Next 6 μL of light or heavy thiocholine chloride solution at the concentration of 
0.03mmol/5mL (by weight) was added directly to the same cuvette and was incubated at 
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room temperature for 15 min. The absorbance of the resultant solution was measured at 
412 nm. The concentration of free thiol in the cuvette was calculated using the equation 
ΔA (net change of absorbance) = ε412nm x CSH, where ε412nm = 13.6 cm-1 mM-1. The results 
indicated a 98% free thiol content in the prepared thiocholine samples. The overall 
reaction yield for light thiocholine was 72% and 50% for heavy thiocholine chloride.  
 
BEMA of Model Phosphopeptide FQpSEEQQQTEDELQDK with Thiocholine 
The phosphopeptide FQpSEEQQQTEDELQDK was modified via BEMA with 
thiocholine according to the method of Shokat et al. with minor modifications [29]. 
Lyophilized FQpSEEQQQTEDELQDK was suspended in water to make a 40 pmol/μL 
stock solution. 12.5 μL of this stock solution was mixed with 9.5 μL DMSO and 3 μL 
absolute ethanol followed by the addition of 12.5 μL of freshly prepared saturated 
Ba(OH)2. The reaction was incubated at room temperature under nitrogen for 1 h with 
gentle vortexing every 20 min. The final pH was 12~13. Next, 25 μL of 1 M thiocholine 
solution freshly prepared in water was directly added to the reaction. The reaction 
mixture was incubated at room temperature under nitrogen for 3 h at pH 8~9 and then 
terminated by the addition of 5 μL of 10% TFA. 
 
BEMA of Model Phosphopeptide DHTGFLpTEYVATR with Thiocholine 
Lyophilized DHTGFLpTEYVATR was suspended in water to make a 40 pmol/μL stock 
solution. 12.5 μL of this peptide stock solution was mixed with 9.5 μL DMSO and 3 μL 
absolute ethanol followed by the addition of 12.5 μL freshly prepared saturated Ba(OH)2. 
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The reaction was incubated at room temperature under nitrogen for 3 h with gentle 
vortexing every 20 min. The final pH was 12~13. Next, the β-elimination reaction was 
terminated by addition of 5 μL of 10% TFA and the resulting solution was desalted with a 
POROS 20 R2 micro column. The purified peptide solution was dried and reconstituted 
in 50 μL of 0.5 M thiocholine solution freshly prepared in 0.1 M NaOH. The mixture was 
incubated at 50 C° under nitrogen for 5 h at pH 8~9. The reaction was terminated by the 
addition of 5 μL 10% TFA. 
 
Phosphorylation of Calcium-independent Phospholipase A2β by Protein Kinase A  
Purified iPLA2β(His)6 was obtained as previously described by Jenkins et al. [33]. The 
catalytic subunit of protein kinase A (400U) was incubated with 100 μg of purified 
iPLA2β(His)6 in 40 mM Tris-HCl buffer, pH 7.4 containing 20 mM magnesium acetate 
and 0.3 mM ATP for 1 h at 30°C. The resultant phosphorylated enzyme was dialyzed 
against 1L deionized water for 8 h using a Slide-A-Lyzer® MINI Dialysis Unit. The 
dialyzed iPLA2β sample was dried in a SpeedVac apparatus (Savant, Holbrook, NY) and 
reconstituted in 50 μL of 0.2% Rapigest in 50 mM NH4HCO3. Next, 2.5 μL of 100 mM 
DTT was added to a final concentration of 5 mM. The sample was then incubated at 60°C 
for 30 min before 6 μL 150 mM iodoacetamide was added to quench the reduction and 
initiate alkylation. The sample was incubated for an additional 30 min in the dark. 
Trypsin was added to the solution at an enzyme to protein ratio of 1:30 (w:w). The total 
volume of the sample solution was adjusted to 100 μL with 50 mM NH4HCO3. 
500fmol/μL protein sample was incubated at 37 °C for 2 h then acidified with 10 μL 10% 
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TFA to lower the pH to < 2. The sample was again incubated at 37 °C for 30 min and 
centrifuged at 13,000 rpm to pellet the hydrolyzed Rapigest. The resultant supernatant 
was used for thiocholine modification. 
 
BEMA of Trypsinized Calcium-independent Phospholipase A2β with Thiocholine 
Trypsinized iPLA2β samples were dried in a SpeedVac apparatus and reconstituted in 50 
μL deionized water follow by the addition of 38 μL DMSO and 12 μL of absolute ethanol. 
The trypsinized protein solution was then divided into 2 equal aliquots of 50 μL that were 
separately modified with one of two protocols. 
Protocol I: 25 μL of saturated Ba(OH)2 was added to the sample and the reaction was 
incubated at room temperature under a nitrogen atmosphere for 1 h and gently vortexed 
every 20 min. The final pH of the reaction mixture was pH 12~13. 1M thiocholine was 
freshly prepared in water and 50 μL was directly added to each reaction. This reaction 
was incubated at room temperature for 3 h at pH 8-9 and then terminated by the addition 
of 10 μL 10% TFA. 
Protocol II: 25 μL of saturated Ba(OH)2 was added to the sample and the reaction was 
incubated at room temperature under a nitrogen atmosphere for 3 h and gently vortexed 
every 20 min. The final pH was 12-13. Next, the β-elimination was terminated by 
addition of 10 μL of 10% TFA and the resulting solution was desalted with a POROS 20 
R2 micro column. The purified peptide solution was dried and reconstituted in 50 μL of 
0.5 M thiocholine solution freshly prepared in 0.1 M NaOH. This reaction was incubated 
at 50C° under nitrogen for 5 h at pH 8-9. The reaction was terminated by the addition of 
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5 μL 10% TFA. 
 
Comparative Quantitation of Phosphoproteins using Natural Abundance Thiocholine 
and Thiocholine-13C,d3 with the Model Protein β-Casein 
50 μL 1 mg/mL β-Casein solution prepared in water was mixed with 50 μL 0.2% 
Rapigest in 100 mM NH4CO3. The protein sample was subjected to in-solution tryptic 
digestion as described above. The resulting trypsinized β-Casein was concentrated with a 
SpeedVac to ~50 μL and divided to 2 equal aliquots. Aliquot 1 was subject to BEMA with 
natural abundance thiocholine as the Michael donor while aliquot 2 was modified with 
stable isotope labeled thiocholine-13C,d3 both using Protocol I for iPLA2β covalent 
modification as described above. Modified trypsinized β-Casein in aliquots 1 and 2 were 
then mixed in selected ratios (v:v; aliquot 1: aliquot 2, or light: heavy): five independent 
replicates at 1:1 and three independent replicates at 1:2, 1:3, 1:4, 4:1, 3:1 and 2:1 ratios 
respectively were performed. Experimental ratios from mass spectrometric analyses were 
compared to expected ratios to evaluate the reproducibility and linearity of the method. 
 
Sample Purification 
All samples subject to mass spectrometric analysis were desalted with POROS 20 R2 
micro columns according to the procedure by Thingholm et al. [34]. Briefly, a POROS 20 
R2 micro column was assembled by stamping out a small plug of C8 material from a 3 M 
Empore C8 extraction disk using a HPLC syringe needle and placing this plug in the 
constricted end of a GELoader tip. Next, POROS R2 beads that were suspended 50% 
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acetonitrile at 5mg/200 µL were packed in the GELoader tip by pressing air through the 
micro column using an Eppendorf syringe. The length of the packed POROS R2 resin 
was about 3-6 mm. Then the column was washed with 30 µL 50% acetonitrile and 
equilibrated with 30 µL 0.1% trifluoroacetic acid. Sample solution was then loaded onto 
the POROS R2 micro column. The sample was slowly passed through the micro column 
by pressing air through the using a Eppendorf syringe. The column was washed twice 
with 30 µL 0.1% trifluoroacetic acid and the bounded peptides were eluted first using 30 
µL 70% acetonitrile with 0.05 % trifluoroacetic acid, then 5 µL 30% acetonitrile with 
0.05% trifluoroacetic acid. 
 
MALDI-TOF/TOF Mass Spectrometric Analyses 
MALDI-TOF/TOF mass spectrometric analyses were performed using a 4800 
MALDI-TOF/TOF Analyzer (Applied Biosystems, Foster City, CA). 1 μL of each peptide 
sample eluted from a POROS R2 micro column was mixed with 1μL α-CHCA solution 
and 0.5 μL of the mixture was spotted on an Opti-TOF 384 well plate. Mass spectra of all 
peptide samples were acquired in the positive ion mode by averaging 500 consecutive 
laser shots (50 shots per subspectrum with ten total subspectra) with default calibration. 
MS2 analyses of the peptide samples were accomplished by collision-induced 
dissociation (CID) using air at medium pressure.  
 
HPLC-ESI-MS2/MS3 Mass Spectrometric Analyses 
Trypsinized protein and peptide samples desalted with POROS 20 R2 micro columns 
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were dried and reconstituted in 0.1% formic acid before injection and separation using a 
Surveyor HPLC system (Autosampler and Pump, ThermoFisher, San Jose, CA) equipped 
with a reverse-phase C18 PepMap100 Nano-LC column (75 μm I.D. x 15 cm, 3 μm, 100 
angstrom; Dionex, Sunnyvale, CA). Flow rate was maintained at 220-280 nL/min. 
Samples eluting from the column were directed to the nanospray apparatus (i.e. 
NanoMate HD with LC coupler, Advion Bioscience Ltd., Ithaca, NY) and sprayed 
directly into an LTQ-Orbitrap mass spectrometer (ThermoFisher, San Jose, CA) at a 
spray voltage of 1.7 kV in the positive ion mode. Model peptides and trypsinized β-casein 
samples were eluted with a gradient from 100% A to 50% A, 50% B in 20 min (Buffer A: 
90% water, 10% acetonitrile, 0.1% formic acid; Buffer B: 10% water, 90% acetonitrile, 
0.1% formic acid, v:v) and were subject to data-dependent MS2 analyses: full mass scans 
were acquired using an Orbitrap (300-1600 m/z, mass resolution = 30,000) followed by 
product-ion scans in the LTQ of the five most abundant ions. iPLA2β samples, modified 
by the two optimized protocols, were analyzed first in survey runs, which consisted of a 
90-min gradient from 100% A to 50% A, 50% B and data-dependent MS2 analyses: full 
mass scans in the Orbitrap (300-1600 m/z, mass resolution = 30,000) were followed by 
product-ion scans in the LTQ of the five most abundant ions. The ions of interest from the 
survey runs were then included in the parent mass list of the target runs. The target runs 
consisted of a 180-min gradient from 100% A to 75% A, 25% B (120 min), then to 50% 
A, 50% B (60 min) and data-dependent MS2/MS3 analyses: full mass scan in the Orbitrap 
(300-1600 m/z, mass resolution = 30,000) were followed by product-ion scans in the LTQ 
of the three most abundant ions from the parent mass list and the MS3 scans in the LTQ 
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of the ten most abundant fragment ions following each of the three product-ion scans. 
The normalized collision energy for CID was set at 25 for all data-dependent scans.  
 
Data Processing 
The local MASCOT server was used to conduct all database searches. A single-protein 
(iPLA2β) database was created by in silico trypsinolysis. Thiocholine and 
thiocholine-13C,d3 with neutral loss trimethylamine and thiolate were integrated into 
MASCOT for customized processing of the designed covalent modifications for serine 
and threonine residues at the MS2 level. Carbamidomethylation (C) was set as the fixed 
modification for trypsinized iPLA2β samples.  
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2.4 Results and Discussion 
 
      The chemical replacement of the phosphate on serine and threonine residues via 
β-elimination and Michael addition has been widely used for analyses of 
phosphopeptides. However, an efficient method that concomitantly yields high sensitivity, 
minimal side reactions and informative diagnostic ions suitable for quantitative analyses 
of both pS and pT-containing peptides in the phosphoproteome has remained elusive. 
Thiocholine was chosen as the Michael donor in this study because of the extraordinary 
sensitivity of the quaternary amine for ionization during ESI and its utility in creating 
diagnostic fragment ions resulting from the neutral loss of trimethylamine and the 
thiocholine thiolate. The syntheses of both thiocholine and stable isotope labeled 
thiocholine-13C,d3 are straightforward (Scheme 1.3). Model peptides containing either 
phosphoserine (FQpSEEQQQTEDELQDK) or phosphothreonine (DHTGFLpTEYVATR) 
were chosen to assure that reaction conditions were developed that facilitate assessment 
of either serine or threonine phosphorylation sites. For proteins, either the traditionally 
employed model protein β-Casein was used or phosphorylation of the signaling protein 
iPLA2β by protein kinase A (PKA) was studied.  
 
Optimization of BEMA Conditions and Ionization Efficiency 
      The overall reaction yield is an important factor for the success of the BEMA 
strategy. Given that the reaction rates of phosphorylated serine and threonine residues are 
quite different for either β-elimination or Michael addition owing to the electron-donating 
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effect of the β-methyl group of threonine residue (Appendix C), the reaction conditions 
were optimized for phosphorylated serines and threonines individually by using the 
model phosphopeptides FQpSEEQQQTEDELQDK and DHTGFLpTEYVATR. Through 
the use of Ba(OH)2, a controlled high-yield conversion of FQpSEEQQQTEDELQDK to 
its corresponding dehydro-alanine derivative was accomplished within 40 min (Figure 
2.1). The addition of thiocholine then resulted in the rapid (< 60 min) synthesis of the 
desired thiocholine adduct. Based upon integrated UV absorbance, these sequential 
transformations were accomplished in near quantitative yield (Figure 2.1). To ensure the 
completeness of the reaction for more complicated samples, the reaction times were set at 
1 h and 3 h for β-elimination and Michael addition, respectively.  
      The mass spectrometric utility of this covalent conversion was demonstrated by a 
marked increase in ionization efficiency with ESI illustrated by the total ion current 
tracing obtained during reversed-phase chromatography after injection of identical 
amounts of the thiocholine-modified peptide and its non-modified phosphopeptide 
precursor. This remarkable increase in ionization efficiency is engendered by the 
replacement of acidic phosphate with quaternary amine bearing thiocholine that possesses 
an endogenous positive charge and is extraordinarily sensitive to ionization during the 
electrospray process (Figure 2.2-A). The detection limit of this method using ESI is at the 
attomole level (Figure 2.3). Using MALDI, a 3-fold increase in MS signal was present 
after derivatization as demonstrated by analysis of a sample containing equal amounts of 
phosphopeptide and thiocholine-modified phosphopeptide onto a MALDI plate using 
α-CHCA as matrix (Figure 2.2-B). 
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      Phosphorylated threonines, possessing secondary hydroxyls, generally have 
slower reaction rates during both β-elimination and Michael addition in comparison to 
their primary hydroxyl counterparts [35]. Simply increasing the incubation temperature 
and/or incubation time results in increased formation of side products and is not 
productive [11, 36-37]. However, by purification of the dehydro-alanine intermediate 
from β-elimination and through the use of nitrogen protection, the overall reaction yield 
for Michael addition using the model peptide, DHTGFLpTEYVATR, has been greatly 
improved (Figure 2.4-2.6). These modification strategies individualized for pS or pT 
residues greatly maximize the effectiveness of BEMA for phosphoproteomics. 
Phosphorylated tyrosines are stable and are not altered under the alkaline conditions 
employed in this study [35]. 
 
Fragmentation of Thiocholine-modified Peptides 
      In addition to dramatically increasing ionization efficiency in ESI-MS, 
thiocholine derivatization exhibits the unique ability to generate diagnostic triads of 
informative fragment ions resulting from both the routine peptide bond cleavage and the 
facile neutral loss of either trimethylamine (59 Da) or thiocholine thiolate (119 Da) 
during CID in MS2 and MS3 scanning. This results in a greatly improved identification 
algorithm for target peptides. A representative ESI-product-ion spectrum of the triply 
charged molecular ion of the thiocholine-modified peptide FQS*EEQQQTEDELQDK is 
shown in Figure 2.7-A. Analysis of the fragmentation pattern demonstrated multiple 
informative b and y ions necessary for sequence identification. As shown in the expanded 
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spectrum, a representative peptidic fragment ion b5+ (m/z = 722.3) is accompanied by its 
neutral loss counterparts b5 - 59+ (m/z = 663.2) and b5 - 119+ (m/z = 603.2) after loss of 
trimethylamine or thiocholine thiolate, respectively (nomenclature of peptide fragment 
ions is presented in Appendix D). The concurrence of these diagnostic triads of fragment 
ions obtained through conventional CID represent key informative features that can 
further facilitate the identification of peptides and increase the confidence of assignment 
of the phosphorylated residue(s) on peptides containing multiple potential 
phosphorylation sites.. Furthermore, use of MS3 for the thiocholine-containing ion y14+2 
(m/z = 904.4) demonstrated that neutral loss of trimethylamine is the dominant 
fragmentation pathway leading to a signature neutral loss product at m/z 875.1 (M - 59) 
(Figure 2.7-B). Thus, introduction of the thiocholine side chain and subsequent 
fragmentation resulted in the generation of suites of diagnostic triads of fragment ions in 
both MS2 and MS3 experiments that helped not only to enhance sequence coverage, but 
also to increase the confidence of the phosphopeptide identification and the specific 
location of the modified residue. Tandem mass spectrometric analyses of 
FQS*EEQQQTEDELQDK were also conducted on the singly charged molecular ion 
with MALDI and the doubly charged molecular ion with ESI. In MALDI experiments, 
the product-ion spectrum of the molecular ion at m/z 2082.62 (+) contains a dominant 
signature ion at m/z 2023.7 (+) (Figure 2.7-C). This ion resulted from the neutral loss of 
trimethylamine (59 Da) from the thiocholine side chain of the molecular ion with 
minimal sequence-informative b and y ions. The product-ion spectrum obtained with ESI 
of the doubly charged molecular ion showed a strong neutral loss peak from the 
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molecular ion at m/z 1012.5 (+2) (Figure 2.8). In MALDI, peptides are almost always 
singly charged [38]. With the low kinetic energy, singly charged thiocholine-containing 
peptides require higher collision energy to induce peptidic chain fragmentation relative to 
the neutral loss of trimethylamine. Therefore, the neutral loss is more prone to occur than 
the formation of b and y ions in low-energy CID, leading to a dominant neutral loss 
pattern. Similarly, in ESI, neutral loss represents a pathway that requires lower energy to 
induce fragmentation of the doubly charged parent ion. However, when the peptide is 
triply charged, with the higher vibrational energy derived from collisions at the increased 
kinetic energy gained during acceleration, peptide chain fragmentation becomes more 
favorable than the neutral loss of trimethylamine leading to the production of a sequence 
of informative b and y ions [39]. Although neutral loss of trimethylamine is no longer 
dominant in this case, it can still occur on thiocholine containing fragment ions, which 
together with the ions from neutral loss of thiocholine thiolate provides additional 
confirmatory sequence information and facilitates the assignment of phosphorylation 
sites. Moreover, as described above (Figure 2.7-B), neutral loss of trimethylamine 
becomes favorable again in MS3, producing a signature neutral loss (SNL) peak during 
CID, which adds an additional dimension to the identification of peptide phosphosites. 
Although the majority of the tryptic peptides are doubly charged using ESI owing to 
basic amino acid residues on both N- and C- termini using conventional trypsinolysis, the 
modified phosphopeptides typically possess a charge state of 3 or higher due to the 
additional positive charge introduced by thiocholine. Through combining tryptic 
proteolysis with thiocholine modification, the majority of the thiocholine-modified 
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peptides will be triply charged or higher, thereby leading to a rich repertoire of diagnostic 
triads of peptidic fragment ions and ions from neutral loss of trimethylamine and the 
thiocholine thiolate for significant improvement in the identification of phosphorylation 
sites during ESI-MS2 analyses. In addition, ions containing intact thiocholine side chains 
losing trimethylamine produce a signature neutral loss pattern in MS3, greatly improving 
the confidence of the identification of phosphopeptides and the localization of the 
phosphorylated residue(s) in peptides containing more than one potential phosphosite or 
in the elucidation of phosphorylation patterns in cases where multiple sites are 
phosphorylated.  
 
Identification of Protein Kinase A Phosphorylation Sites in Calcium-independent 
Phospholipase A2β (iPLA2β) 
      iPLA2β is an important phospholipase in cellular signaling that contributes to 
diverse cellular processes including arachidonic acid release, insulin secretion, calcium 
signaling, and apoptosis [33, 40-42]. We used the developed method to identify in vitro 
PKA phosphorylation sites of iPLA2β to demonstrate the application of this method in a 
biologically relevant system. Prior to BEMA modification, the potential interference from 
free thiols must be eliminated [43]. Previously, perfomic acid oxidation was widely used 
to oxidize cysteine residues directly or convert cysteine disulfide bonds to cysteic acid 
residues [44-45]. However, although harsh oxidation may convert all cysteines to cysteic 
acid, it also leads to additional oxidation and an undesirable increase the chemical 
diversity and complexity of the sample [46-47]. Other potentially susceptible moieties 
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include alkylated cysteines, either endogenous or introduced by reductive alkylation, as 
well as O-glycosylated serines and threonines. These residues could cause ambiguities 
similar to an intact cysteine because they could also be converted to the same modified 
residues as pS/pT under alkaline conditions in the presence of strong nucleophiles 
[48-49]. However, using Ba2+ as the catalyst coupled with well-controlled reaction 
conditions, β-elimination of alkylated cysteines or O-glycosylated serines and threonines 
occurs at rates two orders of magnitude more slowly than β-elimination from pS/pT 
whereas unphosphorylated serine and threonine residues are unaffected [35]. Under the 
conditions employed in this study, reductive alkylation does not interfere with BEMA 
targeting of phosphopeptides, and, thus, many side products and potential ambiguities are 
avoided. The identification of peptide CaNdVMGPS*GFPIHTAMK in iPLA2β contains 
both alkylated cysteine and thiocholine-modified serine residues showing the 
compatibility of the routine reductive alkylation with Ba2+ catalyzed BEMA (Figure 2.9).  
      The fragmentation patterns and sequence coverage of the trypsin-generated 
phosphopeptides that were identified in the PKA phosphorylated iPLA2β with and 
without thiocholine modification are demonstrated for the peptide SSGAAPTYFRPNGR 
(582-595). The product-ion spectrum of the phosphopeptide p(SS)GAAPTYFRPNdGR 
(Figure 2.10-B) exhibits a strong peak corresponding to the neutral loss of H3PO4 from 
the doubly charged molecular ion with key peptidic chain cleavage products y13 and b1 at 
the Ser-Ser peptide bond missing from the spectrum precluding discrimination of 
phosphorylation at residues Ser582 or Ser583.  In sharp contrast, the product-ion 
spectrum of SS*GAAPTYFRPNdGR (Figure 2.10-A) shows an abundant diagnostic y13+3 
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ion at m/z 499.4 as well as its satellite neutral loss ions (shown in the expanded spectrum), 
which led to the unambiguous assignment of phosphorylation at residue Ser583. In 
low-energy CID, phosphopeptides are prone to lose a neutral phosphoric acid to form a 
five-member oxazole ring, which is a preferred fragmentation pathway for 
phosphopeptides [12]. The five-member ring prevents peptide bond cleavage at the site of 
phosphorylation and informative b and y ions resulting from that particular bond cleavage 
are missing, thus preventing conclusive identification of the phosphorylation site(s) in 
many cases. Therefore, although a phosphopeptide is easily identified through its neutral 
loss of 98 Da, the site of phosphorylation is often difficult to determine precisely by 
conventional means. In summary, replacing the phosphate with thiocholine prevents the 
cyclo-elimination of phosphoric acid in CID owing to the increased charge state of 
modified peptides thus improving sequence coverage and facilitating the unambiguous 
identification of the specific phosphorylated residue. 
      As shown in Table 1, 32 different phosphorylation sites were identified in iPLA2β 
phosphorylated samples examined using the customized protocols optimized for either pS 
or pT. These phosphorylation sites originated from a total of 16 unique sequences. Figure 
2.11-A shows the product-ion spectrum of triply charged peptide EIS*VADYTSHER 
(26-37). The spectrum consists of b and y ions with diagnostic triads of all thiocholine 
containing peptidic fragment ions. Shown in the expanded spectrum are representative 
diagnostic triads from y10+2 and b6+ fragmentation ions resulting from peptide bond 
cleavage (m/z = 633.6 and 716.3) and further neutral loss of trimethylamine (-59 Da, m/z 
= 603.3 and 657.2) and the thiocholine thiolate (-119 Da, m/z = 574.1 and 597.2). The 
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characteristic neutral losses in MS2 level are incorporated into MASCOT to contribute to 
the identification of the peptide and location of the phosphorylation site(s).  
      A promising future prospect of this approach is the use of this chemical property 
in a weighted scoring system for ion identification that uses these unique and predictable 
diagnostic triads of fragmentation ions from thiocholine-modified peptides to facilitate 
identification of phosphorylated peptides and phosphosites in singly and multiply 
phosphorylated peptides. Among the ions generated in MS2 fragmentation, the ten most 
abundant ions were chosen to be further fragmented at the MS3 level. Examination of the 
y10+2 ion at m/z 633.6 (amongst the top ten ions selected) demonstrated that it also 
possesses the intact thiocholine side chain, which led to its signature neutral loss pattern 
in its MS3 spectrum (Figure 2.11-B). The ion peak at m/z 604.0 corresponds to the neutral 
loss of trimethylamine from the precursor y10+2 at m/z 633.6. From the example of the 
peptide EIS*VADYTSHER, it is clear that the thiocholine side chain enabled a unique 
tandem fragmentation pattern ideal for proteomic analyses, since sequencing of the 
peptide at the MS2 level is not disrupted by the neutral losses of either trimethylamine or 
thiocholine thiolate but rather strengthened by the presence of diagnostic triads of 
fragment ions in conjunction with the signature neutral loss at MS3 level. Collectively, 
these features serve to provide important structural information facilitating both the 
identification of the peptide as well as the location of the precursor ion to facilitate 
unambiguous identification of the phosphorylated residues. In the current study, nine out 
of 16 unique sequences demonstrated at least one ion with a signature neutral loss during 
MS3 scanning underscoring the utility of the developed method. Although neutral-loss 
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information has been incorporated in MASCOT as part of the variable modification of 
thiocholine, MS3 spectra with signature neutral loss patterns must be manually selected at 
the present time. 
 
Comparative Quantitation of Phosphoproteins using Natural Abundance Thiocholine 
and Thiocholine-13C,d3 with Model Protein β-Casein 
      Comparative quantitation via BEMA with thiocholine and thiocholine-13C,d3 was 
evaluated with the model phosphoprotein β-casein to determine the reproducibility and 
linearity of the developed method. As described in experimental procedures, two equal 
aliquots of trypsinized β-casein were modified with either thiocholine or 
thiocholine-13C,d3. The light and heavy  thiocholine containing peptides of β-casein 
were then mixed at different ratios (v:v) as follows;: five independent replicates at 1:1, 
three independent replicates at 1:2, 1:3, 1:4, 4:1, 3:1 and 2:1 respectively. The tryptic 
phosphopeptide FQpSEEQQQTEDELQDK was chosen to characterize the quantitation 
of the phosphorylation of β-casein. Thiocholine and thiocholine-13C,d3-modified peptides 
FQS*EEQQQTEDELQDK and FQS**EEQQQTEDELQDK were compared by their ion 
intensities at their prevailing charge state (+3) at the time of elution. The average adjusted 
experimental ratio of ion intensities for five replicates at 1:1 is 0.96 with a standard 
deviation of 0.02. Thus, this method shows comparable reliability to similar experiments 
employing isotope-coded affinity tags [50]. The full-mass spectrum from the XIC of two 
modified peptides at the time of the elution is shown in Figure 2.12 with the well 
recognized (M + 4) isotopologue pattern. The experimental ratios of peak intensities were 
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obtained for samples mixed in selected ratios and plotted against theoretical values to 
yield a correlation coefficient of R2 = 0.99. Furthermore, there was no chromatographic 
shift between the light and heavy thiocholine-modified peptides (Figure 2.13). Overall, 
stable isotope ratiometric comparisons demonstrated the anticipated quantitative accuracy 
in both reproducibility and linearity using heavy and light thiocholine modification.  
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2.5 Conclusion and Perspective 
 
      We have demonstrated a strategy for the facile, sensitive and precise detection, 
identification and quantitation of serine/threonine phosphorylation in proteins. By 
introducing thiocholine into the target peptides, a powerful mass spectrometric 
methodology is added that greatly increases the sensitivity of phosphosite identification, 
enriches the repertoire of observable fragmentation ions from the production of a higher 
charge state, and provides diagnostic triads of fragment ions through signature neutral 
loss patterns. The development of an affinity purification method for quaternary amines 
such as those previously demonstrated using calixirenes [52] may greatly facilitate the 
large scale integrated use of this strategy in cellular systems.  
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2.7 Table Legends 
 
Table 2.1 
Identification of phosphorylation sites in iPLA2β phosphorylated by protein kinase 
A (PKA). Tryptic iPLA2β peptides were modified by two different protocols 
optimized for either phosphoserine or phosphothreonine as described in the 
Materials and Methods section. The thiocholine-modified peptides were desalted, 
separated using reverse-phase nanobore HPLC and analyzed with an LTQ-Orbitrap 
system. Candidate peptides were identified using MASCOT with the designated 
thiocholine modification as well as common amino acid modifications as described 
in the Materials and Methods section.  
16 unique sequences and 32 different phosphorylation sites were identified. “*” denotes 
phosphorylation sites; “(*)” denotes that more than one phosphorylation site was 
identified in the same peptide. Those that were not concurrent are indicated by “/” 
whereas “+” indicates peptides that possessed multiple concurrent phosphorylation sites. 
Superscripts “ace”, “ac”, “d” and “o” denote the following modifications: acetylation 
(N-terminus), acetylation (K), deamidation (NQ) and oxidation (M), respectively. All 
cysteine residues were carbamidomethylated. Identified peptides with missed cleavages 
are listed together with the completely trypsinized peptides as indicated by bold bordered 
boxes. Peptides which yielded a signature neutral loss pattern in MS3 are highlighted in 
bold.  
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Table 2.1 
Sequence# Sequence 
Phosphorylation 
Site(s) 
Δm 
(ppm) 
Ion Score 
1-23 MQFFGRLVNdTLSSVTNdLFS*NdPFR S13/S19 2.99 10.8 
24-37 VKEIS*VADYTS(*)HER S28/S34 -1.79 38.7 
24-37 VKEIS*VADYTS*HER S28+S34 -1.69 23.7 
26-37 EIS*VADYTS(*)HER S28/S34 -1.86 32.5 
26-37 EIS*VADYTS*HER S28+S34 -0.99 23.0 
38-53 VREEGQLILFQNAS*NR S51 -1.01 33.8 
208-232 NAS*AGLNQVNdKQGLTPLHLACQMGK S210 2.87 5.7 
246-261 CNdVMGPS*GFPIHT(*)AMK S252/T258 -1.24 31.7 
266-282 aceGCAEMoIISMDS*S*QIHS*Kac S276+S277+S281 -1.35 12.2 
306-327 aceRGCDVDST*S*AAGNdT*ALHVAVMoR T313+S314+T319 0.45 4.6 
307-327 GCDVDSTSAAGNT*ALHVAVMoR T319 1.29 12.2 
393-405 aceISKacQdLQdDLMPIS*R S404 3.91 7.4 
396-405 QLQdDLMPIS*R S404 -3.46 12.5 
406-417 ARKPAFILS*S(*)MR S414/S415 -1.02 37.0 
406-420 ARKPAFILS*S(*)MRDEK S414/S415 -2.00 9.3 
408-417 KPAFILS*S(*)MR S414/S415 -1.76 32.0 
408-420 KPAFILS*S(*)MRDEK S414/S415 -1.29 20.0 
479-489 S*MAYMRGVYFR S479 -5.00 13.6 
492-511 DEVFRGS*RPYESGPLEEFLKac S498 1.60 6.2 
497-511 GS*RPYES*GPLEEFLK S498+S503 -1.78 13.2 
497-511 GS*RPYES(*)GPLEEFLK S498/S503 -0.28 54.5 
513-524 EFGEHT*KMoT(*)DVK T518/T521 -3.32 6.3 
520-527 aceMT(*)DVKacKPK T521 3.18 16.3 
528-537 VMLT*GTLS(*)DR T531/S535 -1.84 28.0 
528-537 VMoLT*GTLS*DR T531+T533 0.61 15.5 
582-595 SS*GAAPT(*)YFRPNdGR S583/T588 -0.89 39.9 
632-643 aceKacLS*IVVS(*)LGT(*)GR S634/S638/T641 3.54 13.1 
644-665 SPQVPVTCVDVFRPS*NPWELAK S658 1.07 3.6 
692-705 aceARAWS*EMoVGIQdYFR S696 2.56 4.5 
694-705 AWS*EMVGIQYFR S696 -1.95 22.1 
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2.8 Figure Legends 
 
Figure 2.1 Optimization of β-elimination and Michael addition (BEMA) reaction 
conditions for phosphorylated serine containing peptides using the model peptide 
FQpSEEQQQTEDELQDK. 
The model peptide FQpSEEQQQTEDELQDK was modified using BEMA with 
thiocholine as described in the Materials and Methods section. The β-elimination and 
Michael addition reactions were terminated at the indicated time intervals. The resultant 
reaction mixtures were separated on an HPLC reverse-phase column (C18, 150 x 4.6mm) 
and the peptides were detected with a UV monitor at λ = 206 nm. The β-elimination 
reaction was complete within 40 mins and Michael addition was complete in 
approximately 60 min. 
 
Figure 2.2 Comparison of the ionization efficiency of the phosphopeptide 
FQpSEEQQQTEDELQDK (▲) and its thiocholine-modified derivative 
FQS*EEQQQTEDELQDK (■).  
The model peptide FQpSEEQQQTEDELQDK was modified via BEMA with thiocholine 
as described in the Materials and Methods section and an equivalent amount of the 
original unmodified phosphopeptide FQpSEEQQQTEDELQDK was added. The 
quantitative yields of the BEMA reactions were   similar to those shown in Figure 1. 
“pS” indicates the phosphorylation site and “S*” indicates the thiocholine-modified site. 
A. Separation of the peptide mixture using a reverse-phase C18 column and analysis 
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employing an ESI-LTQ-Orbitrap as described in the Materials and Methods section. The 
full-mass scan extracted ion chromatography (XIC) of ions at m/z 694.983 (+3) and 
1031.417 (+2) with normalized ion intensities is presented. The ion at m/z 694.983 
corresponds to the triply charged molecular ion (dominant charge state) of 
FQS*EEQQQTEDELQDK (■) and the ion at m/z 1031.417 corresponds to the doubly 
charged molecular ion (dominant charge state) of FQpSEEQQQTEDELQDK (▲). The 
XIC shows a marked increase in ionization efficiency of the peptide after thiocholine 
modification. 
B. The full mass spectrum of the 1:1 peptide mixture obtained with a 4800 
MALDI-TOF/TOF Analyzer with normalized ion intensity. The ion peak at m/z 2061.52 
corresponds to the singly charged molecular ion of FQpSEEQQQTEDELQDK (▲) and 
the ion peak at m/z 2082.62 corresponds to the singly charged molecular ion of 
FQS*EEQQQTEDELQDK (■) . A 3-fold increase in ionization efficiency of the peptide 
after thiocholine modification was observed with MALDI-MS. 
 
Figure 2.3 Detection limit for the thiocholine-modified peptide 
FQS*EEQQQTEDELQDK. 
Extracted ion chromatogram (XIC) and product-ion spectra were acquired with an 
LTQ-Orbitrap as described in the Materials and Methods section.  
A. Extracted ion chromatogram of the thiocholine-modified model peptide 
FQS*EEQQQTEDELQDK at m/z 694.983 (+3) at the concentration of 500 amol/ul (Ion 
counts = 2.01E3).  
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B. The full mass spectrum of the thiocholine-modified model peptide 
FQS*EEQQQTEDELQDK at m/z 694.983 (+3) at the concentration of 500 amol/ul (Ion 
counts = 2.01E3, Signal-to-Noise = 4). 
 
Figure 2.4 Optimization of β-elimination and Michael addition reaction conditions 
for the phosphorylated threonine containing peptide: DHTGFLpTEYVATR (i).  
The β-elimination of DHTGFLpTEYVATR was terminated at the indicated time intervals. 
The resultant reaction mixtures were separated on an HPLC reverse-phase column (C18, 
150x4.6mm) and the peptides were detected with a UV monitor at λ = 206 nm. 
 
Figure 2.5 Optimization of β-elimination and Michael addition reaction conditions 
for the phosphorylated threonine containing peptide: DHTGFLpTEYVATR (ii).  
The phosphothreonine containing peptide, DHTGFLpTEYVATR, was subject to 3h 
Ba(OH)2 catalyzed β-elimination followed by overnight room-temperature incubation 
with thiocholine to effect Michael addition. The full mass spectrum of the resulting 
thiocholine addition product was acquired on a 4800 MALDI-TOF/TOF analyzer. The 
spectrum was remarkable for the predominance of the undesired oxidation of the histidine 
residue (denoted Ho) and N-terminal acetylation (denoted aceD) (m/z 1549.47). Only 
minimal amounts of the desired Michael adduct (m/z 1610.47) was observed under these 
conditions. 
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Figure 2.6 Optimization of β-elimination and Michael addition reaction conditions 
for the phosphorylated threonine containing peptide: DHTGFLpTEYVATR (iii).  
The β-elimination and Michael addition of thiocholine to DHTGFLpTEYVATR were 
carried out under nitrogen and the intermediate products of β-elimination were purified 
with a POROS R2 micro-column as described in the Materials and Methods section 
before undergoing Michael addition at pH = 8-9. Extracted ion chromatogram (XIC) and 
product-ion spectra were acquired with an LTQ-Orbitrap as described in the Materials 
and Methods section. 
A. Extracted ion chromatogram of the thiocholine-modified peptide 
DHTGFLT*EYVATR and its β-elimination product DHTGFLTdeEYVATR after 5h of 
incubation with thiocholine at room temperature demonstrated minimal thiocholine 
addition. 
B. Extracted ion chromatogram of the thiocholine-modified peptide 
DHTGFLT*EYVATR and its β-elimination product DHTGFLTdeEYVATR after 5h of 
incubation with thiocholine at 50°C showing a significantly improved yield. 
C./ D. The product-ion spectra of DHTGFLT*EYVATR of the two XIC peaks from 
Figure S3-B at RT = 21.96 min and 25.32 min. No substantial differences between the 
spectra were observed. The difference in retention times implies the formation of 
diastereomers during the Michael addition reaction. 
E. The product-ion spectrum of the β-elimination product DHTGFLTdeEYVATR. 
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Figure 2.7 Fragmentation of the thiocholine-modified peptide 
FQS*EEQQQTEDELQDK.  
A. The product-ion spectrum of the triply charged molecular ion of 
FQS*EEQQQTEDELQDK at m/z 694.983 was obtained with an ESI-LTQ-Orbitrap as 
described in the Materials and Methods section. The fragment ion resulting from the 
neutral loss of trimethylamine from the parent ion was not detected. Shown in the 
expanded spectrum is an example of the diagnostic triad consisting of the b5+ ion 
resulting from peptide bond cleavage (m/z = 722.3) and further neutral losses of 
trimethylamine (-59 Da, m/z = 663.2) or the thiocholine thiolate (-119 Da, m/z = 603.2). 
“S*” indicates the thiocholine-modified site. 
B. The MS3 spectrum of the y14+2 ion at m/z 904.4 resulting from the fragmentation of the 
triply charged molecular ion of FQS*EEQQQTEDELQDK at m/z 694.983. The ion peak 
at m/z 875.1 corresponds to the doubly charged fragment ion generated from the neutral 
loss of trimethylamine from the parent ion y14+2. 
C. The product-ion spectrum of the singly charged molecular ion of 
FQS*EEQQQTEDELQDK at m/z 2082.62, obtained with a 4800 MALDI-TOF/TOF 
Analyzer as described in the Materials and Methods section. The ion peak at m/z 2023.72 
corresponds to the fragment ion resulting from the neutral loss of trimethylamine from 
the parent ion. Shown in the expanded spectrum are the low-abundance y ions. 
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Figure 2.8 The product-ion spectrum of the doubly charged molecular ion for the 
thiocholine-modified model peptide FQS*EEQQQTEDELQDK at m/z 1041.964, 
acquired with an LTQ-Orbitrap as described in the Materials and Methods section. 
The ion peak at m/z 1012.5 corresponds to the fragment ion generated from the neutral 
loss of trimethylamine from the parent ion. 
 
Figure 2.9 The product-ion spectrum of the thiocholine-modified peptide 
CaNdVMGPS*GFPIHTAMK at m/z 616.958, acquired with an LTQ-Orbitrap as 
described in the Materials and Methods section.  
The identification of the PKA mediated phosphorylation of iPLA2β at Ser252 following 
reductive alkylation and thiocholine modification demonstrates that the peptide contains 
both an alkylated cysteine and a thiocholine-modified serine, showing the compatibility 
of routine reductive alkylation with Ba2+ catalyzed BEMA. 
 
Figure 2.10 Sequence coverage comparison between the thiocholine-modified 
peptide SS*GAAPTYFRPNdGR and the phosphopeptide p(SS)GAAPTYFRPNdGR 
identified in protein kinase A (PKA) phosphorylated calcium-independent 
phospholipase A2β (iPLA2β). 
A. Identification of PKA mediated phosphorylation of iPLA2β at Ser583 via thiocholine 
modification. SS*GAAPTYFRPNdGR was identified after in vitro PKA catalyzed 
phosphorylation of iPLA2β with subsequent thiocholine modification as described in the 
Materials and Methods section. Spectra were acquired using an LTQ-Orbitrap equipped 
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with an electrospray ion source. The product-ion spectrum of the triply charged molecular 
ion (dominant charge state) at m/z 528.264 shows a dominant y13+3 peak leading to 
unambiguous assignment of the phosphosites. Also shown in the expanded spectrum 
(relative intensity zoom = 25%) are the diagnostic triad consisting of y13+3 (m/z = 499.4), 
the ion from the neutral loss of trimethylamine, y13 - 59+3 (m/z = 479.1), and the ion from 
neutral loss of the thiocholine thiolate, y13 - 119+3 (m/z = 459.3), as well as the peak 
corresponding to the loss of the thiocholine thiolate from the molecular ion M - 119+3 
(m/z = 488.9). 
B. Identification of PKA mediated phosphorylation of iPLA2β at Ser582/Ser583 without 
thiocholine modification. p(SS)GAAPTYFRPNdGR was identified in PKA 
phosphorylated iPLA2β without thiocholine modification by ESI-LTQ-Orbitrap. The 
product-ion spectrum of the doubly charged molecular ion (dominant charge state) at m/z 
781.336 shows a strong ion peak at m/z 732.1 which corresponds to the neutral loss of 
H3PO4 from the parent ion. The fragment ions from Ser-Ser peptide bond cleavage are 
missing due to the cyclo-elimination of H3PO4. The specific site of phosphorylation could 
not be assigned from this approach. “p(SS)” indicates either serine residue may be 
phosphorylated, “S*” indicates the thiocholine-modified site and “Nd” indicates the 
deamidation of the asparagine residue. 
 
Figure 2.11 Fragmentation of the thiocholine-modified peptide EIS*VADYTSHER 
identified in PKA phosphorylated iPLA2β at both the MS2 and MS3 levels. 
A. The product-ion spectrum of the triply charged molecular ion at m/z 536.933 
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(EIS*VADYTSHER) was obtained with an ESI-LTQ-Orbitrap as described in the 
Materials and Methods section. The fragment ion resulting from the neutral loss of 
trimethylamine from the parent ion was not detected. Shown in the expanded spectrum 
are examples of the diagnostic triad consisting of the y10+2 and b6+ fragmentation ions 
resulting from peptide bond cleavage (m/z = 633.6 and 716.3) and further neutral loss of 
trimethylamine (-59 Da, m/z = 603.3 and 657.2) or the thiocholine thiolate (-119 Da, m/z 
= 574.1 and 597.2). “S*” indicates the thiocholine-modified site. 
B. MS3 spectrum of the y10+2 ion at m/z 633.6 resulting from the fragmentation of the 
triply charged molecular ion at m/z 536.933 (EIS*VADYTSHER) obtained with an 
ESI-LTQ-Orbitrap as described in the Materials and Methods section. The ion peak at m/z 
604.0 corresponds to the doubly charged fragment ion generated from the neutral loss of 
trimethylamine from the parent ion y10+2.  
 
Figure 2.12 Comparative quantification of phosphoproteins evaluated using β-casein 
as a model protein.  
Equal amounts of trypsinized β-Casein were modified with either “light” (12C,1H) or 
“heavy” (13C,d3) thiocholine and mixed at a 1:1 ratio (v/v). The mixture was separated on 
a reverse-phase C18 column and analyzed by an ESI-LTQ-Orbitrap as described in the 
Materials and Methods section. The full mass spectrum of the modified peptides is shown 
at the time of their co-elution. A doublet pattern of the peptides modified by “light” and 
“heavy” thiocholine is evident. The ion intensity ratio of “light” vs. “heavy” 
thiocholine-modified peptides obtained from full-mass spectra was 0.96±0.02 (average 
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adjusted ratio of five replicates with an expected ion intensity ratio of 1).  “S*” indicates 
the 12C,1H-thiocholine-modified site; “S**” indicates the 13C,d3 thiocholine-modified 
site. 
 
Figure 2.13 Comparison of the retention time of the thiocholine(*) and 
thiocholine-13C,d3(**)-modified peptides FQS*EEQQQTEDELQDK and 
FQS**EEQQQTEDELQDK from the model protein β-casein.  
Two equal aliquots (1 and 2) of trypsinized β-casein were modified with thiocholine and 
thiocholine-13C,d3 respectively as described in the Materials and Methods section. 
Modified peptides of β-casein in aliquots 1 and 2 were then mixed at 1:1 (v:v; aliquot 1: 
aliquot 2, or light: heavy). The mixture was analyzed with a reverse phase 
HPLC-ESI-Orbitrap system as described in the Materials and Methods section. Shown 
are the extracted ion chromatograms of the thiocholine and thiocholine-13C,d3-modified 
peptides: FQS*EEQQQTEDELQDK (m/z 694.983; dashed line “---”) and 
FQS**EEQQQTEDELQDK (m/z 696.323; solid line “—”). No chromatographic shift 
was observed between light and heavy thiocholine-modified peptides. The light versus 
heavy ratios (from data points A, B and C) are consistent at 0.96±0.02 with an expected 
ratio of 1 during the elution of the peak. 
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Figure 2.12 
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CHAPTER 3 
 
 
Identification of Endogenous Phosphorylation Sites of iPLA2β from Sf-9 Cells with 
and Without Thiocholine Modification  
 
 
3.1 Abstract 
 
      In the previous chapter, the chemical replacement of the phosphate on 
phosphoserine and phosphothreonine residues via β-elimination and Michael addition 
with thiocholine was identified as an effective strategy for the characterization of 
phosphosites on model phosphoproteins. The increased ionization efficiency, improved 
sensitivity and the generation of characteristic diagnostic triads of fragmentation ions 
from signature neutral losses in tandem mass spectrometric analysis of thiocholine 
derivatives markedly improved peptide identification. To demonstrate further the utility 
of these procedures in living cells, BEMA with thiocholine was applied to identify the 
endogenous phosphorylation sites of calcium-independent phospholipase A2β (iPLA2β) 
heterologously expressed in Spodoptera frugiperda (Sf-9) cells. In parallel, traditional 
direct analysis of phosphopeptides with data-dependent acquisition MS2 and neutral loss 
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of phosphoric acid triggered MS3 was also performed to analyze iPLA2β phosphorylation. 
The two methods were compared and evaluated to show that a total of 12 unique 
phosphopeptides and 19 phosphorylation sites were identified using the thiocholine 
BEMA strategy, whereas only five peptides and six phosphorylation sites on iPLA2β were 
found with the traditional direct analysis. The larger number of phosphopeptides 
identified with the BEMA method with thiocholine resulted in improved sequence 
coverage compared to the traditional method. Finally, molecular modeling of iPLA2β was 
performed with the I-TASSER server to reveal the close spatial proximity of the 
phosphorylated residues to the catalytic site of the enzyme, suggesting the presence of 
phosphorylation mediated regulation of iPLA2β.    
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3.2 Introduction  
 
      Reversible phosphorylation on serine and threonine residues is regarded as one of 
the most important molecular switches for the regulation of cellular signal transduction 
pathways [1-3]. However, the intrinsic chemical properties of phosphorylated serine and 
threonine-containing peptides hinder the detection and identification of phosphopeptides 
as well as the exact localization of phosphorylated residues in mass spectrometric 
analyses owing to poor ionization efficiency and subsequent low detection threshold. 
Furthermore, the facile neutral loss of phosphoric acid through cyclo-elimination during 
low-energy, collision-induced dissociation (CID) also contributes to the loss of 
phosphoprotein sequence coverage [4-6].  
      As reported in Chapter 2, a novel strategy was developed to overcome these 
hurdles for the sensitive detection and improved identification of pS/pT containing 
peptides [7]. Briefly, thiocholine is introduced into the peptide at the phosphorylation site 
via high-yield Ba2+ catalyzed β-elimination of phosphate and subsequent Michael 
addition (Scheme 1.1). Sample complexity is reduced through reductive alkylation of 
cysteines and development of optimized BEMA conditions for either pS or pT 
individually. This charge-switch strategy results in much improved ionization efficiencies 
during ESI with detection limits in the sub 500 amol/μL range. The sequence coverage of 
the modified peptides is also increased owing to the higher charge states of 
thiocholine-labeled tryptic peptides enabled by the endogenous positive charge on the 
 
95 
 
quaternary amine. Phosphopeptide identification has been substantially improved by 
exploiting the facile neutral loss of trimethylamine (m = 59 Da) and the thiocholine 
thiolate (m = 119 Da) from the thiocholine adduct (Scheme 1.2) during MS2 and MS3 
analyses.   
      To demonstrate further the utility of these procedures in the detection of proteins 
phosphorylated in vivo, BEMA with thiocholine was applied to identify the endogenous 
phosphorylation sites of the calcium-independent phospholipase A2β (iPLA2β) 
heterologously expressed in Sf-9 cells. In parallel, traditional direct analysis of 
phosphopeptides with data-dependent product-ion scan and neutral loss of phosphoric 
acid triggered MS3 was also used for comparison with the current method. A total of 12 
unique phosphopeptides and 19 phosphorylation sites were identified with the BEMA 
strategy compared to five peptides and six phosphorylation sites with the traditional 
method. The phosphopeptides identified with BEMA also showed better sequence 
coverage and higher ion scores than the traditional method.  
      A 3-dimensional (3-D) model of iPLA2β was also derived with the I-TASSER 
server [8-10]. All the phosphorylation sites identified either with BEMA with thiocholine 
or the traditional direct analysis were placed in the 3-D model to reveal the potential 
influence of these phosphorylated residues on the catalytic activity of the enzyme.  
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3.3 Materials and Methods 
 
Materials 
POROS 20 R2 resin was purchased from ABI (Foster City, CA); Slide-A-Lyzer MINI 
Dialysis Units, 7K MWCO were purchased from Pierce (Rockford, IL); Rapigest was 
purchased from Waters (Milford, MA); trypsin was purchased from Promega (Madison, 
WI); Solvents for mass spectrometric analyses were obtained from Honeywell 
Burdick&Jackson (Muskegon, MI). Other chemicals were obtained from Sigma-Aldrich 
(St. Louis, MO). 
 
Synthesis of Thiocholine Chloride  
Thiocholine chloride was prepared and the free thiol concentration of thiocholine 
chloride was determined as previously described in Chapter 2.  
 
Purification of Calcium-independent Phospholipase A2β from Sf-9 Cells  
Hexahistidine tagged calcium-independent phospholipase A2β (iPLA2β) was expressed in 
Sf9 cells and purified as previously described by Jenkins et al. [11]. Sf9 cells grown to a 
density of 1 x 106 cells/mL were infected with a baculovirus encoding recombinant 
iPLA2β with a C-terminal 6x His tag at an MOI of ~2 viral particles/cell. The cells were 
incubated with constant agitation at 27 oC for 48 h. Next, cells suspended in the presence 
of Trypan blue were inspected for evidence of infection (cell swelling, limited cell death). 
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Infected cells were then centrifuged at 900 RPM for 10 min. The media was discarded 
and the cells were resuspended in an equal volume Graces’s Insect Media without serum. 
Cells were centrifuged again 900 RPM for 10 min and resuspended in 10% of the original 
media volume of 25 mM potassium phosphate (pH 7.8) with 2 mM 2-mercaptoethanol, 
and 20% glycerol with 5 µg/mL each of aprotinin and leupeptin. Cells were sonicated at 
30% max power for 30 x 1 s bursts and centrifuged at 100,000 g for 1 h. The supernatant 
was then applied to Co2+ metal affinity resin at 1mL resin per 200 mL original culture 
volume pre-equilibrated with 25 mM potassium phosphate (pH 7.8) with 2 mM 
2-mercaptoethanol, and 20% glycerol. The column was washed with 25 mM potassium 
phosphate (pH 7.8) containing 2 mM 2-mercaptoethanol, 20% glycerol, and 5000 mM 
NaCl. A continuous gradient of 0-200 mM imidazole over 20 column volumes was 
employed to elute the bound iPLA2β(His)6. The fractions collected were tested for 
phospholipase activity. Active fractions were pooled and applied to a 1 mL ATP agarose 
pre-equilibrated with 20 mM imidazole (pH 7.6), 2mM 2-mercaptoethanol and 20% 
glycerol. The column was next washed with 20 mM imidazole (pH 7.6) 2 mM 
2-mercaptoethanol, and 20% glycerol with 150mM NaCl and 1 mM AMP. Bound 
iPLA2β(His)6  was eluted with 20 mM imidazole (pH 7.6), 2 mM 2-mercaptoethanol and 
20% glycerol with 150 mM NaCl, 5 mM ATP, in 1 mL fractions. All fractions were tested 
for the phospholipase activity and the most active fractions were pooled together. The 
protein concentration was determined using a Bradford assay [13].  
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Tryptic Proteolysis of Calcium-independent Phospholipase A2β Prepared from Sf-9 
Cells  
The calcium-independent phospholipase A2β (iPLA2β) prepared from Sf-9 cells was 
dialyzed against deionized water for 8 h using a Slide-A-Lyzer MINI Dialysis Unit, dried 
in a SpeedVac apparatus (Savant, Holbrook, NY), and dissolved in 50 μL of 0.2% 
Rapigest in 50 mM NH4HCO3. Next, 2.5 μL of 100 mM dithiothreitol (DTT) was added 
to a final concentration of 5 mM. The sample was incubated at 60 °C for 30 min before 6 
μL of 150 mM iodoacetamide was added to quench the reduction reaction and initiate 
alkylation. The sample was incubated for an additional 30 min in the dark at room 
temperature. Trypsin was added to the solution at a protease to protein ratio of 1:30 (w/w). 
The total volume of the sample solution was adjusted to 100 μL with 50 mM NH4HCO3. 
A total of 500 fmol/μL protein sample was incubated at 37 °C for 2 h and then acidified 
with 10 μL of 10% TFA to lower the pH to < 2. The sample was again incubated at 37 °C 
for 30 min and centrifuged at 13000 rpm to pellet the hydrolyzed Rapigest. Half of the 
resultant supernatant was used for thiocholine modification while the rest of the sample 
was subjected to MS analyses without modification. 
 
BEMA of Trypsinized Calcium-independent Phospholipase A2β with Thiocholine 
Half of the trypsinized iPLA2β sample was dried in a SpeedVac apparatus and 
reconstituted in 50 μL deionized water followed by the addition of 38 μL DMSO and 12 
μL of absolute ethanol. The trypsinized protein solution was then divided into 2 equal 
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aliquots of 50 μL. The first aliquot was modified with a protocol optimized for pS 
containing peptides and the second aliquot was modified with a protocol optimized for pT 
containing peptides as follows: Aliquot 1 was mixed with 25 μL of freshly prepared 
saturated Ba(OH)2. The reaction was incubated at room temperature under nitrogen for 1 
h with gentle vortexing every 20 min. The final pH was 12~13. Next, 50 μL of 1 M 
thiocholine solution freshly prepared in water was directly added to the reaction. The 
reaction mixture was incubated at room temperature under nitrogen for 3 h at pH 8~9 and 
then terminated by the addition of 5 μL of 10% TFA and the resultant solution was 
desalted with a POROS 20 R2 microcolumn and dried. Aliquot 2 was mixed with 25 μL 
of freshly prepared saturated Ba(OH)2. The reaction was incubated at room temperature 
under nitrogen for 3 h with gentle vortexing every 20 min. The final pH was 12~13. Next, 
the β-elimination reaction was terminated by addition of 10 μL of 10% TFA and the 
resultant solution was desalted with a POROS 20 R2 micro column [12]. Briefly, a 
POROS 20 R2 micro column was assembled by stamping out a small plug of C8 material 
from a 3 M Empore C8 extraction disk using a HPLC syringe needle and placing this 
plug in the constricted end of a GELoader tip. Next, POROS R2 beads that were 
suspended 50% acetonitrile at 5mg/200 µL were packed in the GELoader tip by pressing 
air through the micro column using an Eppendorf syringe. The length of the packed 
POROS R2 resin was about 3~6 mm. Then the column was washed with 30 µL 50% 
acetonitrile and equilibrated with 30 µL 0.1% trifluoroacetic acid. The sample solution 
was then loaded onto the POROS R2 micro column. The sample was slowly passed 
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through the micro column by pressing air through using a Eppendorf syringe. The column 
was washed twice with 30 µL 0.1% trifluoroacetic acid and the bounded peptides were 
eluted first using 30 µL 70% acetonitrile with 0.05 % trifluoroacetic acid, then 5 µL 30% 
acetonitrile with 0.05% trifluoroacetic acid. The purified peptide solution was dried and 
reconstituted in 50 μL of 0.5 M thiocholine solution freshly prepared in 0.1 M NaOH. 
The mixture was incubated at 50 °C under nitrogen for 5 h at pH 8~9. The reaction was 
terminated by the addition of 5 μL 10% TFA and the resultant solution was again desalted 
with a POROS 20 R2 microcolumn and dried. 
 
HPLC-ESI-MS2/MS3 Mass Spectrometric Analyses 
The desalted and dried peptide samples were  reconstituted in 0.1% formic acid before 
injection and separation using a Surveyor HPLC system (Autosampler and pump, 
ThermoFisher, San Jose, CA) equipped with a reverse-phase C18 PepMap100 Nano-LC 
column (75 μm I.D. × 15 cm, 3 μm, 100 Å; Dionex, Sunnyvale, CA). The flow rate was 
maintained at 220−280 nL/min. Samples elut ing from the column were directed to the 
nanospray apparatus (i.e., NanoMate HD with LC coupler, Advion Bioscience Ltd., 
Ithaca, NY) and sprayed directly into a linear ion trap in tandem with an Orbitrap 
(LTQ-Orbitrap) mass spectrometer (ThermoFisher, San Jose, CA) at a spray voltage of 
1.7 kV in the positive ion mode. iPLA2β samples, modified by the two optimized 
protocols, were analyzed first in survey runs, which consisted of a 90 min gradient from 
100% A to 50% A, 50% B (Buffer A: 90% water, 10% acetonitrile, 0.1% formic acid; 
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Buffer B: 10% water, 90% acetonitrile, 0.1% formic acid, v:v)) and data-dependent MS2 
analyses: full mass scans in the Orbitrap (300−1600 m/z, mass resolution = 30000) were 
followed by product-ion scans in the LTQ for the five most abundant ions. The ions of 
interest from the survey runs were then included in the parent mass list of the target runs. 
The target runs consisted of a 180 min gradient from 100% A to 75% A, 25% B (120 min), 
then to 50% A, 50% B (60 min) and data-dependent MS2/MS3 analyses: full mass scans 
in the Orbitrap (300−1600 m/z, mass resolution = 30000) were followed by product-ion 
scans in the LTQ of the three most abundant ions from the parent mass list and the MS3 
scans in the LTQ of the 10 most intense fragment ions following each of the three 
product-ion scans. A control unmodified trypsinized iPLA2β sample was analyzed using 
the same survey run method as the thiocholine-modified samples. The target run for the 
unmodified sample consisted of an inclusion list generated from the survey run, a 180 
min gradient (100% A to 75% A, 25% B (120 min), then to 50% A, 50% B (60 min)), and 
data-dependent MS2/MS3 analyses which consisted of an initial full mass scans in the 
Orbitrap (300−1600 m/z, mass resolution = 30000) followed by product-ion scans of the 
five most abundant ions from the parent mass list with neutral loss of H3PO4 triggered 
MS3 scans in the LTQ. The normalized collision energy for CID was set at 25 for all 
data-dependent scans. 
 
Data Processing 
The local MASCOT server was used to conduct all database searches. A single-protein 
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(iPLA2β) database was created by in silico trypsinolysis. Thiocholine with neutral losses 
of trimethylamine and thiolate were integrated into MASCOT for customized processing 
of the designed covalent modifications for serine and threonine residues. 
Carbamidomethylation of cysteine(C) residues was set as a fixed modification for the 
trypsinized iPLA2β samples. Common variable modifications included N-terminal and 
lysine acetylation (N-terminus, K), asparagine and glutamine deamidation (N,Q) and 
methionine oxidation (M). A maximum of two missed cleavages were allowed. Full mass 
and product-ion mass accuracy were set at 5 ppm and 1 Da, respectively. All 
identifications by MASCOT were manually verified. All MS3 scans were analyzed 
manually. The 3-D model of iPLA2β was generated by a web based program on the 
I-TASSER server developed by Y. Zhang at the University of Michigan [8-10]. The 
results are presented in the format of a PDB file visualized using ViewerLite freeware 
and the distances between the amino acid residues were measured using the 
“Monitor--Distance” feature included in the software. 
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3.4 Results and Discussion 
 
      Calcium-independent phospholipase A2β (iPLA2β) belongs to the superfamily of 
phospholipases A2 [14]. Phospholipases A2 catalyze the hydrolysis of phospholipids at the 
sn-2 position to release fatty acids [15-16], such as arachidonic acids and 
lysophospholipids, which are the precursors of multiple bioactive messengers [17-18]. 
According to their different properties, such as sequence homology, substrate selectivity, 
subcellular location and dependence on calcium ion, phospholipases A2 can be grouped 
into three categories: secretory phospholipases A2 (sPLA2s), cytosolic phospholipases A2 
(cPLA2s) and calcium-independent phospholipases A2 (iPLA2s) [19-20]. Cytosolic 
phospholipases A2 are important intracellular phospholipases whose members contain 
(with the exception of cPLA2γ) a calcium-binding domain (C2), which upon binding Ca2+  
results in their translocation from cytosol to intercellular membrane compartments to 
hydrolyze their phospholipid substrates at the sn-2 position and release fatty acids [21].  
      The phosphorylation and Ca2+ mediated regulation of cPLA2α was extensively 
studied [22-24]. The endogenous phosphorylation sites of cPLA2α heterologously 
expressed in Sf-9 cells were previously identified as ser-437, ser-454, ser-505 and ser-727 
by mass spectrometry and automated Edman sequencing [25]. Treatment of cPLA2α with 
the phosphatase inhibitor okadaic acid resulted in a 4.5 fold increase in the 
phosphorylation at serine 727 and an increased release of arachidonic acid. These results, 
in conjunction with previous studies demonstrated that 
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phosphorylation/dephosphorylation of cPLA2α is an important molecular mechanism 
underlying the regulation of arachidonic acid release [25]. Similarly, iPLA2β is likely 
regulated by phosphorylation/dephosphorylation mechanism, although current methods 
have failed to identify specific residues whose phosphorylation correlate with alterations 
in catalytic activity. Thus, it is of particular importance to gain insight into the 
phosphorylation state of iPLA2β in vivo to provide a molecular foundation for further 
investigation of the role of phosphorylation/dephosphorylation of iPLA2β in diverse 
processes of substantial biologic significance such as cardiac function, arachidonic acid 
release, cell proliferation and apoptosis [26-29]. A primary purpose of this study is to 
compare the utility of the developed BEMA strategy with a traditional direct analysis 
method in a system where the protein phosphorylation level is not artificially elevated.   
      Hexahistidine-tagged calcium-independent phospholipase A2β (iPLA2β) was 
expressed in Sf9 cells and purified as previously described by Jenkins et al. [11]. Purified 
iPLA2β was modified with thiocholine by using two separate protocols optimized for 
either pS or pT-containing phosphopeptides. Modified and unmodified peptides were 
analyzed with HPLC-ESI-MS2/MS3 as described in the Materials and Methods section.   
      As shown in Table 3.1, six different endogenous phosphorylated sites, originating 
from five unique phosphopeptides, were identified in iPLA2β without thiocholine 
modification using the traditional MS analysis strategy as described in the Materials and 
Methods. No neutral loss of phosphoric acid triggered MS3 were obtained for any of the 
identified peptides.  
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      Conversely, as shown in Table 3.2, with the β-elimination and Michael addition 
strategy, a total of 19 different phosphorylated residues were identified. These 
phosphorylation sites originated from 14 phosphopeptides. Identified peptides with 
missed tryptic cleavages are listed together with the completely trypsinized peptides 
indicated by bold-bordered boxes. The peptides contained within the bold-bordered boxes 
are considered as one unique sequence. Thus, there are 12 unique phosphopeptides found 
by the BEMA method. The phosphorylation sites listed in the table separated with a “/” 
indicate that the monophosphopeptide has more than one non-concurrent phosphorylation 
site. The product-ion spectra of all the peptides identified were verified manually, all of 
which contained signature peaks generated by the neutral loss of trimethylamine and/or 
thiocholine thiolate. As indicated in bold font in Table 3.1, 11 phosphopeptides from nine  
unique sequences showed at least one dominant peak resulting from the neutral loss of 
trimethylamine (-59 Da) at the level of MS3 analyses out of 14 phosphopeptides and 12 
unique sequences.  
      The sequence coverage of the identified peptides was calculated using all b and y 
ions present in the product-ion spectra over the number of all possible b and y ions. The 
phosphopeptides identified with the BEMA strategy showed better sequence coverage 
than those identified with the traditional method. Eleven out of 14 phosphopeptides 
modified with thiocholine had sequence coverage greater than 50%; whereas three out of 
five phosphopeptides without any modification identified with traditional mass 
spectrometric methods showed sequence coverage above 50%.  
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      Figure 3.1-A shows the product-ion spectrum of the triply charged 
thiocholine-modified peptide VKEIS*VADYTSHER (24−37). This spectrum consists of 
b and y ions with diagnostic triads of all thiocholine containing peptidic fragment ions. 
Shown in the expanded spectrum are the representative diagnostic triads from y12+2 
fragment ions resulting from peptide bond cleavage (m/z = 754.7) and further neutral loss 
of trimethylamine (-59 Da, m/z = 725.1) and the thiocholine thiolate (-119 Da, m/z = 
695.2). Of the ions generated at MS2 level, the ten most abundant ions were chosen to be 
further fragmented at the MS3 level. Examination of the y10+2 ion at m/z 633.5 (among the 
top ten ions selected) demonstrated that it also possessed an intact thiocholine side chain, 
which led to a signature neutral loss pattern in its MS3 spectrum (Figure 3.1-B). The ion 
at m/z 603.9 is formed by the neutral loss of trimethylamine from the precursor y10+2 at 
m/z 633.5.  
      The product-ion spectrum shown in Figure 3.2 is the triply charged peptide 
VKEIpSVADYTSHERVR (24-39) identified with the traditional method, corresponding 
to the phosphopeptide VKEIS*VADYTSHER (Figure 3.1-A) with one additional missed 
cleavage. The spectrum provides minimal sequence informative ions in comparison to 
that of the thiocholine-modified peptide with lower sequence coverage and a lower ion 
score.  
      Examination of the fragmentation pattern of VKEIS*VADYTSHER demonstrated 
that the thiocholine side chain enabled a unique tandem fragmentation pattern ideal for 
proteomic analyses, since sequencing of the peptide at the MS2 level is not compromised 
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by subsequent neutral losses but rather strengthened by the presence of diagnostic triads 
of fragment ions in conjunction with the signature neutral loss at the MS3 level. As 
previously discussed, one of the promising prospects of this approach is the use of these 
unique and predictable diagnostic triads of fragmentation ions from thiocholine-modified 
peptides in a weighted scoring system, where the intrinsic chemical properties of the 
modified peptide could enhance identification of phosphorylated peptides and 
phosphosites. Even though such a scoring system is not currently available, combining 
the current MASCOT score with high mass accuracy ( < 5ppm) and the diagnostic triad 
of fragment ions in both MS2 and MS3 levels will ensure the identification of the 
modified peptides are made with high confidence.  
      To gain insight into the potential mechanistic significance of the identified 
iPLA2β phosphosites, a three-dimensional model of iPLA2β was generated using the 
I-TASSER server, an internet service that predicts protein structures and generates protein 
3-D models [8-10]. The I-TASSER program was developed by Yang et al. at the 
University of Michigan. 3D models are predicted based on multiple-threading alignments 
generated by Local Meta-Threading-Server (LOMETS) that generates protein 3-D 
models by collecting target-to-template alignments with high scores as well as iterative 
TASSER simulations. The I-TASSER server was ranked as the No. 1 server with the best 
global distance test total score (GDT-TS), which is a measure of the similarity between 
two different protein structures with the same primary structure, but different tertiary 
structures, in the server section of both the 7th and 8th CASPs (Critical Assessment of 
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Techniques for Protein Structure Prediction). As shown in Figure 3.3-A, the catalytic 
serine located within the lipase consensus sequence GXSXG resides within the central 
catalytic core adjacent to the nucleotide binding motif (GXGXXG) (S465) [30]. All the 
phosphorylation sites identified either with BEMA with thiocholine or through the 
traditional direct analysis were located in the 3-D model. The distance (in Å) between 
these phosphorylated serine/threonine residues and the active site of serine 465 measured 
by using atom-to-atom distances between the hydroxyl oxygen of phosphorylated 
serines/threonines residues and the hydroxyl oxygen of serine 465 are listed in Table 3.3. 
The closest of the identified phosphorylated residues, threonine 521 is predicted to be at a 
distance of 8.67 Å from the catalytic site in this model, which is also labeled in Figure 
3.3-A. At this distance, the phosphorylation/dephosphorylation of threonine 521 could 
significantly influence the catalytic activity of the enzyme.  
      Other phosphorylated serines/threonines within the catalytic core, labeled in 
Figure 3.3-B, undergo phosphorylation/dephosphorylation that could also affect the 
activity of iPLA2β. As shown in Figure 3.3-C, many of the observed phosphosites in 
iPLA2β are located within the ankyrin repeat domain; these residues  likely facilitate 
specific binding to protein partners in a phosphorylation-dependent fashion. The 
phosphorylation/dephosphorylation cycling of these residues could impact the regulation 
of protein-protein interactions during the binding of iPLA2β to cellular membranes that 
contain ankyrin-binding proteins.  
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3.5 Conclusion and Perspective 
 
      We demonstrated the utility of the β-elimination and Michael addition strategy in 
the identification of endogenous phosphorylation sites of iPLA2β heterologously 
expressed in Sf-9 cells. In comparison to the traditional direct mass spectrometric 
analyses of phosphopeptides, the BEMA strategy identified more phosphopeptides with 
more phosphorylation sites, and demonstrated improved sequence coverage and ion 
scores. A diagnostic triad of fragment ions also facilitated improved phosphosite 
determination at higher confidence levels of the peptides identified by MASCOT. The 
3-D model of iPLA2β showed that threonine 521 was spatially the closest identified 
phosphosite to serine 465 in the catalytic domain. The 
phosphorylation/dephosphorylation of these sites likely affects the catalytic activity, 
membrane binding and trafficking of iPLA2β. 
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3.7 Table Legends 
 
Table 3.1  
Identification of endogenous phosphorylation sites in iPLA2β heterologously 
expressed in Sf-9 cells without thiocholine modification. 
Tryptic iPLA2β peptides were desalted, separated using reverse-phase nanobore HPLC, 
and analyzed with an LTQ-Orbitrap system. Candidate peptides were identified using 
MASCOT with the designated thiocholine modification as well as common amino acid 
modifications as described in the Materials and Methods. A total of five unique 
phosphopeptides and six different phosphorylated residues were identified. “p” denotes 
identified phosphorylation sites; “(p)” denotes that more than one phosphorylation site 
was identified in the same peptide. Those that were not concurrent are indicated by “/”. 
The superscripts “ace”, “d”, and “o” denote the following modifications: acetylation 
(N-terminus), deamidation (NQ), and oxidation (M), respectively. All cysteine residues 
were carbamidomethylated.  
 
Table 3.2  
Identification of endogenous phosphorylation sites in iPLA2β heterologously 
expressed in Sf-9 cells with thiocholine modification. 
Tryptic iPLA2β peptides were modified with thiocholine using two different protocols 
optimized for either phosphoserine or phosphothreonine as described in the Materials and 
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Methods. The thiocholine-modified peptides were desalted, separated using reverse-phase 
nanobore HPLC, and analyzed with an LTQ-Orbitrap system. Candidate peptides were 
identified using MASCOT with the designated thiocholine modification as well as 
common amino acid modifications as described in Materials and Methods. A total of 12 
unique phosphopeptides and 19 different phosphorylated residues were identified. “*” 
denotes identified phosphorylation sites; “(*)” denotes that more than one 
phosphorylation site was identified in the same peptide. Those that were not concurrent 
are indicated by “/”. The superscripts “d”, and “o” denote the following modifications: 
deamidation (NQ) and oxidation (M), respectively. All cysteine residues were 
carbamidomethylated. Identified peptides with missed cleavages are listed together with 
the completely trypsinized peptides outlined by bold-bordered boxes. Peptides which 
yielded a signature neutral loss pattern in MS3 are highlighted in bold. 
 
Table 3.3  
Calculated distances between the catalytic site serine 465 of iPLA2β and the 
identified phosphorylation sites of iPLA2β heterologously expressed in Sf-9 cells 
utilizing the BEMA strategy or traditional direct analysis in the 3-D model of 
iPLA2β molecule generated by I-TASSER.  
A 3-D model of iPLA2β was generated using the I-TASSER server. All the 
phosphorylation sites identified either with β-elimination and Michael with thiocholine 
addition (denoted as “BEMA” in the table) or the traditional direct mass spectrometric 
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method (denoted as “Direct” in the table) were located in the 3-D model. The distance 
between the identified phosphorylated residues and the catalytic site serine 465 are given 
in Å. The distance measured is the atom-to-atom distance between the hydroxyl oxygen 
of serine 465 and the hydroxyl oxygens of the phosphorylated serines/threonines. 
Threonine 521 is the most proximal residue (8.67 Å) to the catalytic site in this model. 
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Table 3.1 
Sequence# Sequence 
Phosphorylation 
Site 
Ion Score 
Δm 
(ppm) 
Coverage% 
24-39 VKEIpSVADYTSHERVR S28 5.7 -2.34 63% 
208-218 aceNApSAGLNQVNK S210 16.3 -2.59 82% 
266-282 aceGCAEMIISMoDSpSQIHSK S277 6.34 1.23 35% 
396-407 QdLQdDLMPIpSRAR S404 8.15 -1.86 42% 
633-643 LSIVV(p)SLGpTGR S638/T641 22.87 -3.39 91% 
 
Table 3.2 
Sequence# Sequence 
Phosphorylation 
Site 
Ion Score 
Δm 
(ppm) 
Coverage% 
24-37 VKEIS*VADYTS(*)HER S28/S34 54.62 -2.02 86% 
26-37 EIS*VADYTS(*)HER S28/S34 34.13 -2.52 92% 
38-53 VREEGQLILFQNAS*NR S51 58.41 -1.06 81% 
246-261 CNdVMGPSGFPIHT*AMK S252/S258 7.47 -1.03 75% 
307-327 GCDVDSTS*AAGNTALHVAVMoR S314 3.72 -0.98 38% 
396-405 QdLQDLMPIS*R S404 16.69 -3.99 70% 
408-417 KPAFILS*S(*)MR S414/S415 14.77 -1.36 70% 
408-420 KPAFILS*S(*)MRDEK S414/S415 19.21 -2.71 69% 
479-489 S*MAYMRGVYFR S479 9.31 -3.31 45% 
497-511 GS*RPYES(*)GPLEEFLK S498/S503 33.45 -1.66 80% 
513-524 EFGEHTKMoT*DVK T521 9.85 0.72 42% 
528-537 VMLT*GT(*)LS(*)DR T531/T533/S535 33.06 -1.68 90% 
582-595 SS*GAAPT(*)YFRPNdGR S583/T588 29.26 -1.14 71% 
694-705 AWS*EMVGIQYFR S696 34.15 -1.51 92% 
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Table 3.3 
Residue number Identification Method Distance to Serine 465 (Å) 
Serine 28 BEMA/Direct 35.88 
Serine 34 BEMA 33.99 
Serine 51 BEMA 45.80 
Serine 210 Direct 49.78 
Serine 252 BEMA 43.60 
Serine 258 BEMA 39.18 
Serine 277 Direct 48.68 
Serine 314 BEMA 45.88 
Serine 404 BEMA/Direct 56.62 
Serine 414 BEMA 54.70 
Serine 415 BEMA 50.77 
Serine 479 BEMA 27.49 
Serine 498 BEMA 27.53 
Serine 503 BEMA 26.44 
Threonine 521 BEMA 8.67 
Threonine 531 BEMA 17.09 
Threonine 533 BEMA 17.66 
Serine 535 BEMA 22.70 
Serine 583 BEMA 25.98 
Threonine 588 BEMA 26.00 
Serine 638 Direct 34.45 
Threonine 641 Direct 27.08 
Serine 696 BEMA 43.57 
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3.8 Figure Legends 
 
Figure 3.1 Fragmentation of the thiocholine-modified peptide 
VKEIS*VADYTSHER identified in iPLA2β at both the MS2 and MS3 levels. 
A. The product-ion spectrum of the triply charged molecular ion at m/z 578.966 
(VKEIS*VADYTSHER) was obtained with an ESI-LTQ-Orbitrap as described in 
the Materials and Methods. The fragment ion resulting from the neutral loss of 
trimethylamine from the parent ion was present at m/z 559.5. Shown in the expanded 
spectrum (relative intensity zoom = 24%) are examples of the diagnostic triad consisting 
of the y12+2 fragmentation ions resulting from peptide bond cleavage (m/z = 754.7) and 
further neutral loss of trimethylamine (-59 Da, m/z = 725.1) or the thiocholine thiolate 
(-119 Da, m/z = 695.2). Also shown is the y11+2 (m/z = 690.1) and its corresponding ion 
peak of the neutral loss of trimethylamine (-59 Da) at m/z = 660.5. “S*” indicates the 
thiocholine-modified site.  
B. The MS3 spectrum of the y10+2 ion at m/z 633.5 resulting from the fragmentation of the 
triply charged molecular ion at m/z578.966 (VKEIS*VADYTSHER) obtained with an 
ESI-LTQ-Orbitrap as described in the Materials and Methods section. The ion peak 
at m/z 603.9 corresponds to the doubly charged fragment ion generated from the neutral 
loss of trimethylamine from the parent ion y10+2. 
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Figure 3.2 Fragmentation of the phosphopeptide VKEIpSVADYTSHERVR 
identified in iPLA2β without thiocholine modification.  
The product-ion spectrum of the triply charged molecular ion at m/z 656.988 
(VKEIpSVADYTSHERVR) was obtained with an ESI-LTQ-Orbitrap as described in 
the Materials and Methods section. The fragment ion resulting from the neutral loss of 
H3PO4 from the parent ion was not observed. “pS” indicates the phosphorylated site. 
 
Figure 3.3 3-D model of iPLA2β generated by the I-TASSER server. 
The primary amino acid sequence file of iPLA2β was submitted to I-TASSER server 
located at http://zhanglab.ccmb.med.umich.edu/I-TASSER/. The 3-D model in PDB 
format was generated and displayed with ViewerLite freeware. 
A. The catalytic site serine 465 and phosphorylated residue threonine 521 are labeled. 
The atom-to-atom distance between the hydroxyl oxygen of serine 465 and the hydroxyl 
oxygen of the threonine 521 is calculated to be 8.67 Å in this model.  
B. Phosphorylated residues within the catalytic core are labeled as follows: serine 28, 
serine 34, serine 51, serine 210, serine 252, serine 258, serine 277, serine 314, serine 304, 
serine 414, and serine 415. 
C. Phosphorylated residues within the ankyrin domain of iPLA2β are labeled as follows: 
serine 479, serine 498, serine 503, threonine 521, threonine 531, threonine 533, serine 
535, serine 583, threonine 588, serine 638, threonine 641, and serine 696.  
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Figure 3.1 
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Figure 3.2 
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Figure 3.3 
A. 
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B. 
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CHAPTER 4 
 
 
Quantitative Analysis of Alterations in the Myocardial Mitochondrial 
Phosphoproteome Induced by Cardiac Ischemia Assessed using β-Elimination and 
Michael Addition with Light and Heavy Thiocholine 
 
 
4.1 Abstract 
 
      Quantitative analysis of alterations in the murine myocardial mitochondrial 
phosphoproteome induced by global cardiac ischemia was performed using the developed 
mass spectrometric strategy of β-elimination of phosphate and subsequent Michael 
addition (BEMA) with natural abundance (light) thiocholine and stable-isotope labeled 
(heavy) thiocholine. The developed strategy exploited the increased ionization efficiency, 
sensitivity and diagnostic triads of fragmentation ions to identify 141 phosphopeptides 
from 133 distinct proteins that include the identification of 36 phosphopeptides from 35 
mitochondrial proteins containing 37 previously unreported mitochondrial phosphosites. 
The identities of these novel phosphosites were first determined using the MASCOT 
search engine and were substantiated through rescoring using the Percolator algorithm. 
Quantitation of alterations in mitochondrial protein phosphorylation resulting from 
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cardiac ischemia were achieved by comparing phosphopeptides modified by heavy 
thiocholine obtained from mitochondria in ischemic hearts (i.e., global ischemia) to those 
modified by light thiocholine in control hearts ( i.e., normal flow perfusion). Collectively, 
these results demonstrate that β-elimination of phosphate and subsequent Michael 
addition (BEMA) using light and heavy thiocholine represent an effective mass-
spectrometry-based strategy for comparative quantitative phosphoproteomics in whole 
organ systems during pathophysiologic perturbations.  
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4.2 Introduction  
 
      The reversible protein phosphorylation and dephosphorylation of serine and threonine 
residues are the most ubiquitous posttranslational modifications that regulate critical 
signaling pathways in eukaryotic cells [1-3]. As in most biologic systems, protein 
phosphorylation plays multiple roles in regulating a diverse array of mitochondrial 
functions. Prior work demonstrated that numerous proteins are phosphorylated in the 
mitochondria of yeast [4], mouse liver [5], mouse brain [6], bovine heart [7], and in 
virtually every cell type and organ system studied [8-9]. In mitochondria, it is well 
established that the activities of enzymes, such as pyruvate dehydrogenase [10-14] and 
cytochrome oxidase [15-16] are regulated by reversible protein phosphorylation that 
contributes to cellular bioenergetics, substrate utilization and the deleterious sequelae of 
oxidative stress. However, a quantitative mass spectrometric approach for 
phosphoproteome analysis on a global scale identifying the number and magnitude of 
alterations in the phosphorylation at specific phosphosites of mitochondrial proteins after 
pathophysiologic perturbations has not been well defined. 
      Radiolabeling of biologic tissues with [γ-32P]-ATP is a traditional quantitative 
approach that has been used to provide early insights into the mitochondrial 
phosphoproteome [8, 17]. Radiolabeling is a very sensitive technique for the detection of 
phosphoproteins and the characterization of overall changes in the level of protein 
phosphorylation. However, its utility is limited by its inability to localize readily the 
phosphosite without additional approaches such as site-directed mutagenesis, enrichment 
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processes, or Edman degradation. Although fluorescence labeling represents a sensitive 
nonradioactive alternative to 32P radiolabeling [7] it suffers multiple limitations because 
fluorescence labeling alone cannot provide primary sequence information of the 
phosphorylated peptide or its phosphosite. Meanwhile, mass spectrometric approaches 
for phosphoproteome analysis are complicated by facile cyclo-elimination of phosphoric 
acid, resulting in ambiguities in phosphosite assignment and poor ionization efficiencies 
of phosphopeptides rendering their detection difficult. Thus, these techniques are not 
amenable to high-throughput quantitative analysis required for comprehensive 
phosphoproteome determination. [18]. 
      Isobaric tags for relative and absolute quantitation (iTRAQ) is an effective mass-
spectrometry-based labeling technique for multiplexed quantitative phosphoproteomics 
[19-21]. For this approach, tryptic peptides from proteins of different biological states are 
modified with different isobaric tags. The same phosphopeptides from different states are 
identical in the full-mass scan but can produce unique reporter ions during the tandem 
mass spectrometric analysis, thus providing information of comparative quantitation 
based on the relative abundances of the reporter ions. However, given that quantitation is 
achieved at the MS2 level, the sensitivity of this strategy is limited and could lead to large 
run-to-run deviations and, thus, poor reproducibility. 
      Previously, we developed a sensitive method taking advantage of the unique 
chemistry of the quaternary amine to enhance ionization efficiency in conjunction with 
the strong nucleophilicity of the thiol present in thiocholine to effect the BEMA strategy 
with thiocholine as the Michael donor (as described in Chapter 2). This strategy results in 
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marked increase in ionization sensitivity during ESI accompanied by increased sequence 
coverage in model compounds as described in Chapters 2 and 3. More specifically, the 
definitive localization of phosphorylated residues is greatly facilitated by the thiocholine 
side chain through the generation of diagnostic triads of fragment ions resulting from 
peptide bond cleavage and further neutral loss of either trimethylamine (-59 Da/-63 Da) 
or thiocholine thiolate (-119 Da/-123 Da) during CID in MS2 and MS3experiments. 
Through utilization of titanium dioxide resin (TiO2) for phosphopeptide enrichment, 
sample complexity is greatly reduced [23] leading to improved chromatographic 
coverage of the phosphopeptides of interest. To minimize false discovery rates, all 
database searches generated by MASCOT [24] were re-scored by Percolator [25-26], a 
semi-supervised machine learning algorithm further substantiating the identification of 
the observed phosphosites.  
      In this study, we successfully identified 141 phosphopeptides from 133 unique 
proteins with 228 phosphorylation sites from six independent biological replicates 
generated from 24 perfused mouse hearts (12 control-perfused, 12 global ischemic). 
Importantly, these data included 36 phosphopeptides from 35 mitochondrial proteins with 
50 phosphosites, 37 of which are new mitochondrial phosphosites that have not been 
reported previously. Relative alterations in the magnitude of phosphorylation were 
evaluated for all phosphopeptides identified in three independent replicate samples using 
relative molecular ion peak intensity ratios. This study has demonstrated that β-
elimination of phosphate and subsequent Michael addition (BEMA) using light and 
heavy thiocholine represents an effective mass-spectrometry based strategy for 
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comparative quantitative phosphoproteome analyses of intact organs subjected to 
pathologic perturbations.  
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4.3 Materials and Methods 
 
Materials 
Rapigest was purchased from Waters (Milford, MA); Protein concentrations or amounts 
were determined using a BCA protein assay kit was purchased from Pierce (Rockford, 
IL); trypsin was purchased from Promega (Madison, MI); Titansphere Titanium dioxide 
resin was purchased from GL Sciences (Torrance, CA); POROS 20 R2 resin was 
purchased from ABI (Foster City, CA). All solvents for mass spectrometric analyses were 
obtained from Honeywell Burdick&Jackson (Muskegon, MI); all other chemicals were 
obtained from Sigma-Aldrich (St. Louis, MO) 
 
Synthesis of Thiocholine Chloride (Light) and Thiocholine-13C,d3 Chloride (Heavy) 
Thiocholine chloride was prepared and the free thiol concentration of thiocholine 
chloride was determined as previously described in Chapter 2.  
 
Perfusion of Isolated Langendorff Mouse Hearts 
Animal protocols used were in strict accordance with the National Institutes of Health 
guidelines for humane treatment of animals and were reviewed and approved by the 
Animal Care Committee of Washington University. Mouse hearts were either perfused 
normally as controls or subjected to global ischemia, as previously described [28]. Briefly, 
mice were anesthetized with sodium pentobarbital and their hearts were excised and 
immersed in oxygenated Krebs-Henseleit buffer containing : 137 mM NaCl, 4.7 mM KCl, 
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1.2 mM MgSO4, 1.2 mM KH2PO4, 15 mM NaHCO3, 3mM CaCl2, 0.5 mM NaEDTA and 
11mM glucose equilibrated with O2/CO2  (95:5), plus insulin (70 mU/L) and BSA (2.8%), 
at 37 °C. Mouse hearts were then perfused by retrograde aortic flow with oxygenated 
buffer at 37 °C. Perfusion pressures were maintained constant at 45 to 50 mm Hg. All 
hearts were initially perfused with oxygenated buffer for a 15-minute equilibration period. 
12 mouse hearts were perfused with oxygenated buffer for an additional 30 mins and 
served as controls. Another 12 mouse hearts were subjected to global ischemia for an 
additional 30 min. 
 
Preparation of Mouse Mitochondria  
Mitochondria were prepared as previously described with minor modifications [29-30]. 
Each perfused heart prepared as described above was immediately placed at 10% (w/v) in 
ice-cold pH 7.4 HEPES buffer containing 1 mM EDTA, 250 mM sucrose, phosphatase 
inhibitor cocktail (1 (Sigma) at a 100-fold dilution) and a customized phosphatase 
inhibitor cocktail (10 mM sodium fluoride, 4 mM sodium tartrate, 2 mM β-
glycerophosphate, 2 mM sodium pyrophosphate). Hearts tissues were homogenized with 
a glass dounce homogenizer, centrifuged at 700 g for 10 min and the supernatant was 
collected. Next, the supernatant was centrifuged at 10,000 g for 15 min to pellet 
mitochondria. Mitochondria from two control hearts were pooled together to give six 
individual control samples while the same was done for the ischemic samples. All control 
and ischemic samples were processed using the same protocol except that light 
thiocholine was used for control hearts and heavy thiocholine was utilized for ischemic 
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hearts for the Michael addition reaction.  
 
Tryptic Proteolysis of Mitochondrial Proteins 
Mitochondria were re-suspended in 750 µL of 80% aqueous methanol solution in a 1.5-
mL micro centrifuge tube and mitochondrial proteins were precipitated as previously 
described [31]. Briefly, 150 µL of CHCl3 was added to the above mitochondrial 
suspension and vortexed, followed by the addition of 450 µL of H2O. The mixture was 
vortexed again before centrifugation at 14,000 g for 15 min, separated into two layers, 
and the protein located at the interface appeared as a white layer. The upper layer 
(methanol and H2O) was removed and another 450 µL of methanol was added. The 
sample was vortexed and centrifuged at 14,000 g for 10 min. The protein pelleted at the 
bottom of the tube was air-dried and re-suspended in 1000 µL of 0.2% Rapigest in 50 
mM NH4HCO3 and incubated at 100 °C for 5 min. Protein content was determined using 
the micro-BCA protein assay kit (Pierce). 1 mg of total protein from each sample was 
used for subsequent preparations. The volume of each sample was adjusted to 1 mL using 
50 mM NH4HCO3. Next, 52 µL of 100 mM dithiothreitol (DTT) was added to a final 
concentration of 5 mM. The sample was incubated at 60 °C for 30 min before 120 µL of 
150 mM iodoacetamide was added to quench the reduction reaction and initiate 
alkylation. The sample was incubated for an additional 30 min in the dark. Trypsin was 
added to the solution at a protease to protein ratio of 1:30 (w/w). The solution was 
incubated at 37 °C overnight. The pH of the solution was lowered to < 2 to terminate the 
digestion and the incubated at 37 °C for 30 min. Hydrolyzed Rapigest was pelleted by 
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centrifugation at 13,000 rpm.  
 
Highly Selective Enrichment of Phosphorylated Peptides by Titanium Dioxide (TiO2) 
Micro Column Chromatography  
Trypsinized protein samples were dried in a SpeedVac apparatus (Savant, Holbrook, NY), 
and reconstituted in 280 mg/mL 2,5-Dihydroxybenzoic acid (2,5-DHB) in 60% 
acetonitrile (ACN), 1.5% Trifluoroacetic acid (TFA). Phosphorylated peptides in the 
trypsinized samples were enriched using TiO2 micro columns as previously described 
with minor modifications [32]. Bound phosphorylated peptides were eluted twice with 40 
µL 25% ammonium hydroxide (pH > 10.5) and once with 30 µL 30% ACN. The fractions 
containing the eluted phosphopeptides were acidified by the addition of 15 µL 90% 
formic acid. 30 µL of water was added to reduce the organic solvent concentration to < 
5%.  
 
BEMA of Phosphorylated Peptides Enriched by TiO2 Micro Column Chromatography 
with Light and Heavy Thiocholine 
Phosphorylated peptides eluted from the TiO2 micro columns were desalted using 
POROS 20 R2 micro columns as previously described [33]. Briefly, a POROS 20 R2 
micro column was assembled by stamping out a small plug of C8 material from a 3M 
Empore C8 extraction disk using a HPLC syringe needle and placing this plug in the 
constricted end of a GELoader tip. Next, POROS R2 beads that were suspended in 50% 
acetonitrile at 5 mg/200 µL were packed into the GELoader tip by pressing air through 
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the micro column using an Eppendorf syringe. The length of the packed POROS R2 resin 
was about 3-6 mm. The column was then washed with 30 µL 50% acetonitrile and 
equilibrated with 30 µL 0.1% trifluoroacetic acid. Samples containing the 
phosphopeptides were then loaded onto the POROS R2 micro column. The sample was 
slowly passed through the micro column with compressed air from the Eppendorf syringe. 
The column was washed twice with 30 µL of 0.1% trifluoroacetic acid and the bound 
peptides were eluted first using 30 µL of 70% acetonitrile containing 0.05 % 
trifluoroacetic acid, then 5 µL of 30% acetonitrile containing 0.05% trifluoroacetic acid. 
The desalted phosphorylated peptides were dried in a SpeedVac apparatus and 
reconstituted in 50 µL deionized water followed by the addition of 38 µL DMSO and 12 
µL of absolute ethanol. 25 µL of freshly prepared saturated Ba(OH)2 was then added to 
the peptide solution to start the β-elimination reaction. After incubation at room 
temperature under nitrogen for 3 h with gentle vortexing every 20 min. The final pH was 
12~13. 50 µL of 1 M thiocholine chloride was added to each of the six the control 
samples and 50 µL of 1 M thiocholine-13C,d3 chloride was added to each of the six the 
ischemic samples. The reaction mixture was incubated at room temperature under 
nitrogen for 5 h at pH 8~9 and then terminated by the addition of 5 µL of 10% TFA.  
 
HPLC-ESI-MS2/MS3 Mass Spectrometric Analyses 
Six control and six ischemic samples modified by light and heavy thiocholine 
respectively were randomly pooled in pairs to give six mixed samples for six individual 
replicates. The mixed samples were then desalted with POROS 20 R2 micro columns, 
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dried and reconstituted in 0.1% formic acid before injection and separation using a 
Surveyor HPLC system (Autosampler and pump, ThermoFisher, San Jose, CA) equipped 
with a reverse-phase C18 PepMap100 Nano-LC column (75 µm I.D. × 15 cm, 3 µm, 100 
Å; Dionex, Sunnyvale, CA). The flow rate was maintained at 220−280 nL/min. Samples 
eluting from the column were directed to the nanospray apparatus (i.e., NanoMate HD 
with LC coupler, Advion Bioscience Ltd., Ithaca, NY) and sprayed directly into a linear 
ion trap in tandem with an Orbitrap (LTQ-Orbitrap) mass spectrometer (ThermoFisher, 
San Jose, CA) at a spray voltage of 1.7 kV in the positive ion mode. Each of the six 
replicates was analyzed first in a survey run, which consisted of a 180 min gradient from 
100%  A to 75% A, 25% B (Buffer A: 90% water, 10% acetonitrile, 0.1% formic acid; 
Buffer B: 10% water, 90% acetonitrile, 0.1% formic acid, v:v) for 120 min, then to 50% 
A, 50% B (60 min). For data-dependent MS2 analyses, full mass scans in the Orbitrap 
(300−1600 m/z, mass resolution = 30000) were followed by product-ion scans in the LTQ 
of the five most abundant ions. These ions of interest generated from the survey run were 
then included in the parent mass list of a target run. The target run was conducted 
essentially the same as the survey run except that during the MS2 data-dependent 
analyses, the five most abundant ions from the parent mass list were fragmented. A third 
run was conducted for MS3 analyses. It consisted of a 180 min gradient from 100% A to 
75% A, 25% B (120 min), then to 50% A, 50% B (60 min) for data-dependent MS2/MS3 
analyses in which  full mass scans in the Orbitrap (300−1600 m/z, mass resolution = 30
000) were followed by product-ion scans in the LTQ of the three most abundant ions 
from the parent mass list and the MS3 scans in the LTQ of the ten most abundant 
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fragment ions following each of the three product-ion scans.   
 
MASCOT Database Search 
The local MASCOT server (version 2.1.1) with an up-to-date IPI mouse database was 
used to conduct all database searches [24]. The “auto decoy” option was chosen. Light 
and heavy thiocholine with neutral losses of trimethylamine and thiolate were integrated 
into MASCOT for customized processing of the designed covalent modifications for 
serine and threonine residues. Carbamidomethylation (C) was set as the fixed 
modification. Common variable modifications included acetylation (N-terminus, K), 
deamidation (NQ) and oxidation (M). A maximum of two missed cleavages were allowed. 
Full mass and product-ion mass accuracy were set at 5 ppm and 1 Da respectively. 
Database searches were conducted using an automatic decoy database provided by the 
local MASCOT server.  
 
Post-MASCOT Processing using Percolator 
All MASCOT search results were re-scored and re-ranked by a stand-alone version of the 
MASCOT Percolator [25-26]. All the programs utilized were downloaded using links 
from http://www.sanger.ac.uk/resources/software/mascotpercolator. Since the MASCOT 
searches were conducted using the option of “auto decoy”, the target and decoy 
MASCOT result files (.DAT) required by the Percolator program were the same. The 
“rankdelta N” value was set at default = “1”, indicating all peptide hit ranks that have a 
delta score of < 1 relative to the top hit match were processed. The false discovery rate 
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(FDR) was set at 1%. Peptide hits with a posterior error probability (PEP) value < 0.05 
(score > 13) were considered automatic positive identifications. Peptides originating from 
mitochondrial proteins with a PEP > 0.05 but < 0.2 (7 < score < 13) were verified 
manually for false identifications. All MS3 scans were analyzed manually for the 
signature neural loss of trimethylamine (-59 Da/-63 Da). 
 
Comparative Quantitation of Light and Heavy Thiocholine-Modified Peptides  
Relative changes in phosphorylation state were evaluated for all phosphopeptides 
identified in three or more independent replicate samples using relative peak intensity 
ratios of the molecular ions of light and heavy thiocholine-modified peptides at the time 
of their co-elution. The relative ratio was calculated by dividing the light peak intensity 
by the heavy peak intensity. Dixon's Q [34] test was used to eliminate outlier(s) with 95% 
confidence prior to calculations of sample average and standard deviation. The 
subcellular locations of the phosphoproteins identified were determined using the protein 
database UniProt [35-36] and LOCATE database [37-38].   
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4.4 Results and Discussion 
 
      In this study, the phosphoproteome of mitochondria isolated from Langendorff-
perfused mouse hearts subjected to global ischemia was investigated. During prolonged 
ischemia, flux through the mitochondrial electron transport chain (ETC) is attenuated 
owing to the accumulation of reducing equivalents in the mitochondrial matrix in the 
absence of oxygen. This results in the dramatic reduction of ATP production because 
during ischemia, the redox reactions involving oxygen become the rate limiting steps for 
the production of ATP. This ultimately leads to profound decreases in cellular ATP, 
resulting in hemodynamic dysfunction [39-42]. The chain of signaling events in response 
to the depletion of oxygen is regulated, at least in part, by changes in protein 
phosphorylation [43-46]. However, the role of alterations in mitochondrial protein 
phosphorylation in this process is at its early stages of understanding. Specifically, the 
identity of the mitochondrial phosphoproteins and their specific phosphosites during 
ischemia are largely unknown. Accordingly, we sought to determine specifically changes 
in protein phosphorylation following myocardial ischemia using quantitative 
phosphoproteomics to gain insight into the signaling pathways and molecular 
mechanisms that are activated during myocardial ischemia and result in alterations in 
mitochondrial bioenergetics and signaling.  
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Comparative Quantitative Phosphoproteomics using β-Elimination and Michael 
Addition with Light and Heavy Thiocholine 
      As reported in Chapters 2 and 3, β-elimination of phosphate and subsequent Michael 
addition (BEMA) with light and heavy thiocholine as the Michael donors is a sensitive 
and effective strategy for the detection, identification, and quantitation of phosphoserine 
and phosphothreonine residues. The overall workflow based on BEMA with light and 
heavy thiocholine for the comparative quantitative phosphoproteomics of mitochondria 
from mouse hearts upon induction of cardiac ischemia is detailed in Figure 4.1. 
Mitochondria were isolated from both normally perfused and globally ischemic mouse 
hearts by differential centrifugation. Mitochondrial proteins were then isolated by 
methanol/chloroform precipitation, reconstituted in 0.2% Rapigest, and total protein 
content was determined using a BCA protein assay. Next, 1 mg of protein from each 
sample was subjected to trypsinolysis. The resultant tryptic peptides were affinity 
purified using a TiO2 micro column for the selective enrichment of phosphopeptides. The 
affinity purified phosphopeptides were desalted and modified with either light thiocholine 
(control samples) or heavy thiocholine (ischemic samples). After the reactions were 
terminated, control and ischemic samples were mixed together, desalted and analyzed by 
using LC-MS/MS. The mass spectrometric data was searched by using MASCOT and re-
scored by Percolator to identify phosphopeptides. Quantitative information was obtained 
from the relative peak intensity of the molecular ions of the phosphopeptides modified by 
light and heavy thiocholine, respectively. The subcellular localization of the identified 
proteins was determined using UniProt [35-36] and LOCATE [37-38] databases. Our 
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strategy emphasized the rapid purification of mitochondrial to prevent intrapreparative 
artifacts, recognizing that all mitochondrial preparations contain mitochondria-associated 
proteins.   
      Mass spectrometric analysis of BEMA thiocholine-modified samples of mitochondria 
from control and ischemic murine myocardium showed multiple ions which were 
identified by sequential MASCOT and Percolator. The total ion chromatography (TIC) 
obtained from a representative sample is shown in Figure 4.2-A. The extracted ion 
chromatography (XIC) of the full-mass scans is presented in Figure 4.2-B.   
      A representative example of the diagnostic triad present in thiocholine-modified 
peptides is shown in Figure 4.3-A. The product-ion spectrum of the quadruply charged 
molecular ion at m/z 425.200 of the heavy thiocholine-modified peptide 
YHGHS*MSDPGVSYR was identified as originating from the pyruvate dehydrogenase 
E1 component subunit α. The spectrum shows the peptide bond cleavage fragment ions 
B8+2 at m/z 510.9, B10+2 at m/z 588.2, B11+2 at m/z 637.5, B12+3 at m/z 454.6 and A11+3 at 
m/z 416.2 (all fragment ions resulting from heavy thiocholine-modified peptides are 
presented in capital letters, such as B, A). Also shown in the spectrum are representative 
diagnostic triads consisting of the B10+2 fragmentation ions resulting from peptide bond 
cleavage (to give an ion at m/z = 510.9) and further neutral loss of 13C,d3-trimethylamine 
(-63 Da, m/z = 556.8) or the 13C,d3-thiocholine thiolate (-123 Da, m/z = 526.7). Figure 
4.3-B displays the expanded product-ion spectrum of the quadruply charged molecular 
ion modified by heavy thiocholine at m/z 425.200 (YHGHS*MSDPGVSYR) ranging 
from m/z 380 to m/z 640. The spectrum shows that the heavy thiocholine-containing B 
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ions are accompanied by the corresponding light thiocholine-containing b ions (all 
fragment ions resulting from light thiocholine-modified peptides are presented in lower-
case letters) resulting from the fragmentation of the light thiocholine-modified molecular 
ion at m/z 424.195 (YHGHS*MSDPGVSYR): B8+2 at m/z 510.9 with b8+2 at m/z 509.0, 
B10+2 at m/z 588.2 with b10+2 at m/z 586.2, B11+2 at m/z 637.5 with b11+2 at m/z 635.7, B12+3 
at m/z 454.6 with b12+3 at m/z 453.3 and B10+3 at m/z 392.6 with b10+3 at m/z 390.5. This 
indicates that during the data-dependent analysis both the light and heavy thiocholine-
modified peptides were included for collision induced dissociation (CID). Given that the 
structures of the peptides are identical, they produced the same corresponding B/b ions in 
the Product-ion spectrum as indicated by the presence of multiple doublets. This is due to 
the low-resolution capability of the linear ion trap when selecting the ion of interest for 
fragmentation. With molecular mass 4 Da apart, both light and heavy thiocholine-
modified peptides were included in the mass selection window at +4. The doublets of 
peptide bond cleavage fragment ions resulting from light and heavy thiocholine-modified 
peptides further confirm the identification of the peptide, the localization of the modified 
residue(s), and the phosphorylation site(s). The relative peak intensities of the doublets 
also serve as a redundant confirmation for the comparative quantitation conducted at the 
molecular level.  Figure 4.3-C, D, E and F illustrate  the signature neutral loss 
fragmentation pattern (loss of 13C,d3-trimethylamine, -63 Da) at the MS3 level of the 
heavy thiocholine containing fragment ions resulting  from the peptide bond cleavages of 
the quadruply charged molecular ion modified by heavy thiocholine at m/z 425.200 
(YHGHS*MSDPGVSYR). In Figure 4.3-C, B11 - 63+2 at m/z 606.1 is the dominant 
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neutral loss ion; in Figure 4.3-D, B10 - 63+2 at m/z 566.6 is the dominant neutral loss ion; 
in Figure 4.3-E, B8 - 63+2 at m/z 479.5 is the dominant neutral loss ion; in Figure 4.3-F, 
B12 - 63+3 at m/z 433.6 is the dominant neutral loss ion.  
      Collectively, the BEMA with light and heavy thiocholine strategy  provides a rich 
repertoire of information at the MS2 and MS3 levels that not only reveals the 
identification of the modified phosphopeptide, and the localization of thiocholine 
modification (phosphorylation), but also provides redundant comparative quantitative 
information at MS2 level. 
 
Improved MASCOT Results using the Post-Processing algorithm Percolator 
      MASCOT is one of the most widely used database search engines for the 
identification of proteins and peptides based on tandem mass spectrometric data [24]. 
MASCOT employs an algorithm that ranks the correlation between the experimental 
product-ion spectra and calculated peptide spectra based on the peptide sequences 
included in the protein database. The correlation between an experimental and a 
calculated spectrum is expressed by a score called peptide spectrum match (PSM). 
However, the ranking based on PSMs does not constitute formal proof of the peptide of 
interest in all cases. To substantiate results from MASCOT, the strategy of using decoy 
protein databases that randomize and reverse the protein sequences in the original 
databases [47-48] enabled the evaluation of peptide identifications using PSMs resulting 
from both original and decoy databases, thereby allowing the subsequent detection of 
false positives to determine the false discovery rate (FDR) [49]. MASCOT identifies 
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peptides based on the comparison between the PSM of each mass spectrum and a 
probability-based peptide identity score. If a PSM exceeds the threshold, the peptide 
identification is a true identification with a certain confidence interval (e.g., a value of 95% 
confidence is typically used). In addition, a second measurement of experimental vs. 
calculated spectra is the peptide homology threshold. If the PSM is lower than the 
homology threshold, it is considered an outlier [50]. As shown in Table 4.1, use of the 
decoy database in combination with identity and homology thresholds, the performance 
of MASCOT is not ideal, generating a FDR of over 11% FDR in each of the six 
individual samples, and an overall FDR of 12.49%. Therefore, the Percolator algorithm 
was employed to decrease the FDR obtained from MASCOT analysis alone. Percolator 
utilizes a semi-supervised machine-learning based algorithm called support vector 
machine (SVM) to compare the identifications resulting from the target and decoy 
databases using MASCOT [25-26]. The detailed workflow of the algorithm of Percolator 
is illustrated in Figure 4.4 (reproduced with permission from Figure 1 of the original 
publication (Journal of Proteome Research, 2009, 8, 3176-3181 by M, Brosch, L. Yu, T. 
Hubbard, and J. Choudhary)). All MASCOT search results were re-scored and re-ranked 
by a stand-alone version of the Percolator downloaded from the website 
http://www.sanger.ac.uk/resources/software/mascotpercolator. The “rank delta N” value 
was set at default = “1”, which means all peptide hit ranks that have a delta score of < 1 
to the top hit match were processed. The false discovery rate (FDR) was set at 1%. Table 
4.1 shows that Percolator not only increased the total peptide hits by 15%, but also 
significantly decreased the FDR to 0.64% from the original 12.49%.   
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      Collectively, Percolator provided a standard post-MASCOT approach for the 
significant improvement in increasing authentic phosphopeptide identification, and 
reducing false positives resulting in a decreased FDR.    
  
Statistical Analysis of the Quantitation and Identification of Light and Heavy 
Thiocholine-Modified Phosphopeptides.  
      In our previous study, we  employed BEMA with light and heavy thiocholine using 
the tryptic phosphopeptide FQpSEEQQQTEDELQDK from β-casein to show that five 
independent replicates at a theoretical ratio of 1:1 (light:heavy) produced an experimental 
average of 0.96 ± 0.02; three independent replicates at theoretical ratios of 1:2, 1:3, 1:4, 
4:1, 3:1, 2:1 together with five independent replicates at a theoretical ratio of 1:1 
(light:heavy) yielded an experimental correlation coefficient of R2 = 0.99 (as described in 
Chapter 2). These results show that the BEMA strategy with light and heavy thiocholine 
is a reliable, reproducible and precise approach towards quantitative phosphoproteomics. 
However, when dealing with complex tissue based systems, such as subject of the current 
study, large deviations in the comparative quantitation analysis can be introduced through 
multi-step sample preparation, run-to-run fluctuations in instrumentation parameters, or 
simply by the intrinsic differences between individual biological replicates. Although 
useful information could still be obtained by a limited number of replicates [21], relative 
changes in phosphorylation were exclusively evaluated for all phosphopeptides identified 
in three or more independent replicate samples (six samples overall) using relative peak 
intensity ratios of the molecular ions of light and heavy thiocholine-modified peptides at 
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the time of their co-elution. The relative ratio was calculated by dividing the light peak 
intensity by the heavy peak intensity. Dixon's Q [34] test was used to eliminate the 
outlier(s) with 95% confidence prior to the calculations of sample average and standard 
deviation. A representative “M + 4” doublet pattern of the quadruply charged molecular 
ions of light and heavy thiocholine-modified YHGHS*MSDPGVSYR at m/z 424.195 and 
425.200, respectively is evident in Figure 4.5. The greater peak intensity of the heavy 
thiocholine-modified YHGHS*MSDPGVSYR indicates that the phosphorylation level 
was increased for this peptide following the induction of cardiac ischemia. 
      Peptide hits with a Percolator-processed posterior error probability (PEP) value < 
0.05 (score > 13) indicating a confidence level of 95%, were considered automatic 
positive identifications. Non-mitochondrial peptides with a score < 13 were considered 
false positives. Peptides originating from mitochondrial proteins with a PEP > 0.05 but < 
0.2 (7 < score < 13), indicating a confidence level between 80% and 95%) were verified 
manually. Four mitochondrial peptides with a score between 7 and 13 were verified as 
positive identifications. The mass spectra of these peptides are shown in Figure 4.6. 
Phosphopeptides identified were categorized into six groups according to the number of 
hits from the six individual biological replicates. Table 4.2-A contains thiocholine-
modified peptides identified in all six individual biological replicates. There are 21 
unique peptides identified containing 36 phosphorylation sites, 16 of which were not  
reported in the literature. Ten out of the 21 peptides yielded a signature neutral loss in 
MS3 which are highlighted in bold. The ratios in italic font indicate that the ratios are 
calculated using heavy peak intensity over light peak intensity. Table 4.2-B contains 
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thiocholine-modified peptides identified in five out of six individual biological replicates. 
There are eight unique peptides identified containing 13 phosphorylation sites, five of 
which were not reported before. Four out of the eight peptides yielded a signature neutral 
loss in MS3.  Table 4.2-C contains thiocholine-modified peptides identified in four out of 
six individual biological replicates. There are nine unique peptides identified containing 
17 phosphorylation sites, 15 of which were not reported before. Five out of the nine 
peptides yielded a signature neutral loss in MS3. Table 4.2-D contains thiocholine-
modified peptides identified in three out six of individual biological replicates. There are 
eight unique peptides identified containing 16 phosphorylation sites, 14 of which were 
not reported before. One out of the eight peptides yielded a signature neutral loss in MS3.  
Table 4.2-E shows the thiocholine-modified peptides identified in two out of six 
individual biological replicates. There are 11 unique peptides identified containing 20 
phosphorylation sites, all of which were not reported before. Four out of the 11 peptides 
yielded a signature neutral loss in MS3.  Table 4.2-F shows thiocholine-modified peptides 
identified in one out of six individual biological replicates. There are 84 unique peptides 
identified containing 126 phosphorylation sites, 119 of which are novel. Three out of the 
84 peptides yielded a signature neutral loss in MS3. No evaluation of quantitation was 
assessed for peptides in the 1-hit and 2-hit groups out of six. Overall, 141 
phosphopeptides were identified from 133 unique proteins with 228 phosphorylated sites 
from six independent biological replicates, with 189 novel sites. Twenty-seven out 141 
thiocholine-modified peptides yielded a signature neutral loss in MS3, with 24 out 57 if 1-
hit peptides are not included. Mitochondrial proteins were determined using the protein 
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database UniProt [35-36] and the LOCATE database [37-38].  Proteins identified with 
either the UniProt or LOCATE databases as mitochondrial proteins were considered to be 
mitochondrial in origin. There are 36 phosphopeptides identified from 35 mitochondrial 
proteins with 50 phosphorylated sites, of which 37 were not reported before. As shown in 
Table 4.3, relative changes in phosphorylation were evaluated for mitochondrial 
phosphopeptides identified in three or more independent replicate samples  
      To validate the above strategy, the well-characterized phosphorylation of cardiac 
phospholamban at serine 16 induced during global cardiac ischemia in mouse hearts was 
used as a test case for the methodology developed in this study. As previously reported, 
phosphorylation at serine 16 of cardiac phospholamban was increased by 20-40 fold upon 
20-min of ischemia in Langendorff-perfused rat hearts [17]. In our study, we identified 
the light and heavy thiocholine-modified peptide RAS*TIEMPQQAR with a light over 
heavy ratio of 0.05 ± 0.00 calculated from six replicates indicating an approximately 20-
fold increase in phosphorylation of the peptide, which is consistent the previous results 
obtained using a traditional 32P-radiolabeling method from a similar system thereby 
validating the quantitative approach employed in the current study. 
      Among all the mitochondrial peptides indentified, the peptide IVS*AQSLAEDDVE 
showed the most significant and consistent change throughout all six samples. The heavy 
thiocholine-modified peptide IVS*AQSLAEDDVE was identified, with extremely high 
confidence and high mass accuracy (Table 4.3), in each and every sample. The absence of 
the ion peak corresponding to the light thiocholine-modified IVS*AQSLAEDDVE 
indicates that the net phosphorylation level was increased dramatically during the 
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induced cardiac ischemia. The peptide IVS*AQSLAEDDVE (133-145) is a tryptic 
peptide from the protein called mitochondrial import receptor subunit TOM20 located in 
the outer membranes of mitochondria, which is an important receptor protein for 
precursors of mitochondrial proteins that are synthesized in cytoplasm [51]. The 
phosphorylation site of serine residue 135 is located within a domain that was 
characterized in previous study [52] as a critical region responsible for the recognition of 
protein possessing internal signaling sequence, rendering the phosphorylation of serine 
135 a potential mechanism for the adaptive reactions of mitochondria during oxygen 
deficiency.   
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4.5 Conclusion 
 
      We demonstrated that β-elimination of phosphate and subsequent Michael addition 
(BEMA) with light and heavy thiocholine together with TiO2 phosphopeptide enrichment 
and the Percolator machine learning algorithm based MASCOT re-scoring program 
provides a highly effective strategy for in vivo quantitative phosphoproteomics of tissue-
based systems. The application of this strategy for the quantitative analysis of alterations 
in the murine myocardial mitochondrial phosphoproteome subjected to global cardiac 
ischemia resulted in the identification of 141 phosphopeptides from 133 unique proteins 
with 228 phosphorylated sites, 189 of which were not reported before. Among all the 
peptides identified, 36 were phosphopeptides from 35 mitochondrial proteins containing 
50 phosphosites, 37 of which were not reported before. The strategy was validated by the 
well-characterized phosphorylation of phospholamban at serine 16 during induced global 
cardiac ischemia in mouse myocardium.  
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4.7 Table Legends 
 
Table 4.1  
Improvement of peptide identification in MASCOT search results using Percolator.  
A local MASCOT server with an up-to-date IPI mouse database was used to conduct all 
searches as described in Materials and Methods. Database searches were conducted using 
an automatic decoy database provided by the local MASCOT server. All MASCOT 
search results were re-scored and re-ranked by a stand-alone version of the MASCOT 
Percolator as described in Materials and Methods. The false discovery rate (FDR) was set 
at 1%. All peptide hits with ion score greater than the “identification score” or the 
“homology score” in the direct output results generated by MASCOT were counted. For 
the Percolator processed results, all peptide hits with a posterior error probability (PEP) 
value < 0.05 (score > 13) were counted. The “decoy hits” were those product-ion spectra 
that matched peptide sequences in the decoy database. The False Identification Rate 
(FDR%) was calculated by dividing the overall hits using the decoy hits. The Percolator 
program not only increased the total hit number in each of the six samples, but also 
significantly lowered the FDR%. Percolator increased the total number of peptide hits by 
roughly 15% and lowered the overall FDR% from 12.29% to 0.64%.  
 
Table 4.2  
Identification of phosphorylation sites in proteins from mitochondria isolated from 
control and ischemic mouse hearts using BEMA with light and heavy thiocholine.  
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Tryptic peptides from proteins associated with mitochondria isolated from control and 
ischemic mouse hearts were TiO2-enriched, and modified by light and heavy thiocholine, 
respectively. The resultant light and heavy thiocholine samples were mixed, desalted, 
separated using reverse-phase nanobore HPLC, and analyzed with an LTQ-Orbitrap 
system as described in Materials and Methods. Mass spectrometry data were searched 
utilizing MASCOT with the designated thiocholine modification as well as common 
amino acid modifications as described in the Materials and Methods. Peptides were 
identified using Percolator-processed MASCOT results as described in the Materials and 
Methods. Relative change in phosphorylation due to ischemia was evaluated for all 
phosphopeptides identified in three or more independent replicates as described in the 
Materials and Methods. The ratios in italic font indicate that they were calculated using 
heavy peak intensity over light peak intensity. “*” denotes phosphorylation sites; “(*)” 
denotes that more than one phosphorylation site was identified in the same peptide and 
that they were not concurrent. The superscripts “ace”, “ac”, “d”, and “o” denote the 
following modifications: acetylation (N-terminus), acetylation (K), deamidation (NQ) 
and oxidation (M), respectively. All cysteine residues were carbamidomethylated. 
Peptides which yielded a signature neutral loss pattern in MS3 are highlighted in bold. 
 
A. Thiocholine-modified peptides identified in all six individual biological replicates. 
There are 21 unique peptides identified containing 36 phosphorylation sites, 16 of which 
were not reported before. Ten out of the 21 peptides yielded a signature neutral loss in 
MS3.   
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B. Thiocholine-modified peptides identified in five out of six individual biological 
replicates. There are eight unique peptides identified containing 13 phosphorylation sites, 
five of which were not reported before. Four out of the eight peptides yielded a signature 
neutral loss in MS3.   
C. Thiocholine-modified peptides identified in four out of six individual biological 
replicates. There are nine unique peptides identified containing 17 phosphorylation sites, 
15 of which were not reported before. Five out of the nine peptides yielded a signature 
neutral loss in MS3.   
D. Thiocholine-modified peptides identified in three out six of individual biological 
replicates. There are eight unique peptides identified containing 16 phosphorylation sites, 
14 of which were not reported before. One out of the eight peptides yielded a signature 
neutral loss in MS3.   
E. Thiocholine-modified peptides identified in two out of six individual biological 
replicates. There are 11 unique peptides identified containing 20 phosphorylation sites, all 
of which were not reported before. Four out of the 11 peptides yielded a signature neutral 
loss in MS3.   
F. Thiocholine-modified peptides identified in one out of six individual biological 
replicates. There are 84 unique peptides identified with 126 phosphorylation sites, 119 of 
which were not reported before. Three out of the 84 peptides yielded a signature neutral 
loss in MS3.   
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Table 4.3  
Identification of phosphorylation sites from mitochondrial proteins isolated from 
control and ischemic mouse hearts using BEMA with light and heavy thiocholine.  
Tryptic peptides from proteins associated with mitochondria isolated from control and 
ischemic mouse hearts were TiO2-enriched, and modified by light and heavy thiocholine, 
respectively. The modified peptides were mixed, desalted, and separated using reverse-
phase nanobore HPLC, before analysis with an LTQ-Orbitrap system as described in 
Materials and Methods. Mass spectrometry data were searched utilizing MASCOT with 
the designated thiocholine modification as well as common amino acid modifications as 
described in the Materials and Methods. Peptides were identified using Percolator-
processed MASCOT results as described in the Materials and Methods. Mitochondrial 
proteins were identified using both UniProt and LOCATE. No attempts have been made 
to reassign the subcellular locations predicted by UniProt and LOCATE. Relative changes 
in phosphorylation were evaluated only for mitochondrial phosphopeptides identified in 
three or more independent replicates as described in the Materials and Methods. The 
ratios in italic font indicate that they were calculated using heavy peak intensity over light 
peak intensity. “*” denotes phosphorylation sites; “(*)” denotes that more than one 
phosphorylation site was identified in the same peptide that were not concurrent with 
other phosphorylation sites within the same peptide. The superscripts “ace”, “ac”, “d”, 
and “o” denote the following modifications: acetylation (N-terminus), acetylation (K), 
deamidation (NQ) and oxidation (M), respectively. All cysteine residues were 
carbamidomethylated. Peptides which yielded a signature neutral loss pattern in MS3 are 
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highlighted in bold. Collectively, there were 36 unique peptides identified with 50 
phosphorylation sites, 37 (indicated with underscore) of which were not reported before. 
Eight out of the 36 peptides yielded a signature neutral loss in MS3.     
“a”: Proteins that are known to be other subcellular locations but are associated with 
mitochondria and are listed as mitochondrial proteins in UniProt and LOCATE.   
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Table 4.1 
Sample MASCOT Hits 
MASCOT Decoy 
Hits FDR% Percolator Hits
 Percolator Decoy 
Hits FDR% 
1 1509 194 12.86 1782 9 0.51 
2 1815 210 11.57 2165 14 0.65 
3 2156 274 12.71 2429 17 0.70 
4 1867 241 12.91 2177 15 0.69 
5 2013 259 12.87 2288 14 0.61 
6 2177 263 12.08 2464 16 0.65 
Total 11537 1441 12.49 13305 85 0.64 
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Table 4.2 
A. 
Protein Peptide Sequence Δm (ppm) 
Percolator 
Score Ratio 
Isoform 1 of 
Tropomyosin alpha-1 
chain 
AISEELDHALNDMT(*)S*I 1.2 152.2 1.08±0.36 
Alpha-crystallin B 
chain APS*WIDTGLSEMR 1.4 94.6 0.00±0.00 
Vinculin DPNAS*PGDAGEQAIR 0.1 152.7 0.67±0.25 
Prostaglandin E 
synthase 3 DWEDDS*DEDMSNFDR -0.1 114.5 0.53±0.40 
Uncharacterized 
protein C6orf203 
homolog 
EADEEDS*DEETS(*)YPER 1.0 127.2 1.15±0.23 
Isoform SERCA2A 
of 
Sarcoplasmic/endopla
smic reticulum 
calcium ATPase 2 
EFDELSPS*AQR 1.7 16.4 1.22±0.21 
Isoform 2 of Spectrin 
beta chain, brain 1 GDQVS*Q
dNGLPAEQGSPR 2.2 106.4 0.91±0.11 
Isoform Somatic of 
Angiotensin-
converting enzyme 
GPQFGS*EVELR 1.7 44.3 2.13±0.79 
Mitochondrial import 
receptor subunit 
TOM20 homolog 
IVS*AQSLAEDDVE -0.6 152.7 0.00±0.00 
AHNAK 
nucleoprotein isoform 
1 
LPSGS*GPAS(*)PTTGSAVDIR 2.0 88.3 0.52±0.19 
Gap junction protein QAS*EQNWANYSAEQNR 1.3 152.9 1.48±0.32 
Isoform A of Heat 
shock protein beta-1 QLS*SGVSEIR 1.9 29.0 0.04±0.08 
Cardiac 
phospholamban RAS*T(*)IEMPQQAR 3.4 151.0 0.05±0.05 
Tensin 1 S(*)QS*FPDVEPQLPQAPTR 2.0 63.6 0.65±0.33 
Ras GTPase-
activating protein-
binding protein 1 
S(*)T(*)S*PAPADVAPAQEDLR 2.2 69.2 0.79±0.28 
Isoform 1 of Protein 
NDRG2 TAS(*)LT*S(*)AASIDGSR 1.0 152.4 0.34±0.28 
Oxsr1 
Serine/threonine-
protein kinase OSR1 
TEDGGWEWS*DDEFDEESEEGR -3.1 152.7 0.80±0.40 
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Protein Peptide Sequence Δm (ppm) 
Percolator 
Score Ratio 
Putative 
uncharacterized 
protein 
T(*)LS(*)PT*PS(*)AEGYQDVR 1.4 152.9 0.87±0.18 
Isoform 1 of Protein 
NDRG2 
T(*)LS*QSS(*)ESGTLPSGPPGHTMEV
SC 0.6 152.7 0.39±0.29 
Pyruvate 
dehydrogenase E1 
component subunit 
alpha 
YHGHS(*)MS*DPGVSYR 0.8 39.5 0.57±0.43 
Ubiquinone 
biosynthesis protein 
COQ9, mitochondrial 
YTDQS*GEEEEDYESEEQLQHR 1.1 152.6 1.36±0.37 
 
B. 
Protein Peptide Sequence Δm 
(ppm) 
Percolator 
Score Ratio
 
EH domain-
containing 
protein 2 
GPDEAIEDGEEGS*EDDAEWVVTK 1.2 152.9 0.61±0.27 
Ubiquitin-
associated 
protein 2 
GVS*VS(*)SGTGLPDMoT*GSVYNKac 3.2 21.7 0.00±0.00 
ATP synthase 
subunit alpha, 
mitochondrial 
ILGADT*S(*)VDLEETGR 0.0 56.2 1.49±0.52 
Gap junction 
protein 
MGQAGS*T(*)IS(*)NSHAQPFDFPDDSQNA
K -0.5 128.6 1.00±0.08 
Isoform 1 of 
Cyclin-Y S*ASADNLILPR 1.0 35.5 0.81±0.21 
Histone H1.4 aceS*ET(*)APAAPAAPAPAEK 1.2 45.6 1.02±0.25 
Catenin alpha-1 TPEELDDS*DFETEDFDVR -1.7 47.1 0.83±0.13 
Thioredoxin-
related 
transmembrane 
protein 1 
VEEEQEADEEDVS*EEEAEDR 0.8 152.9 1.28±0.43 
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C. 
Protein Peptide Sequence Δm (ppm) 
Percolator 
Score Ratio
 
Isoform 3 of 
LIM domain-
binding protein 
3 
DPALDTNdGSLATPS*PS(*)PEAR -0.3 48.5 0.37±0.17 
Signal 
transducer and 
activator of 
transcription 
5B 
aceEANdNdGSSPAGSLADAMS*QK 0.8 31.3 1.72±0.61 
Isoform 1 of 
Zinc finger 
protein 106 
aceEQdSRQDEPPSNSQdEVNdS*DDR 0.1 33.6 0.00±0.00 
Creatine 
kinase S-type, 
mitochondrial 
LGYILTCPS(*)NLGT*GLR 0.5 24.8 1.32±0.32 
Gap junction 
protein 
MGQAGS(*)T*IS*NS(*)HAQPFDFPDDSQNA
K 1.6 27.4 0.00±0.00 
Electron 
transfer 
flavoprotein-
ubiquinone 
oxidoreductase
, mitochondrial 
NLS*IYDGPEQR 1.1 20.0 0.88±0.51 
Ryanodine 
receptor 2, 
cardiac 
RIS(*)QT*SQVSIDAAHGYSPR 3.0 47.3 1.06±0.70 
Isoform 1 of 
MAP7 
domain-
containing 
protein 1 
RS*SQPSPT(*)T(*)VPASDSPPAK 1.6 26.2 0.14±0.28 
LIM 
homeobox 
transcription 
factor 1-beta 
S*EDEDGDMoKaPAKaGQGSQSKaGS(*)GDDGK
ac -2.8 50.0 0.00±0.00
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D. 
Protein Peptide Sequence Δm (ppm) 
Percolator 
Score Ratio
 
Troponin I, 
cardiac muscle 
aceADESS*DAAGEPQPAPAPVR 0.4 16.73 1.62±0.70 
Isoform 1 of 
Protein 
FAM54B 
AS(*)S*FADMMGILK 1.2 65.52 0.00±0.00 
Putative 
uncharacterize
d protein 
aceDQPGHES(*)NT(*)SGNGSNMoWPNFPS*QdD
K -0.1 17.19 0.00±0.00 
Discs, large 
homolog 3 
aceENMoAQENdSIQdEQGVTSNT*SDSES(*)SS(*)
K -1.7 61.24 0.00±0.00 
Isoform 1 of 
Trinucleotide 
repeat-
containing 
gene 6B 
protein 
GPSGTDT*VS(*)GQSNSGNdNGNNGKDR -3.1 31.50 0.00±0.00 
Isoform 1 of 
Mitochondrial 
fission factor 
NDS*IVTPSPPQAR 0.3 19.41 0.32±0.30 
Similar to E1B 
19K/Bcl-2-
binding protein 
homolog 
NST(*)LS*EEDYIER 4.2 19.87 1.05±0.12 
ATP synthase 
subunit alpha, 
mitochondrial 
TGTAEMS(*)S*ILEER 1.8 51.80 0.73±0.78 
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E. 
Protein Peptide Sequence Δm (ppm) 
Percolator 
Score 
Metabotropic glutamate 
receptor 8 
aceAVNdFNGS*AGTPVTFNENdGDAPGR 0.9 15.6 
5'-AMP-activated protein 
kinase subunit beta-2 DLS*SS(*)PPGPYGQEMYVFR -0.8 114.1 
Similar to mKIAA1614 
protein isoform 1 EN
dLQNGNLNDPS*SIESS(*)NGQdWPKac 0.2 14.0 
Transcription factor Sp4 ENdNVS*QdPASS(*)SSSSSSSNdNdGSSSPTKTK 3.6 16.7 
Myosin regulatory light 
chain 2, 
ventricular/cardiac muscle 
isoform 
IEGGS(*)SNVFS*MFEQTQIQEFK 0.6 60.0 
Ryanodine receptor 2, 
cardiac IS(*)QTS*QVSIDAAHGYSPR 1.0 67.0 
Isoform 1 of Coiled-coil 
domain-containing 
transmembrane protein 
C7orf53 homolog 
LYVVDS*INDLNK 0.5 24.2 
CXXC-type zinc finger 
protein 5 
aceMoS*SLGGGSQDAGGSSSSSNdTNdSSSGS*GQd 
Kac 4.7 19.1 
Solute carrier family 2 
(facilitated glucose 
transporter), member 4 
T(*)PS*LLEQEVKPSTELEYLGPDEND 0.3 34.5 
Putative uncharacterized 
protein VAEPEES*EAEEPAAEGR 0.0 20.9 
Vasodilator-stimulated 
phosphoprotein WLPAGTGPQAFSR 3.2 27.4 
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F. 
Protein Peptide Sequence Δm (ppm) 
Percolator 
Score 
Poliovirus receptor AGGDIRVLVPYNSTGVLGGSTTLHCSLT*S*N
dENdVT*
ITQdITWMKKac -3.3 80.4 
Coiled-coil domain-
containing protein 
93 
YS*DRKK 2.2 56.0 
Putative 
uncharacterized 
protein 
DRSDSDDQMLVANdGSPS*SNLSSSVR 0.1 50.0 
Rap1 GTPase-
activating protein SENS*STQ
dSSPEMoPTTKNR 4.0 47.9 
Isoform 2 of Protein 
MRVI1 
FNALNdLPGQdAPS*S*SPMoPSLPALSESSNGKacSSISVS
*PALPALLENGK -4.1 43.0 
Dnajc5 protein SLS*TSGESLYHVLGLDK 1.0 40.0 
Synaptotagmin-12 NVST*GVVELK -0.5 38.0 
Isoform 2 of 
YEATS domain-
containing protein 2 
T*IVVGNdVSK 2.1 31.7 
Metallothionein aceMDPNdCS*CAAGDSCTCAGSCKac 0.0 31.5 
Isoform 1 of PDZ 
domain-containing 
RING finger protein 
3 
aceVAEGSS*EGATANIEAYRPSPK 1.4 31.3 
Proteasome activator 
complex subunit 1 EPALNEAN
dLS*NLK 5.0 31.0 
Isoform 1 of CAP-
Gly domain-
containing linker 
protein 4 
TVAENDAAQdPGSMSSSSSS*SSLDHK 0.0 30.7 
Isoform 1 of LIM 
domain-binding 
protein 1 
KacMSGGSTMoS*S*GGGNTNNdSNSKacK 1.8 29.7 
Tyrosine 3-
monooxygenase 
aceAVSEQdDT*KQAEAVT*SPR -0.7 26.6 
Aspartyl-tRNA 
synthetase, 
cytoplasmic 
QSNS*YDMFMoRGEEILSGAQdR 4.5 26.5 
Olfactory receptor 
Olfr270 
S*IS*FLGCALQMVIS*LGLGS*TECVLLAVMAYDRYA
AICNPLR 0.1 26.3 
Isoform 2 of 
SWI/SNF-related 
matrix-associated 
actin-dependent 
regulator of 
chromatin subfamily 
A containing 
DEAD/H box 1 
GEESNESAEASS*NdWEK 3.5 26.1 
FUN14 domain- NPPPQDYES*DDESYEVLDLTEYAR 2.8 25.9 
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Protein Peptide Sequence Δm (ppm) 
Percolator 
Score 
containing protein 1 
Tensin 1 HLGGSGSVVPGS*PSLDR 2.0 25.4 
Diphosphoinositol 
polyphosphate 
phosphohydrolase 3-
alpha 
aceLGGSPTNdGNS*AAPS*PPES*EP 3.8 22.5 
Membrane-spanning 
4-domains, 
subfamily A, 
member 4C 
MQGQEQdT*T*MoAVVPGGAPPSENSVMoK 0.1 22.3 
60S acidic ribosomal 
protein P1 EES*EES*EDDMGFGLFD -0.3 21.4 
Ep300 protein TDGKEEEEQPSTS*ATQSSPAPGQSK 2.8 21.2 
Isoform 1 of GAS2-
like protein 1 YSGDSDSSASSAQS*GPM
oGARSDDSATGSR 2.8 20.9 
Junctophilin-2 RSDSAPPSPVS*ATVPEEEPPAPR 2.4 20.6 
Putative 
uncharacterized 
protein 
EVQNdDLMLQdS*NdGS*QYSPNEIRENSPSVS*PT*ANI
AAPFGLKPR 4.1 20.4 
Ring finger protein 
112 
aceSFMoGNSSNdSWS*HAS*FPKac 1.1 20.0 
Isoform 2 of CCR4-
NOT transcription 
complex subunit 10 
aceQENdGSKSSSQLGGNTESSES*SETCSKac -3.6 19.7 
IgE-binding protein TDNGPAYT*SQdK 1.4 19.7 
[Protein ADP-
ribosylarginine] 
hydrolase-like 
protein 1 
ENS*VLGSIQEELQK 2.2 19.6 
Secreted seminal-
vesicle Ly-6 protein 
1 
LNS*SGICETAETSCEAT*NdNdR 1.4 19.5 
Isoform 1 of Xin 
actin-binding repeat-
containing protein 2 
aceQEGIQNSSDASQSKLACET*SQdSHKa 5.0 18.9 
Similar to 
LOC635138 protein 
MoAASAAAATAAGIAMoATSVQSSTTVEQLS*S*S*VA
EVIDQdHSVLSAQLK 2.9 18.8 
Cell surface 
glycoprotein CD200 
receptor 2 
aceNIT*WAS*TPDHIPDLQIS*AVALQHEGNYLCEITT*P
EGNFHK 4.8 18.6 
ADAM DEC1 NdNdVALVALMS*HELGHALGMoK -2.4 18.5 
Isoform 1 of 
Pleckstrin homology 
domain-containing 
family H member 2 
S*QSGVK 4.4 18.4 
Glycerol-3-
phosphate 
acyltransferase 1, 
mitochondrial 
SDEEDEDS*DFGEEQR 0.2 18.2 
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Protein Peptide Sequence Δm (ppm) 
Percolator 
Score 
COMM domain-
containing protein 4 
VDYT*LS*SSLLHSVEEPMoVHLQLQdVVPAPGTQAQP
VSMoSLS*ADKac 0.9 18.1 
Ankyrin repeat and 
SOCS box protein 7 
aceMLYNYGADT*NTR -4.1 18.1 
22 kDa protein 
aceAEKLS*EQdPQS*AAS*GSSAAGPSQSKacQGSLLNdLL
AEPSKPVGHASIFK 0.0 18.1 
Vomeronasal 2, 
receptor 95 
aceCTPCAVNEIS*NETDVDQdCVK 0.6 17.4 
Ras GTPase-
activating protein-
binding protein 1 
YQDEVFGGFVTEPQEES*EEEVEEPEER -0.8 17.2 
Transformation/trans
cription domain-
associated protein 
VLQdHILNPAFLYSFEKGEGEQLLGPPNPEGDNdPESIT*
S*VFITKac -0.9 17.0 
Voltage-gated 
potassium channel 
subunit beta-1 
NdEGVSSVLLGS*S*T*PEQdLIENLGAIQdVLPKacMoTSH
VVNdEIDNdILR 0.3 16.6 
Protocadherin-21 
aceMASSMoVAQQdTVPTVSGSLTPQdPSPQdLPTPKTLGG
PVQS*SLVSELKQK -2.2 16.3 
Hypothetical protein 
isoform 2 GDTTS*S*AET*Q
dPASSSSAEGPAAK -2.7 16.3 
Hydrocephalus 
inducing protein FS*VNdAVYS*K -0.1 16.1 
Isoform 1 of 
Voltage-dependent 
L-type calcium 
channel subunit 
beta-4 
aceHS*NHSTENdSPIER -0.4 16.1 
Isoform 1 of 
Transmembrane 
protein 154 
aceQEPSSQGSQS*ALQdTHELGGETLK -1.7 16.1 
ADP/ATP 
translocase 1 DFLAGGIAAAVS*K 0.8 16.0 
60 kDa SS-A/Ro 
ribonucleoprotein ALGSVLN
dAS*TVAAAMCMVVTR -2.0 15.7 
B-cell 
CLL/lymphoma 9 
protein 
aceGMAADVGMGGFS*QdGPGNdPGNdMMF -3.3 15.5 
THO complex 
subunit 1 
aceS*GLSDLAESLTNDTET*NS* 2.1 15.3 
Isoform 1 of 
Fibroblast growth 
factor receptor 3 
DDAT*DKacDLSDLVS*EMoEMMK 3.8 15.2 
Biorientation of 
chromosomes in cell 
division 1-like 
aceNdEECDGLMAS*TASCDVSNdKDSLAGSK -1.6 15.2 
Expressed sequence 
AA415398 HTEESAQMVET*PR 1.1 15.2 
Isoform 1 of 
Perilipin-4 
aceDTVCAGVTS*AMNMAK 0.8 15.1 
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Protein Peptide Sequence Δm (ppm) 
Percolator 
Score 
Prickle-like 2 
isoform a 
aceMoEQNQdS*QdSPLQdLLSQdCNIR -1.6 15.1 
Signal recognition 
particle receptor 
subunit alpha 
LIDGIVLTKFDTIDDKacVGAAISMoT*YITSKacPIVFVGT
GQTYCDLR -3.3 15.0 
Putative 
uncharacterized 
protein 
TTS*LQdNGT*FHLK 0.4 14.9 
Putative 
uncharacterized 
protein 
CRAS*AWASISMAS*TVHGCMR -1.3 14.8 
Nucleolar protein 12 aceQEEGSTS*QEGGGTPR -0.1 14.7 
Coiled-coil domain-
containing protein 
87 
QdSCTFTGSSSQdALVAPGNdT*PTTH -0.8 14.6 
Protocadherin 15 
isoform CD1-4 
aceETTSTT*QPPASNdPQdWGAEPHR 2.0 14.5 
Isoform 1 of DENN 
domain-containing 
protein 5B 
aceKacS*DSGVMLPTLR -4.0 14.5 
Isoform 1 of 
Calcium/calmodulin
-dependent protein 
kinase kinase 2 
aceMSLQdEPSQGGPASSSNS*LDMNGR 2.2 14.4 
Protein AF-10 TYTSTSNNdSISGSLNRLEDT*AAR 4.3 14.4 
Zinc finger, FYVE 
domain containing 9 
aceTDLGISNSFSHSS*GELLIK 1.2 14.3 
Isoform 2 of 
Nipped-B-like 
protein 
aceQdNdENRPCDT*KPNdDNK -1.7 14.1 
Isoform 1 of Integrin 
beta-2-like protein CLKDNS*AIK 3.0 14.0 
Isoform 1 of LIM 
domain-binding 
protein 2 
KacNdSTSST*S*NSSAGNTTNdSAGSK 4.2 13.8 
Glutamate [NMDA] 
receptor subunit 
epsilon-1 
aceNdISNMoS*NMNdSSR 1.1 13.8 
Similar to 
hCG2038359 
aceLLGVLATSS*SSLGFESDPETSCR 1.8 13.5 
Mucin 5, subtype B, 
tracheobronchial 
aceS*GFS*KaNGVTVSLSGATTMoSVNISTIGTIIT*FDGNI
FQIWLPYR -0.2 13.5 
Clusterin-associated 
protein 1 SGS*NDDSDIDIQEDDES*DSELEDR 0.7 13.4 
Fibrillin-1 aceCDEGYES*GFMoMoMoKacNdCMDIDECQdR 4.9 13.3 
Sphingosine-1-
phosphate receptor 1 DDGDN
dPET*IMSSGNdVNSSS -3.3 13.3 
Mitochondrial 
import receptor 
aceAAAVAAAGAGEPLS*PEELLPK -0.2 13.3 
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Protein Peptide Sequence Δm (ppm) 
Percolator 
Score 
subunit TOM22 
homolog 
Isoform 2 of Tumor 
protein 63 Q
dT*SMQdSQdSSYGNdSSPPLNKacMNdSMoNdKac 0.3 13.2 
Similar to 
1700001E04Rik 
protein isoform 5 
TMLDMoNdEMTQSIIGS*MQYSK 3.6 13.1 
Trifunctional 
enzyme subunit 
alpha, mitochondrial 
AGLEQGSDAGYLAES*QK 2.1 9.5 
Isoform 3 of A 
kinase anchor 
protein 1, 
mitochondrial 
RLS*EEACPGVLSVAPTVTQPPGR 1.6 9.2 
Cytochrome b-c1 
complex subunit 2, 
mitochondrial 
AVAQGNLSS*ADVQAAK 2.4 9.1 
Branched chain keto 
acid dehydrogenase 
E1, alpha 
polypeptide 
IGHHSTSDDS*SAYR 0.9 8.4 
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Table 4.3 
Protein Peptide Sequence Hits Ratio Source Percolator Score 
Δm 
(ppm) 
Alpha-crystallin B 
chain APS*WIDTGLSEMR 6 0.00±0.00 Both 94.6 1.4 
Uncharacterized 
protein C6orf203 
homolog 
EADEEDS*DEETS(*)YPER 6 1.15±0.23 Both 127.2 1.0 
Mitochondrial 
import receptor 
subunit TOM20 
homolog 
IVS*AQSLAEDDVE 6 0.00±0.00 Both 152.7 -0.6 
Isoform A of Heat 
shock protein beta-1 QLS*SGVSEIR 6 0.04±0.08 LOCATE 29.0 1.9 
Cardiac 
phospholambana RAS*T(*)IEMPQQAR 6 0.05±0.05 Both 151.0 3.4 
Pyruvate 
dehydrogenase E1 
component subunit 
alpha, somatic 
form, mitochondrial 
YHGHS(*)MS*DPGVSYR 6 0.57±0.43 Both 39.5 0.8 
Ubiquinone 
biosynthesis protein 
COQ9, 
mitochondrial 
YTDQS*GEEEEDYESEEQLQHR 6 1.36±0.37 Both 152.6 1.1 
EH domain-
containing protein 2 
GPDEAIEDGEEGS*EDDAEWV
VTK 5 0.61±0.27 LOCATE 152.9 1.2 
ATP synthase 
subunit alpha, 
mitochondrial 
ILGADT*S(*)VDLEETGR 5 1.49±0.52 Both 56.2 0.0 
Creatine kinase S-
type, mitochondrial LGYILTCPS(*)NLGT*GLR 4 1.32±0.32 Both 24.8 0.5 
Electron transfer 
flavoprotein-
ubiquinone 
oxidoreductase, 
mitochondrial 
NLS*IYDGPEQR 4 0.88±0.51 Both 20.0 1.1 
Isoform 1 of 
Mitochondrial 
fission factor 
NDS*IVTPSPPQAR 3 0.32±0.30 UniProt 19.4 0.3 
ATP synthase 
subunit alpha, 
mitochondrial 
TGTAEMS(*)S*ILEER 3 0.73±0.78 Both 51.8 1.8 
Isoform 1 of CAP-
Gly domain-
containing linker 
protein 4 
TVAENDAAQdPGSMSSSSSS*SS
LDHK 1 -- LOCATE 30.7 0.0 
FUN14 domain-
containing protein 1 
NPPPQDYES*DDESYEVLDLTE
YAR 1 -- LOCATE 25.9 2.8 
60S acidic EES*EES*EDDMGFGLFD 1 -- LOCATE 21.4 -0.3 
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Protein Peptide Sequence Hits Ratio Source Percolator Score 
Δm 
(ppm) 
ribosomal protein 
P1 
Ring finger protein 
112 
aceSFMoGNSSNdSWS*HAS*FPKac 1 -- LOCATE 20.0 1.1 
IgE-binding protein TDNGPAYT*SQdK 1 -- LOCATE 19.7 1.4 
[Protein ADP-
ribosylarginine] 
hydrolase-like 
protein 1 
ENS*VLGSIQEELQK 1 -- LOCATE 19.6 2.2 
Glycerol-3-
phosphate 
acyltransferase 1, 
mitochondrial 
SDEEDEDS*DFGEEQR 1 -- Both 18.2 0.2 
COMM domain-
containing protein 4 
VDYT*LS*SSLLHSVEEPMoVHL
QLQdVVPAPGTQAQPVSMoSLS*
ADKac 
1 -- LOCATE 18.1 0.9 
Voltage-gated 
potassium channel 
subunit beta-1 
NdEGVSSVLLGS*S*T*PEQdLIEN
LGAIQdVLPKacMoTSHVVNdEIDN
dILR 
1 -- LOCATE 16.6 0.3 
Protocadherin-21 
aceMASSMoVAQQdTVPTVSGSLT
PQdPSPQdLPTPKTLGGPVQS*SL
VSELKQK 
1 -- LOCATE 16.3 -2.2 
Hydrocephalus 
inducing protein FS*VN
dAVYS*K 1 -- LOCATE 16.1 -0.1 
ADP/ATP 
translocase 1 DFLAGGIAAAVS*K 1 -- Both 16.0 0.8 
Isoform 1 of 
Perilipin-4 
aceDTVCAGVTS*AMNMAK 1 -- LOCATE 15.1 0.8 
Signal recognition 
particle receptor 
subunit alpha 
LIDGIVLTKFDTIDDKacVGAAIS
MoT*YITSKacPIVFVGTGQTYCD
LR 
1 -- LOCATE 15.0 -3.3 
Putative 
uncharacterized 
protein 
TTS*LQdNGT*FHLK 1 -- LOCATE 14.9 0.4 
Protocadherin 15 
isoform CD1-4 
aceETTSTT*QPPASNdPQdWGAEP
HR 1 -- LOCATE 14.5 2.0 
Isoform 1 of DENN 
domain-containing 
protein 5B 
aceKacS*DSGVMLPTLR 1 -- LOCATE 14.5 -4.0 
Clusterin-associated 
protein 1 
SGS*NDDSDIDIQEDDES*DSEL
EDR 1 -- LOCATE 13.4 0.7 
Mitochondrial 
import receptor 
subunit TOM22 
homolog 
aceAAAVAAAGAGEPLS*PEELLP
K 1 -- Both 13.3 -0.2 
Trifunctional 
enzyme subunit 
alpha, 
mitochondrial 
AGLEQGSDAGYLAES*QK 1 -- Both 9.5 2.1 
Isoform 3 of A RLS*EEACPGVLSVAPTVTQPPG 1 -- Both 9.2 1.6 
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Protein Peptide Sequence Hits Ratio Source Percolator Score 
Δm 
(ppm) 
kinase anchor 
protein 1, 
mitochondrial 
R 
Cytochrome b-c1 
complex subunit 2, 
mitochondrial 
AVAQGNLSS*ADVQAAK 1 -- Both 9.1 2.4 
Branched chain 
keto acid 
dehydrogenase E1, 
alpha polypeptide 
IGHHSTSDDS*SAYR 1 -- Both 8.4 0.9 
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4.8 Figure Legends 
 
Figure 4.1 Workflow of comparative quantitative phosphoproteomics of 
mitochondria from control mouse hearts and hearts rendered ischemic.  
Mitochondria were isolated from both normally perfused and global ischemic mouse 
hearts. Next mitochondrial proteins were extracted by methanol/chloroform precipitation. 
Precipitated proteins were solubilized in Rapigest detergent and the protein concentration 
was determined using a BCA kit. From each sample 1 mg of protein was trypsinized in 
the presence of Rapigest. The resultant tryptic peptides were passed through a titanium 
dioxide micro column for the selective enrichment of phosphopeptides. The 
phosphopeptides were then desalted and modified with light thiocholine (control) and 
heavy thiocholine (ischemic). Control and ischemic samples were mixed together, 
desalted and analyzed using LC-MS/MS. The mass spectrometry data were searched 
using MASCOT and re-scored by Percolator program to yield the identification of the 
peptide. Quantitative information was obtained from the relative peak intensity of the 
molecular ions of the phosphopeptides modified by light and heavy thiocholine 
respectively. Proteins of mitochondrial origin were confirmed using both the UniProt and 
LOCATE databases. 
 
Figure 4.2 The total ion chromatography (TIC) (0-185 min) obtained from a 
representative sample using LTQ-Orbitrap as described in Materials and Methods 
(A). The extracted ion chromatography (XIC) (0-185 min) of the full-mass scans 
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from the TIC (B).   
 
Figure 4.3 Fragmentation of the heavy thiocholine-modified peptide 
YHGHS*MSDPGVSYR identified in the subunit α of pyruvate dehydrogenase E1 
at both the MS2 and MS3 levels. All fragment ions resulting from heavy thiocholine-
modified peptides are presented in capital letters (e.g., A, B and Y). All fragment 
ions resulting from light thiocholine-modified peptides are presented in lower case 
letters (e.g., a, b and y). 
A. The product-ion spectrum of the quadruply charged molecular ion modified by heavy 
thiocholine at m/z 425.200 (YHGHS*MSDPGVSYR) was obtained with an ESI-LTQ-
Orbitrap instrument as described in the Materials and Methods. Shown in the spectrum 
are the series of B ions, B8+2 at m/z 510.9, B10+2 at m/z 588.2, B11+2 at m/z 637.5, B12+3 at 
m/z 454.6. Also shown in the spectrum is an example of the diagnostic triad consisting of 
the B10+2 fragmentation ions resulting from peptide bond cleavage (m/z = 510.9) and 
further neutral loss of 13C,d3-trimethylamine (-63 Da, m/z = 556.8) or the 13C,d3-
thiocholine thiolate (-123 Da, m/z = 526.7). “S*” indicates the thiocholine-modified site. 
B. The expanded product-ion spectrum of the quadruply charged molecular ion modified 
by heavy thiocholine at m/z 425.200 (YHGHS*MSDPGVSYR) ranging from m/z 380 to 
m/z 640. As shown in the spectrum, the heavy thiocholine containing B ions are 
accompanied by the corresponding light thiocholine containing b ions resulting from the 
fragmentation of the light thiocholine-modified molecular ion at m/z 424.195 
(YHGHS*MSDPGVSYR) that could not be excluded during the data-dependent 
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dissociation, thereby generating a series of B/b ion doublets at the MS2 level with relative 
ratios that further confirmed the comparative quantitation at the molecular level.  
C. The MS3 spectrum of the B11+2 ion at m/z 637.5 resulting from the fragmentation of 
the quadruply charged molecular ion modified by heavy thiocholine at m/z 425.200 
(YHGHS*MSDPGVSYR) obtained with an ESI-LTQ-Orbitrap as described in 
the Materials and Methods. The ion peak at m/z 606.1 corresponds to the doubly charged 
fragment ion generated from the neutral loss of 13C,d3-trimethylamine (-63 Da) from the 
parent ion B11+2. 
D. The MS3 spectrum of the B10+2 ion at m/z 588.2 resulting from the fragmentation of 
the quadruply charged molecular ion modified by heavy thiocholine at m/z 425.200 
(YHGHS*MSDPGVSYR) obtained with an ESI-LTQ-Orbitrap as described in 
the Materials and Methods. The ion peak at m/z 556.6 corresponds to the doubly charged 
fragment ion generated from the neutral loss of 13C,d3-trimethylamine (-63 Da) from the 
parent ion B10+2. 
E. The MS3 spectrum of the B8+2 ion at m/z 510.9 resulting from the fragmentation of the 
quadruply charged molecular ion modified by heavy thiocholine at m/z 425.200 
(YHGHS*MSDPGVSYR) obtained with an ESI-LTQ-Orbitrap as described in 
the Materials and Methods. The ion peak at m/z 479.5 corresponds to the doubly charged 
fragment ion generated from the neutral loss of 13C,d3-trimethylamine (-63 Da) from the 
parent ion B8+2. 
F. The MS3 spectrum of the B12+3 ion at m/z 454.6 resulting from the fragmentation of the 
quadruply charged molecular ion modified by heavy thiocholine at m/z 425.200 
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(YHGHS*MSDPGVSYR) obtained with an ESI-LTQ-Orbitrap as described in 
the Materials and Methods. The ion peak at m/z 433.6 corresponds to the triply charged 
fragment ion generated from the neutral loss of 13C,d3-trimethylamine (-63 Da) from the 
parent ion B12+3. 
 
Figure 4.4 Workflow of MASCOT Percolator reproduced with permission from 
Journal of Proteome Research, 2009, 8, 3176-3181 by M, Brosch, L. Yu, T. Hubbard, 
and J. Choudhary. 
 
Figure 4.5 Comparative quantitation of light and heavy thiocholine-modified 
peptides. 
Relative changes in phosphorylation were evaluated for all phosphopeptides identified in 
three or more independent replicate samples as described in the Materials and Methods. 
Evident in the spectrum is the “M + 4” doublet pattern of the quadruply charged 
molecular ions of light and heavy thiocholine-modified YHGHS*MSDPGVSYR at m/z 
424.195 and 425.200 respectively. The greater peak intensity of the heavy thiocholine-
modified YHGHS*MSDPGVSYR indicates that the phosphorylation level was increased 
for this peptide during induced cardiac ischemia. The relative ratio of the light and heavy 
molecular ion “S*” indicates that the phosphoserine residue was either modified by light 
or heavy thiocholine.  
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Figure 4.6 Tandem mass spectra of manually verified mitochondrial peptides with a 
score greater than 7 and less than 13. All fragment ions resulting from heavy 
thiocholine-modified peptides are presented in capital letters (e.g., A, B and Y). All 
fragment ions resulting from light thiocholine-modified peptides are presented in 
lower case letters (e.g., a, b and y). 
 
A. The product-ion spectrum of the triply charged molecular ion of 
AGLEQGSDAGYLAES*QK originating from protein trifunctional enzyme subunit α, 
modified by heavy thiocholine at m/z 610.307 was obtained with an ESI-LTQ-Orbitrap 
instrument as described in the Materials and Methods. “S*” indicates the thiocholine-
modified site. 
B. The product-ion spectrum of the triply charged molecular ion of 
AVAQGNLSS*ADVQAAK originating from protein cytochrome b-c1 complex subunit 
2, modified by light thiocholine at m/z 544.292 was obtained with an ESI-LTQ-Orbitrap 
instrument as described in the Materials and Methods. “S*” indicates the thiocholine-
modified site. 
C. The product-ion spectrum of the quadruply charged molecular ion of 
IGHHSTSDDS*SAYR originating from protein branched chain keto acid dehydrogenase 
E1-α polypeptide, modified by light thiocholine at m/z 409.191 was obtained with an 
ESI-LTQ-Orbitrap instrument as described in the Materials and Methods. “S*” indicates 
the thiocholine-modified site. 
D. The product-ion spectrum of the triply charged molecular ion of 
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RLS*EEACPGVLSVAPTVTQPPGR originating from protein isoform 3 of A kinase 
anchor protein 1, modified by heavy thiocholine at m/z 842.788 was obtained with an 
ESI-LTQ-Orbitrap instrument as described in the Materials and Methods. “S*” indicates 
the thiocholine-modified site. 
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Figure 4.1 
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Figure 4.2 
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Figure 4.3 
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Figure 4.4 
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Figure 4.5 
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Figure 4.6 
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CHAPTER 5 
 
Conclusions and Future Directions 
 
 
 
      In this dissertation, we demonstrate a novel strategy employing alkaline 
β-elimination and Michael addition (BEMA) using natural abundance and stable isotope 
labeled thiocholine in conjunction with mass spectrometry for specific detection, 
identification and quantitation of phosphorylated serine/threonine containing peptides. 
This strategy exploits the transformation of negatively charged phosphate groups to 
endogenous positive charge bearing thiocholine moieties that resulted in a marked 
increase in ionization sensitivity during ESI accompanied by enhanced peptide sequence 
coverage during CID. The definitive localization of phosphorylated residues was greatly 
improved through the generation of diagnostic triads of fragmentation ions resulting from 
peptide bond cleavage and further neutral loss of either trimethylamine (-59 Da/-63 Da) 
or thiocholine thiolate (-119 Da/-123 Da) from the thiocholine side chain during CID in 
MS2 and MS3 experiments. The introduction of stable isotope labeled thiocholine enabled 
the quantitation of protein phosphorylation with high precision by ratiometric 
comparisons. The effectiveness of this developed technology was demonstrated in 
proteins isolated from both a living cell system and a perfused tissue system undergoing 
the pathologic alterations induced by myocardial ischemia. The endogenous 
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phosphorylations sites of iPLA2β expressed in Sf-9 cells were identified. Comparison 
with convention methods demonstrated superior results in both identification 
phosphopeptides and localization of phosphosites. Moreover, quantitative analysis of the 
mitochondrial phosphoproteome following cardiac ischemia was performed resulting in 
the identification of 36 mitochondrial phosphopeptides with 37 new mitochondrial 
phosphosites.  
      The effectiveness of the developed BEMA strategy relies heavily on the reduction 
of sample complexity. In this thesis, a highly selective affinity enrichment resin, titanium 
dioxide (TiO2), was utilized to eliminate the majority of the non-phosphorylated peptides 
before conducting the BEMA reactions. This greatly increased the specificity of the 
reactions and thus markedly improved reaction yields. Currently, a single reverse-phase 
(RP) column was used to separate the peptides before mass spectrometry. A 
two-dimensional (2-D) liquid chromatographic approach consisting of tandem strong 
cation exchange (SCX) and reversed-phase (RP) columns can be employed to greatly 
increase the sensitivity and the power of this approach [1-2].  
      Thiocholine possesses unique chemical properties that lead to the enhanced 
ionization and generation of a rich repertoire of signature fragment ions upon CID. This 
compound may also allow the affinity-purification of thiocholine containing peptides. It 
has been previously reported that cavitand-based host molecules formed stable host-guest 
complexes in water with quaternary amine containing small molecules [3]. The reversible 
non-covalent binding between the aromatic pocket of the cavitand and the quaternary 
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amine moiety of small targets is characterized by cation-pi interactions that have been 
well defined [4-5]. Chemical fixation of the cavitand-based host molecules on a resin can 
enable stationary phase extraction (SPE) of thiocholine-modified peptides for affinity 
enrichment. The enrichment step could be either placed offline prior to the LC-MS 
analysis or integrated as an additional dimension in the online HPLC separation.  
      As discussed in previous chapters, although the signature neutral loss of 
trimethylamine and thiocholine thiolate were incorporated in the MASCOT search engine, 
ions generated from neutral loss were not accounted for additional increase of 
probability/confidence levels for identification of the peptides in this study. The 
developed method is well-suited to be used with a weighted scoring algorithm that takes 
into account the intrinsic chemical properties of thiocholine-containing peptides that will 
likely enhance identification of phosphorylated peptides and phosphosites. Also the 
anticipated development of bioinformatics resulting from this approach will increase the 
utility of the current strategy. For example, a target MS3 template can be added to the 
current options for the specific fragmentation of theoretical b and y ions instead of 
fragmenting ions based solely on their relative intensity in product-ion spectra. An 
automated quantitation program proceeding the validation of the peptide identification 
also would greatly improve the efficiency of the current strategy.  
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Appendix 
 
A. 1H NMR (D2O) spectrum of natural abundance thiocholine 
 
Figure A. 
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B. 1H NMR (D2O) spectrum of thiocholine-13C,d3 
 
Figure B. 
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C. The scheme of the electron-donating effect of the β-methyl group of threonine 
affecting the reaction rates of β-elimination and Michael addition 
 
Figure C. 
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D. Nomenclature of peptide fragment ions 
 
Figure D. 
 
 
 
